



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 156447

TO: Jennifer Kim
Location: 4b02 / 4b18
Tuesday, June 21, 2005
Art Unit: 1617
Phone: 571-272-0628
Serial Number: 10 / 731375

From: Jan Delaval
Location: Biotech-Chem Library
Remsen 1a51
Phone: 571-272-2504
jan.delaval@uspto.gov

Search Notes

12/6/2002

Access DB# 1564449

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name Jennifer Kim Examiner # 11469 Date: 6/14/05
An. Unit 1617 Phone Number 301-20628 Serial Number 10/131,375
Mail Box and Bldg Room Location Room 4502 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc. if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Methods and Composition for treatment of otitis media
Inventors (please provide full names): Barr et al.

Earliest Priority Filing Date: 12/6/2002

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search claims 13 - 17, & 8, 11, ~~12~~.

THX,



BEST AVAILABLE COPY

STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher <u>Gar</u>	NA Sequence (#) _____	STN <input checked="" type="checkbox"/> _____
Searcher Phone # <u>22504</u>	AA Sequence (#) _____	Dialog _____
Searcher Location _____	Structure (#) _____	Questel Orbit _____
Date received by staff <u>6/21/05</u>	Bibliographic <input checked="" type="checkbox"/> _____	Intellipoint _____
Date processed <u>6/21/05</u>	Citation _____	Info Nova _____
Searcher Prod & Reel # _____	Full-text _____	Sequence Systems _____
Terms Prep Time <u>20</u>	Patent Family _____	WAW Internet _____
Time to file <u>+120</u>	Other _____	Other vendors _____

=> d his

(FILE 'HOME' ENTERED AT 14:02:58 ON 21 JUN 2005)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 14:03:04 ON 21 JUN 2005

L1 1 S US20040175383/PN OR (US2003-731375# OR WO2003-US39053 OR US20
E BARR P/AU
L2 259 S E3,E7,E22-30
E PEMBERTON P/AU
L3 34 S E3,E4,E8,E10
E ANTONELLI P/AU
L4 12 S E3,E7
E SCHULTZ G/AU
L5 208 S E3,E13
E SCHULTZ GREG/AU
L6 94 S E3-E5,E8,E9
E SUNDIN D/AU
L7 10 S E7,E8
E ARRIVA/PA,CS
L8 9 S E3-E10
E U FL/PA,CS
E U OF FL/PA,CS
E UN FL/PA,CS
E UN OF FL/PA,CS
E UNI FL/PA,CS
E UNI OF FL/PA,CS
E UNIV FL/PA,CS
L9 15 S E5-E10
E UNIV OF FL/PA,CS
L10 59 S E5-E8,E10-E24
L11 4780 S E25-E79
E UNIVER FL/PA,CS
E UNIVER OF FL/PA,CS
E UNIVERS FL/PA,CS
E UNIVERS OF FL/PA,CS
E UNIVERSITY FL/PA,CS
L12 56 S E6-E18
E UNIVERSITY OF FL/PA,CS
L13 1247 S E33-E205
E FLORIDA/PA,CS
L14 69197 S E3,E4

FILE 'REGISTRY' ENTERED AT 14:09:55 ON 21 JUN 2005

L15 1 S ILOMASTAT/CN
E C20H28N4O4/MF
L16 32 S E3 AND NC4-C6/ES AND 2/NR
L17 7 S L16 AND BUTANEDIAMIDE
L18 6 S L17 NOT 200866-76-8
L19 6 S L15,L18
SEL RN
L20 0 S E1-E6/CRN
L21 674 S (?MATRIX?(L)?METALLO?(L)(?PROTEINASE? OR ?PROTEASE?))/CNS
L22 583 S (?MATRIX?(L)(?METALLOPROTEINASE? OR ?METALLOPROTEASE?))/CNS
E MMP
L23 790 S E3-E102
L24 674 S L21,L22
L25 349 S L24 AND L23
L26 674 S L24,L25
L27 441 S L23 NOT L26

L28 83 S E3
 L29 85 S ANTI TRYPSIN
 E AAT
 L30 452 S E3
 E SCAN
 E RAAT
 L31 4 S L30 AND L28,L29
 L32 141 S ALPHA()1() (ANTITRYPSIN OR ANTI TRYPSIN OR TRYPSIN INHIBIT?)

FILE 'HCAPLUS' ENTERED AT 14:18:38 ON 21 JUN 2005

L33 20912 S L28-L32
 L34 5525 S ALPHA()1() (ANTITRYPSIN OR ANTI TRYPSIN)
 L35 5582 S ALPHA()1(L) (ANTITRYPSIN OR ANTI TRYPSIN)
 L36 1441 S ALPHA()1(L) TRYPSIN(L) INHIBIT?
 L37 22445 S L33-L36
 L38 43494 S L26 OR L27
 L39 15830 S ?MATRIX?(L) ?METALLO?(L) (?PROTEINASE? OR ?PROTEASE?)
 L40 15738 S ?MATRIX?(L) (?METALLOPROTEINASE? OR ?METALLOPROTEASE?)
 L41 15 S ?MATRIXMETALLO?(L) (?PROTEINASE? OR ?PROTEASE?)
 L42 15 S ?MATRIXMETALLOPROTEINASE? OR ?MATRIXMETALLOPROTEASE?
 L43 13586 S MMP?
 L44 48294 S L38-L43
 L45 100 S L19
 L46 215 S ILOMASTAT OR CS610 OR CS 610 OR GM6001 OR GM 6001 OR GALARDIN
 L47 227 S L45,L46
 E OTITIS/CT
 E E3+ALL
 L48 471 S E1,E2,E3
 E OTITI? MEDI?
 L49 1294 S OTITI? MEDI?
 L50 1656 S E12
 E TYMPANIC MEMBRANE/CT
 E E3+ALL
 L51 112 S E2
 L52 407 S TYMPAN?(L) MEMBRAN?
 E AUDITORY CANAL/CT
 L53 116 S AUDITORY CANAL
 E MIDDLE EAR
 E MIDDLE EAR/CT
 E E3+ALL
 L54 439 S E2
 E TYMPANOSOMY/CT
 E TYMPANOSTOMY/CT
 L55 35 S TYMPANOSTOM?
 E OTORRHEA/CT
 E OTORRHEA
 L56 37 S E3-E5
 E EAR/CT
 L57 9213 S E3-E63
 L58 12277 S E3+OLD,NT,PFT,RT OR E54+OLD,NT,PFT,RT
 L59 12960 S L48-L58
 L60 23 S L59 AND L37
 L61 73 S L59 AND L44
 L62 2 S L59 AND L47
 L63 4 S L1-L14 AND L60-L62
 E PEMBERTON P/AU
 L64 37 S E3,E4,E9,E10
 L65 4 S L64 AND L60-L62
 L66 4 S L63,L65

L67 84 S L60-L62 NOT L66
 L68 76 S L67 AND (PY<=2002 OR PRY<=2002 OR AY<=2002)
 L69 19 S L68 AND L37
 L70 5 S L69 AND L44
 L71 0 S L69 AND L47
 L72 19 S L69,L70
 SEL DN AN 3-5 10-12 15 16
 L73 8 S L72 AND E1-E24
 L74 57 S L68 NOT L69-L73
 SEL DN AN 17 37 48 49 L74
 L75 4 S E25-E36 AND L74
 L76 3 S L75 NOT 3/SC
 L77 15 S L66,L73,L76 AND L1-L14,L33-L76
 SEL HIT RN

FILE 'REGISTRY' ENTERED AT 14:52:28 ON 21 JUN 2005

L78 6 S E37-E42
 L79 1 S L78 AND L19
 L80 4 S L78 AND L26,L27
 L81 1 S L78 AND L28-L32

=> fil reg

FILE 'REGISTRY' ENTERED AT 14:53:40 ON 21 JUN 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 JUN 2005 HIGHEST RN 852602-49-4

DICTIONARY FILE UPDATES: 20 JUN 2005 HIGHEST RN 852602-49-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

 *
 * The CA roles and document type information have been removed from *
 * the IDE default display format and the ED field has been added, *
 * effective March 20, 2005. A new display format, IDERL, is now *
 * available and contains the CA role and document type information. *
 *

Crossover limits have been increased. See HELP CROSSOVER for details.


Experimental and calculated property data are now available. For more
 information enter HELP PROP at an arrow prompt in the file or refer
 to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d l79 ide can

L79 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 142880-36-2 REGISTRY

ED Entered STN: 12 Aug 1992
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, [S-(R*,S*)]-
OTHER NAMES:
CN CS 610
CN Galardin
CN GM 6001
CN Ilomastat
FS STEREOSEARCH
MF C20 H28 N4 O4
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CHEMCATS, CIN, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, MEDLINE, PHAR, PROMT, PROUSDDR, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
Other Sources: WHO

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

99 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
100 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 142:456684
REFERENCE 2: 142:211519
REFERENCE 3: 142:162531
REFERENCE 4: 142:127629
REFERENCE 5: 142:127066
REFERENCE 6: 142:48885
REFERENCE 7: 142:48821
REFERENCE 8: 142:32962

jan delaval - 21 june 2005

REFERENCE 9: 142:723

REFERENCE 10: 141:376783

=> d 180 ide can tot

L80 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2005 ACS on STN

RN 146480-36-6 REGISTRY

ED Entered STN: 17 Mar 1993

CN Gelatinase B (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 92,000-Mol.-wt. gelatinase

CN 92,000-Mol.-wt. type IV collagenase

CN 92-kD Gelatinase

CN 92-kDa Gelatinase

CN 92-kDa Type IV collagenase

CN 95 kDa Type IV collagenase/gelatinase

CN Collagenase IV

CN Collagenase type IV

CN E.C. 3.4.24.35

CN Gelatinase MMP 9

CN Matrix metalloprotease 9

CN Matrix metalloproteinase-9

CN MMP 9

CN Type IV collagen metalloproteinase

CN Type IV collagenase

CN Type IV collagenase/gelatinase

MF Unspecified

CI MAN

SR CA

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,
CA, CAPLUS, CEN, CHEMCATS, CIN, EMBASE, PROMT, TOXCENTER, USPAT2,
USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

5379 REFERENCES IN FILE CA (1907 TO DATE)

14 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

5407 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 142:487357

REFERENCE 2: 142:480688

REFERENCE 3: 142:480618

REFERENCE 4: 142:480447

REFERENCE 5: 142:480417

REFERENCE 6: 142:479893

REFERENCE 7: 142:479796

REFERENCE 8: 142:479666

REFERENCE 9: 142:479600

REFERENCE 10: 142:479554

L80 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2005 ACS on STN

RN 146480-35-5 REGISTRY

ED Entered STN: 17 Mar 1993

CN Gelatinase A (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 72 kDa Gelatinase

CN 72 kDa Gelatinase type A

CN 72,000-Mol.-wt. gelatinase

CN 72,000-Mol.-wt. type IV collagenase

CN Collagenase IV

CN Collagenase type IV

CN E.C. 3.4.24.24

CN Matrix metalloprotease 2

CN Matrix metalloproteinase 2

CN MMP 2

CN Type IV collagen metalloproteinase

CN Type IV collagenase

CN Type IV collagenase/gelatinase

MF Unspecified

CI MAN

SR CA

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,
CA, CAPLUS, CEN, CHEMCATS, CIN, EMBASE, PROMT, TOXCENTER, USPAT2,
USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5425 REFERENCES IN FILE CA (1907 TO DATE)

14 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

5444 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 142:487357

REFERENCE 2: 142:480688

REFERENCE 3: 142:480417

REFERENCE 4: 142:479901

REFERENCE 5: 142:479835

REFERENCE 6: 142:479796

REFERENCE 7: 142:479759

REFERENCE 8: 142:479697

REFERENCE 9: 142:479666

REFERENCE 10: 142:479600

L80 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2005 ACS on STN

RN 9004-06-2 REGISTRY

ED Entered STN: 16 Nov 1984

CN Elastase (9CI) (CA INDEX NAME)

OTHER NAMES:

CN E.C. 3.4.21.11

jan delaval - 21 june 2005

CN E.C. 3.4.21.36
CN E.C. 3.4.21.37
CN E.C. 3.4.24.65
CN E.C. 3.4.4.7
CN Elaszym
CN Macrophage metalloelastase
CN **Matrix metalloprotease 12**
CN **Matrix metalloproteinase-12**
CN Medullasin
CN Metalloproteinase HME
CN **MMP 12**
CN Neutrophil Elastase
CN Pancreatopeptidase E
CN Peptidase, pancreato-, E
CN Proteinase, bone marrow serine
DR 9001-21-2, 139074-64-9, 75603-19-9, 83682-98-8
MF Unspecified
CI COM, MAN
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,
CA, CABA, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHM,
DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, NAPRALERT, NIOSHTIC,
PHAR, PIRA, PROMT, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8817 REFERENCES IN FILE CA (1907 TO DATE)
286 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
8831 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 142:487681

REFERENCE 2: 142:480766

REFERENCE 3: 142:480732

REFERENCE 4: 142:477174

REFERENCE 5: 142:476193

REFERENCE 6: 142:476177

REFERENCE 7: 142:475648

REFERENCE 8: 142:461611

REFERENCE 9: 142:461532

REFERENCE 10: 142:461258

L80 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2005 ACS on STN
RN 9001-12-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN Collagenase (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Aspergillopeptidase C

CN Azocollase
CN Clostridiopeptidase A
CN Clostridiopeptidase I
CN Clostridiopeptidase II
CN Clostridium histolyticum collagenase
CN Collagen peptidase
CN Collagen protease
CN Collagenase A
CN **Collagenase MMP-1**
CN E.C. 3.4.24.3
CN E.C. 3.4.24.34
CN E.C. 3.4.24.7
CN E.C. 3.4.4.19
CN E.C. 3.4.99.5
CN Euphauysin
CN FPM-MP
CN Interstitial collagenase
CN Iruxol
CN Kollaza
CN Liberase
CN Liberase Blendzyme IV
CN Liberase PI
CN **Matrix metalloprotease MMP-ABT**
CN **Matrix metalloprotease-1**
CN **Matrix metalloproteinase-1**
CN **Matrix metalloproteinase-18**
CN **Matrix metalloproteinase-8**
CN Metallocollagenase
CN Metalloproteinase-1
CN **MMP-1**
CN **MMP-8**
CN Morikraz
CN Nucleolysin
CN Peptidase, clostridio-, A
CN Proteinase, Clostridium histolyticum, A
CN Santyl
CN Soycollagestin
DR 37288-86-1, 39433-96-0
MF Unspecified
CI COM, MAN
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,
CA, CABA, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM,
DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE,
MRCK*, MSDS-OHS, PHAR, PIRA, PROMT, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

9076 REFERENCES IN FILE CA (1907 TO DATE)
79 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
9090 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 142:487693

REFERENCE 2: 142:487681

REFERENCE 3: 142:487569
REFERENCE 4: 142:487205
REFERENCE 5: 142:480766
REFERENCE 6: 142:479692
REFERENCE 7: 142:479593
REFERENCE 8: 142:479317
REFERENCE 9: 142:478226
REFERENCE 10: 142:477174

=> d l81 ide can

L81 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 9041-92-3 REGISTRY
ED Entered STN: 16 Nov 1984
CN Trypsin inhibitor, α 1- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN α 1-Protease inhibitor
CN α 1-Antiprotease
CN α 1-Antiproteinase
CN α 1-Antitrypsin
CN α 1-Antitrypsin Pittsburgh mutant
CN α 1-Antitrypsin Portland
CN α 1-AT
CN α 1-Protease inhibitor
CN α 1-Proteinase inhibitor
CN α 1-Trypsin inhibitor
CN Antitrypsin Pittsburgh
CN Prolastin
CN Respitin
CN SERPINA1
DR 9082-50-2, 124542-00-3
MF Unspecified
CI COM, MAN
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS,
BIOSIS, BIOTECHNO, CA, CAPLUS, CBNB, CEN, CHEMCATS, CHEMLIST, CIN,
CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB,
IMSCOSEARCH, IMSRESEARCH, IPA, MRCK*, NIOSHTIC, PHAR, PROMT, RTECS*,
TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5527 REFERENCES IN FILE CA (1907 TO DATE)
311 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
5538 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 142:487503

REFERENCE 2: 142:487376
REFERENCE 3: 142:487367
REFERENCE 4: 142:480981
REFERENCE 5: 142:476291
REFERENCE 6: 142:476252
REFERENCE 7: 142:476066
REFERENCE 8: 142:469309
REFERENCE 9: 142:462323
REFERENCE 10: 142:461387

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 14:54:03 ON 21 JUN 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Jun 2005 VOL 142 ISS 26

FILE LAST UPDATED: 20 Jun 2005 (20050620/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all hitstr tot 177

L77 ANSWER 1 OF 15 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:739746 HCAPLUS
DN 141:230746
ED Entered STN: 10 Sep 2004
TI Methods and compositions for treatment of otitis media
IN Barr, Philip J.; Pemberton, Philip A.; Antonelli,
Patrick J.; Schultz, Gregory S.; Sundin, David J.
PA USA
SO U.S. Pat. Appl. Publ., 12 pp.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K039-395
ICS A61K031-56

jan delaval - 21 june 2005

INCL 424146100; 514171000; 424046000

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004175383	A1	20040909	US 2003-731375	20031208 <--
	WO 2004052236	A2	20040624	WO 2003-US39053	20031208 <--
	WO 2004052236	A3	20040826		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2002-431286P	P	20021206	<--	
	US 2002-435985P	P	20021220	<--	

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	US 2004175383	ICM	A61K039-395
		ICS	A61K031-56
		INCL	424146100; 514171000; 424046000
	US 2004175383	NCL	424/146.100; 514/171.000; 424/046.000 <--
AB	The invention is directed to the treatment of otitis media by administration of protease inhibitors. In some embodiments, the protease inhibitors are alpha one- antitrypsin and/or ilomastat . The effects of . alpha.1-antitrypsin and ilomastat on matrix metalloproteinases and human neutrophil elastase activities in middle ear effusion samples were collected from patients with otitis media were examined Also, a solution composition containing recombinant . alpha.1-antitrypsin 51.65 mg/mL, KCl 200 mEq/L, sodium phosphate 0.02, sodium citrate 0.005, and N-acetyl cysteine 0.005 M was formulated.		
ST	protease inhibitor otitis media treatment; antitrypsin otitis media treatment		
IT	Neoplasm (cholesteatoma; methods and compns. for treatment of otitis media with protease inhibitors)		
IT	Antibiotics Human (methods and compns. for treatment of otitis media with protease inhibitors)		
IT	Steroids, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (methods and compns. for treatment of otitis media with protease inhibitors)		
IT	Ear, disease (neoplasm, cholesteatoma; methods and compns. for treatment of otitis media with protease inhibitors)		
IT	Ear, disease Inflammation (otitis media ; methods and compns. for treatment of otitis media with protease inhibitors)		
IT	Ear, disease		

Inflammation

- (otitis; methods and compns. for treatment of otitis media with protease inhibitors)
- IT Drug delivery systems
(powders, dry; methods and compns. for treatment of otitis media with protease inhibitors)
- IT Drug delivery systems
(solns., ear; methods and compns. for treatment of otitis media with protease inhibitors)
- IT 9004-06-2, Neutrophil elastase 146480-35-5,
Matrix metalloproteinase 2 146480-36-6,
Matrix metalloproteinase 9
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(methods and compns. for treatment of otitis media with protease inhibitors)
- IT 9041-92-3 142880-36-2, Ilomastat
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treatment of otitis media with protease inhibitors)
- IT 9004-06-2, Neutrophil elastase 146480-35-5,
Matrix metalloproteinase 2 146480-36-6,
Matrix metalloproteinase 9
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(methods and compns. for treatment of otitis media with protease inhibitors)
- RN 9004-06-2 HCAPLUS
CN Elastase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

- RN 146480-35-5 HCAPLUS
CN Gelatinase A (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

- RN 146480-36-6 HCAPLUS
CN Gelatinase B (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

- IT 9041-92-3 142880-36-2, Ilomastat
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treatment of otitis media with protease inhibitors)
- RN 9041-92-3 HCAPLUS
CN Trypsin inhibitor, α 1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

- RN 142880-36-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L77 ANSWER 2 OF 15 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:453045 HCAPLUS
 DN 141:12313
 ED Entered STN: 04 Jun 2004
 TI Compositions containing protease inhibitors for treating inflammatory diseases
 IN Bathurst, Ian C.; Pemberton, Philip A.; Sundin, David J.
 ; Mayhew, James W.; Angel, Arturo J.; Barr, Philip J.
 PA Arriva-Prometic Inc., Can.
 SO PCT Int. Appl., 51 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K038-00
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 1
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004045634	A1	20040603	WO 2003-GB5049	20031120
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI US 2002-427702P	P	20021120		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004045634	ICM	A61K038-00
WO 2004045634	ECLA	A61K038/55; A61K038/57

AB Compns. containing a protease inhibitor and methods of use and production are described. The compns. contain an effective amount of a protease inhibitor in a carrier or diluent and are used for the treatment of inflammatory or hyperproliferative skin disorders. The carrier or diluent is preferably a gelling agent, and the composition is a topical gel formulation containing . **alpha.-1-antitrypsin** in an aqueous liquid or viscous gel formulation. Thus, a formulation contained **antitrypsin** 10.0, benzyl alc. 1.0, hydroxyethyl cellulose 2.0, and water 97.0%.

ST protease inhibitor inflammatory disease; **alpha 1**

antitrypsin inflammatory disease topical gel

IT Carcinoma
Skin, neoplasm
(Bowen's disease; compns. containing protease inhibitors for treating inflammatory diseases)

IT Sarcoma
(Kaposi's; compns. containing protease inhibitors for treating inflammatory diseases)

IT Skin, disease
(aging; compns. containing protease inhibitors for treating inflammatory diseases)

IT Dermatitis
(atopic; compns. containing protease inhibitors for treating inflammatory diseases)

IT Skin, neoplasm
(basal cell carcinoma; compns. containing protease inhibitors for treating inflammatory diseases)

IT Carcinoma
(basal cell; compns. containing protease inhibitors for treating inflammatory diseases)

IT Inflammation
Intestine, disease
(colitis; compns. containing protease inhibitors for treating inflammatory diseases)

IT Acne
Dermatitis
Digestive tract, disease
Ear, disease
Eye, disease
Gelation agents
Inflammation
Keratosis
Psoriasis
Stability
Ulcer
Urinary tract, disease
(compns. containing protease inhibitors for treating inflammatory diseases)

IT Peptides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. containing protease inhibitors for treating inflammatory diseases)

IT Eye, disease
Inflammation
(conjunctivitis; compns. containing protease inhibitors for treating inflammatory diseases)

IT Drug delivery systems
(gels, topical; compns. containing protease inhibitors for treating inflammatory diseases)

IT Skin, disease
(hyperproliferation; compns. containing protease inhibitors for treating inflammatory diseases)

IT Skin, disease
(irritation; compns. containing protease inhibitors for treating inflammatory diseases)

IT Skin, disease
(lichen planus; compns. containing protease inhibitors for treating inflammatory diseases)

IT **Ear, disease**
Inflammation
(otitis; compns. containing protease inhibitors for treating

inflammatory diseases)
IT Carcinoma
(squamous cell; compns. containing protease inhibitors for treating
inflammatory diseases)
IT Burn
(wound; compns. containing protease inhibitors for treating inflammatory
diseases)
IT 9041-92-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. containing protease inhibitors for treating inflammatory diseases)
IT 9003-01-4, Poly(acrylic acid) 9004-62-0, Hydroxyethyl cellulose
9004-64-2, Hydroxypropyl cellulose 106392-12-5, Pluronic
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gelling agent; compns. containing protease inhibitors for treating
inflammatory diseases)
IT 9001-92-7, Protease
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor; compns. containing protease inhibitors for treating
inflammatory diseases)
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Biotech Australia Pty Ltd; WO 9949887 A 1999 HCAPLUS
(2) Ceskoslovenska Akademie Ved; EP 0420600 A 1991 HCAPLUS
(3) Johnson & Johnson Medical; GB 2318732 A 1998 HCAPLUS
(4) Lezdey, J; WO 9206706 A 1992 HCAPLUS
(5) Nanosystems Llc; WO 9902665 A 1999 HCAPLUS
(6) Quay, S; WO 0130380 A 2001 HCAPLUS
(7) Sharp, P; WO 0007620 A 2000 HCAPLUS
(8) Us Agriculture; WO 0164132 A 2001
(9) Yamazaki, T; JP 57145817 A 1982 HCAPLUS
IT 9041-92-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. containing protease inhibitors for treating inflammatory diseases)
RN 9041-92-3 HCAPLUS
CN Trypsin inhibitor, α 1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L77 ANSWER 3 OF 15 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:592821 HCAPLUS
DN 140:104733
ED Entered STN: 04 Aug 2003
TI **Alpha 1-Antitrypsin and Ilomastat**
Inhibit Inflammatory Proteases Present in Human Middle Ear Effusions
AU **Antonelli, Patrick J.; Schultz, Gregory S.; Kim, Karen**
M.; Cantwell, John S.; Sundin, David J.; Pemberton, Philip
A.; Barr, Philip J.
CS Department of Otolaryngology, University of Florida,
Gainesville, FL 32610, USA
SO Laryngoscope (2003), 113(8), 1347-1351
CODEN: LARYA8; ISSN: 0023-852X
PB Lippincott Williams & Wilkins
DT Journal
LA English
CC 1-7 (Pharmacology)
Section cross-reference(s): 14
AB **Proteases** of both the serine and **metalloproteinase**
families have been shown to play a role in the pathogenesis of
otitis media (OM). Inhibitors of **proteases**
from each of these families have been shown to beneficially impact disease

progression in a number of related chronic inflammatory conditions, but their use has not been studied in OM. The purpose of this study was to assess the activity of the **protease** inhibitors recombinant **alpha 1-antitrypsin** (rAAT) and **ilomastat** on inflammatory **proteases** present in human middle ear effusions (MEEs), with a view to their potential utility in the treatment of OM. The study design was prospective and ex vivo. MEEs were collected from 100 patients presenting for middle ear surgery, most commonly **typanostomy** tube placement or treatment of acute post-**typanostomy otorrhea** (APTO). MEEs were analyzed for the presence of **matrix metalloproteinases** (**MMPs**) and human neutrophil elastase (HNE) and the inhibitory activity of rAAT and **ilomastat** on these **proteases**, resp. **MMP** levels were highest in APTO, and HNE was highest in chronic suppurative OM and APTO. High levels of **MMP** and HNE (>3 mAU/min) were found in 52% and 37% of MEEs, resp. **Ilomastat** and rAAT demonstrated significant inhibition of **MMP** and HNE activity (>30% reduction), resp., in 80% and 82% of MEEs with high levels of activity. **Proteases** are commonly found in OM. **Ilomastat** and rAAT are potent inhibitors of **proteases** in MEEs across a wide range of OM in humans. Investigation into the potential therapeutic benefits of these **protease** inhibitors is warranted.

ST antitrypsin alpha1 ilomastat inhibitor inflammatory proteinase
middle ear effusion; otitis media effusion
inflammatory proteinase inhibitor alpha1 antitrypsin ilomastat

IT Ear, disease
Inflammation
(otitis media; α 1-
antitrypsin and ilomastat inhibit inflammatory
proteinases present in human middle ear effusions)

IT Human
(α 1-antitrypsin and
ilomastat inhibit inflammatory proteinases present in human
middle ear effusions)

IT 9004-06-2, Neutrophil elastase 146480-35-5,
Matrix metalloproteinase-2 146480-36-6,
Matrix metalloproteinase-9
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibition; α 1-antitrypsin and
ilomastat inhibit inflammatory proteinases present in
human middle ear effusions)

IT 9041-92-3, α 1-Antitrypsin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(recombinant; α 1-antitrypsin and
ilomastat inhibit inflammatory proteinases present in human
middle ear effusions)

IT 142880-36-2, Ilomastat
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(α 1-antitrypsin and
ilomastat inhibit inflammatory proteinases present in human
middle ear effusions)

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Alpagot, T; J Periodontal Res 2001, V36, P169 MEDLINE
- (2) Antonelli, P; Laryngoscope (in press) 2003
- (3) Avidano, M; Otolaryngol Head Neck Surg 1998, V119, P346 MEDLINE
- (4) Brand, K; Curr Gene Ther 2002, V2, P255 HCAPLUS
- (5) Carlsson, B; Acta Otolaryngol 1983, V95, P341 MEDLINE

- (6) Cotter, C; Otolaryngol Head Neck Surg 1996, V115, P342 MEDLINE
- (7) Doring, G; Pediatr Pulmonol 1999, V28, P363 MEDLINE
- (8) Galardy, R; Ann N Y Acad Sci 1994, V732, P315 HCAPLUS
- (9) Hamaguchi, Y; Ann Otol Rhinol Laryngol Suppl 1992, V157, P26 MEDLINE
- (10) Heavner, S; Otolaryngol Head Neck Surg 2001, V125, P123 MEDLINE
- (11) Hoyle, B; J Antimicrob Chemother 1990, V26, P1 HCAPLUS
- (12) Hubbard, R; J Clin Invest 1989, V84, P1349 MEDLINE
- (13) Jennings, C; Clin Otolaryngol 2001, V26, P491 MEDLINE
- (14) Juhn, S; Ann Otol Rhinol Laryngol 1976, V85(2 Suppl 25 Pt 2), P110 MEDLINE
- (15) Lehman, D; Otolaryngol Head Neck Surg 2002, V126, P273
- (16) Lowell, S; Otolaryngol Head Neck Surg 1979, V87, P859 HCAPLUS
- (17) Miyajima, S; Microb Pathog 2001, V31, P271 HCAPLUS
- (18) Plaut, A; Vaccine 2000, V18(19(Suppl 1)), PS148
- (19) Post, J; Laryngoscope 2001, V111, P2083 MEDLINE
- (20) Scheiblaue, H; J Infect Dis 1992, V166, P783 MEDLINE
- (21) Schmidt, M; Eur Arch Otorhinolaryngol 2001, V258, P472 MEDLINE
- (22) Sebert, M; Infect Immun 2002, V70, P4059 HCAPLUS
- (23) Stiskal, J; Pediatrics 1998, V101, P89 MEDLINE
- (24) Tasker, A; Lancet 2002, V359, P493
- (25) The Alpha-1-Antitrypsin Deficiency Registry Study Group; Am J Resp Crit Care Med 1998, V158, P49
- (26) Tierney, P; Clin Otolaryngol 1995, V20, P230 MEDLINE
- (27) Travis, J; J Biol Chem 1985, V260, P4384 HCAPLUS
- (28) Trengove, N; Wound Repair Regen 1999, V7, P442 MEDLINE
- (29) Wachter, A; Ann Allergy 1992, V69, P407 MEDLINE
- (30) Weingarten, H; Anal Biochem 1985, V147, P437 HCAPLUS
- (31) Wencker, M; Chest 2001, V119, P737 HCAPLUS
- (32) Woods, D; Infect Immun 1982, V36, P1223 HCAPLUS

IT 9004-06-2, Neutrophil elastase 146480-35-5,

Matrix metalloproteinase-2 146480-36-6,

Matrix metalloproteinase-9

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibition; α 1-antitrypsin and
ilomastat inhibit inflammatory proteinases present in
human middle ear effusions)

RN 9004-06-2 HCAPLUS

CN Elastase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 146480-35-5 HCAPLUS

CN Gelatinase A (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 146480-36-6 HCAPLUS

CN Gelatinase B (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 9041-92-3, α 1-Antitrypsin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(recombinant; α 1-antitrypsin and
ilomastat inhibit inflammatory proteinases present in human
middle ear effusions)

RN 9041-92-3 HCAPLUS

CN Trypsin inhibitor, α 1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 142880-36-2, Ilomastat


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(α 1-antitrypsin and
ilomastat inhibit inflammatory proteinases present in human
middle ear effusions)

RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-
2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L77 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:42066 HCAPLUS

DN 138:112442

ED Entered STN: 17 Jan 2003

TI Compositions comprising bicarbonates and enzymes for removing human cerumen

IN Cagle, Gerald D.; Owen, Geoffrey R.; Ridruejo, Nuria Jimenez; Wall, G. Michael

PA Alcon, Inc., Switz.

SO PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003003976	A2	20030116	WO 2002-US19756	20020621 <--
	WO 2003003976	A3	20030530		
	W: AU, BR, CA, CN, JP, KR, MX, NO, NZ, PH, PL, SG, US, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	CA 2447886	AA	20030116	CA 2002-2447886	20020621 <--
	EP 1337228	A2	20030827	EP 2002-744528	20020621 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	BR 2002010493	A	20040622	BR 2002-10493	20020621 <--
	US 2004126436	A1	20040701	US 2003-705441	20031110 <--
PRAI	US 2001-302959P	P	20010703	<--	
	WO 2002-US19756	W	20020621	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003003976	ICM	A61K
WO 2003003976	ECLA	A61K009/00M; A61K031/047+M; A61K033/00+M; A61K038/48; A61K038/48K1; A61K038/48K1+M; A61K038/48L+M; A61K045/06

<--

US 2004126436 NCL 424/717.000; 514/057.000
 ECLA A61K009/00M; A61K031/047+M; A61K033/00+M; A61K038/48K1;
 A61K038/48K1+M; A61K038/48L; A61K038/48L+M; A61K045/06

<--

AB Compns. for assisting in the removal of human cerumen are disclosed. The compns. may include bicarbonate and an otol. acceptable vehicle; a cerumenolytically acceptable enzyme and an otol. acceptable vehicle; or bicarbonate, a cerumenolytically acceptable enzyme, and an otol. acceptable vehicle.

ST bicarbonate enzyme formulation human cerumen

IT Buffers
 Human
 Preservatives
 Stabilizing agents
 Surfactants
 (compns. comprising bicarbonates and enzymes for removing human cerumen)

IT Enzymes, biological studies
 Polyoxyalkylenes, biological studies
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (compns. comprising bicarbonates and enzymes for removing human cerumen)

IT Fatty acids, biological studies
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (esters; compns. comprising bicarbonates and enzymes for removing human cerumen)

IT Ear
 (external; compns. comprising bicarbonates and enzymes for removing human cerumen)

IT Alkanes, biological studies
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (long-chain, polyoxypropylene ethers; compns. comprising bicarbonates and enzymes for removing human cerumen)

IT Alcohols, biological studies
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (polyhydric; compns. comprising bicarbonates and enzymes for removing human cerumen)

IT Ear
 (wax; compns. comprising bicarbonates and enzymes for removing human cerumen)

IT 55-56-1D, Chlorhexidine, salts 56-81-5, Glycerin, biological studies
 57-55-6, Propylene glycol, biological studies 71-52-3, Bicarbonate, biological studies 144-55-8, Sodium bicarbonate, biological studies 6132-04-3, Sodium citrate dihydrate 8049-47-6, Pancreatin 9000-92-4, Amylase 9001-12-1, Collagenase 9001-62-1, Lipase 9001-73-4, Papain 9001-92-7, Protease 9002-07-7, Trypsin 9002-07-7D, Trypsin, alkyl derivs. 9002-07-7D, Trypsin, methylated derivs. 9002-89-5, Polyvinyl alcohol 9003-39-8, Povidone 9004-06-2, Elastase 9004-34-6D, Cellulose, derivs. 9014-01-1, Subtilisin 9025-49-4 9031-94-1, Aminopeptidase 9031-98-5, Carboxypeptidase 9036-06-0, Pronase E 10043-35-3, Boric acid, biological studies 11129-12-7, Borate 14127-61-8, Calcium ion, biological studies 19010-47-0 22573-93-9D, Alexidine, salts 25322-68-3, Polyethylene glycol 37341-53-0, Keratinase 42613-33-2, Dispase 75345-27-6 106392-12-5, Polyoxyethylene-polyoxypropylene block copolymer 110617-70-4, Tetronic

1304 150977-36-9, Bromelain

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(comps. comprising bicarbonates and enzymes for removing human cerumen)

IT 9001-12-1, Collagenase 9004-06-2, Elastase

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(comps. comprising bicarbonates and enzymes for removing human cerumen)

RN 9001-12-1 HCAPLUS

CN Collagenase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9004-06-2 HCAPLUS

CN Elastase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L77 ANSWER 5 OF 15 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:630455 HCAPLUS

DN 137:367821

ED Entered STN: 22 Aug 2002

TI Genetic polymorphism of α 1-inhibitor of proteinases in patients with chronic suppurative otitis media (COMS), and its complications

AU Shkorbotun, V. A.; Karpenko, G. F.; Goloborodko, O. P.

CS Kiev. Med. Akad., Kiev, Ukraine

SO Laboratorna Diagnostika (2002), (2), 22-26

CODEN: LDAIBX

PB Vidavnitstvo TOV "DIA"

DT Journal

LA Ukrainian

CC 14-10 (Mammalian Pathological Biochemistry)

Section cross-reference(s): 3

AB The paper presents some phenotypical variants and functional activity of α 1-inhibitor of proteinases in blood serum of 148 patients with chronic otitis media, suppurative (COMS) and 110 healthy persons. The M2M2 phenotype occurs in patients with COMS 7 times as often as in the control group; the phenotypical variants - M1I, M1Z and ZZ - are determined in 3 patients with otogenic complications.

ST genetic polymorphism alphas inhibitor proteinase otitis media

IT Genetic polymorphism

Human

(genetic polymorphism of proteinase α 1-inhibitor in human patients with suppurative chronic otitis media and its complications)

IT Blood serum

(genetic polymorphism of proteinase α 1-inhibitor in human patients with suppurative chronic otitis media and its complications in relation to)

IT Allele frequency

Genotypes

Phenotypes

(of genetic polymorphism of proteinase α 1-inhibitor in human patients with suppurative chronic otitis media and its complications)

IT Ear, disease

Inflammation

(otitis media, chronic suppurative; genetic polymorphism of proteinase α 1-inhibitor in human patients with suppurative chronic otitis media and its complications)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(α 1-proteinase inhibitor; genetic polymorphism of proteinase α 1-inhibitor in human patients with suppurative chronic otitis media and its complications)

IT Macroglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α 2-; genetic polymorphism of proteinase α 1-inhibitor in human patients with suppurative chronic otitis media and its complications in relation to)

IT 9041-92-3, Proteinase α 1-inhibitor
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(genetic polymorphism of proteinase α 1-inhibitor in human patients with suppurative chronic otitis media and its complications)

IT 9041-92-3, Proteinase α 1-inhibitor
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(genetic polymorphism of proteinase α 1-inhibitor in human patients with suppurative chronic otitis media and its complications)

RN 9041-92-3 HCAPLUS
CN Trypsin inhibitor, α 1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L77 ANSWER 6 OF 15 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:487756 HCAPLUS
DN 137:57557
ED Entered STN: 28 Jun 2002
TI Fusion proteins of protease inhibitors and their use in treatment of inflammatory disease
IN Barr, Philip J.; Gibson, Helen L.; Pemberton, Philip
PA Arriva Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C12N015-62
ICS C12N015-15; C07K014-81; A61K038-55; A61K038-57
CC 1-7 (Pharmacology)
Section cross-reference(s): 3, 7
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002050287	A2	20020627	WO 2001-US49256	20011218
	WO 2002050287	A3	20030918		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
 GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
 GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2430973	AA	20020627	CA 2001-2430973	20011218
AU 2002041661	A5	20020701	AU 2002-41661	20011218
US 2003073217	A1	20030417	US 2001-25514	20011218
EP 1366175	A2	20031203	EP 2001-988344	20011218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004537970	T2	20041224	JP 2002-552164	20011218
PRAI US 2000-256699P	P	20001218		
US 2001-331966P	P	20011120		
WO 2001-US49256	W	20011218		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002050287	ICM	C12N015-62
	ICS	C12N015-15; C07K014-81; A61K038-55; A61K038-57
WO 2002050287	ECLA	C07K014/81B1B1; C07K014/81B4; C07K014/81B1
US 2003073217	NCL	435/184.000; 435/069.700; 435/320.100; 435/325.000; 536/023.200
	ECLA	C07K014/81B1; C07K014/81B1B1; C07K014/81B4
JP 2004537970	FTERM	4B024/AA01; 4B024/AA11; 4B024/BA19; 4B024/CA04; 4B024/CA07; 4B024/DA02; 4B024/DA05; 4B024/DA06; 4B024/DA11; 4B024/DA12; 4B024/EA04; 4B024/GA11; 4B024/HA12; 4B064/AG23; 4B064/CA02; 4B064/CA05; 4B064/CA06; 4B064/CA10; 4B064/CA19; 4B064/CC24; 4B064/DA01; 4B065/AA01X; 4B065/AA57X; 4B065/AA72X; 4B065/AA90X; 4B065/AB01; 4B065/BA02; 4B065/CA24; 4B065/CA44; 4B065/CA46; 4C084/AA01; 4C084/AA02; 4C084/AA07; 4C084/BA02; 4C084/BA22; 4C084/DC32; 4C084/DC34; 4C084/DC50; 4C084/NA14; 4C084/ZA341; 4C084/ZA591; 4C084/ZA941; 4C084/ZC201; 4C084/ZC551; 4H045/AA10; 4H045/AA20; 4H045/AA30; 4H045/BA10; 4H045/BA41; 4H045/CA40; 4H045/DA56; 4H045/EA20; 4H045/EA29; 4H045/FA74

AB Fusion proteins of protease inhibitors are provided, in particular fusion proteins of **.alpha.1-antitrypsin** (AAT) and a second protease inhibitor, such as secretory leukocyte protease inhibitor (SLPI) or tissue inhibitor of metalloproteases (TIMP). Chimeric genes encoding the fusion proteins, and expression vectors and hosts for manufacture of the proteins are also provided. Methods of making the fusion proteins of the invention are also provide, as well as methods of using the fusion proteins, for example to inhibit protease activity in a biol. sample or in the treatment of an individual suffering from, or at risk for, a disease or disorder involving unwanted protease activity. The construction and expression of chimeric genes for a number of fusion proteins is described. Effective inhibition of elastase and trypsin by the fusion proteins is demonstrated.

ST proteinase inhibitor fusion protein inflammatory disease treatment; antitrypsin fusion protein inflammatory disease treatment; secretory leukocyte protease inhibitor fusion protein inflammatory disease treatment; TIMP1 antitrypsin fusion protein inflammatory disease treatment

IT Lung, disease
 (chronic obstructive, protease inhibition in treatment of; fusion proteins of protease inhibitors and their use in treatment of inflammatory disease)

IT *Saccharomyces cerevisiae*
 (expression host; fusion proteins of protease inhibitors and their use in treatment of inflammatory disease)

- IT Chimeric gene, animal
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(for proteinase inhibitor fusion proteins; fusion proteins of protease inhibitors and their use in treatment of inflammatory disease)
- IT Human
(fusion proteins of protease inhibitors and their use in treatment of inflammatory disease)
- IT Protein sequences
(of proteinase inhibitor fusion proteins of human; fusion proteins of protease inhibitors and their use in treatment of inflammatory disease)
- IT Ear, disease
Inflammation
(otitis media, protease inhibition in treatment of; fusion proteins of protease inhibitors and their use in treatment of inflammatory disease)
- IT Ear, disease
Inflammation
(otitis, otitis externa, protease inhibition in treatment of; fusion proteins of protease inhibitors and their use in treatment of inflammatory disease)
- IT AIDS (disease)
Asthma
Cystic fibrosis
Emphysema
Inflammation
(protease inhibition in treatment of; fusion proteins of protease inhibitors and their use in treatment of inflammatory disease)
- IT Anti-AIDS agents
(protease inhibitor fusion proteins as; fusion proteins of protease inhibitors and their use in treatment of inflammatory disease)
- IT Fermentation
(protein, of proteinase inhibitor fusion proteins, with yeast; fusion proteins of protease inhibitors and their use in treatment of inflammatory disease)
- IT 439122-04-0
RL: PRP (Properties)
(Unclaimed; fusion proteins of protease inhibitors and their use in treatment of inflammatory disease)
- IT 138729-66-5P 439122-02-8P 439540-54-2P 439540-55-3P 439540-56-4P 439540-57-5P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; fusion proteins of protease inhibitors and their use in treatment of inflammatory disease)
- IT 9041-92-3DP, α 1-Antitrypsin,
fusion proteins 122320-05-2DP, Secretory leukocyte protease inhibitor,
fusion proteins 140208-24-8DP, TIMP-1, fusion proteins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fusion proteins of protease inhibitors and their use in treatment of inflammatory disease)
- IT 9004-06-2, Elastase 37259-58-8, Serine proteinase 37353-41-6,
Cysteine proteinase 78169-47-8, Aspartyl proteinase 81669-70-7,
Metalloproteinase 97501-93-4, Trypsin 146480-36-6,
Matrix metalloproteinase 9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic inhibition of; fusion proteins of protease

inhibitors and their use in treatment of inflammatory disease)
IT 439542-29-7, 1: PN: WO0250287 SEQID: 1 unclaimed DNA 439542-31-1, 3: PN: WO0250287 SEQID: 3 unclaimed DNA 439542-33-3, 5: PN: WO0250287 SEQID: 5 unclaimed DNA 439542-35-5, 7: PN: WO0250287 SEQID: 7 unclaimed DNA 439542-36-6, 8: PN: WO0250287 SEQID: 9 unclaimed DNA 439542-37-7, 9: PN: WO0250287 SEQID: 11 unclaimed DNA 439542-38-8 439542-39-9 439542-40-2 439542-41-3 439542-42-4 439542-44-6 439542-46-8 439542-48-0 439542-50-4 439542-54-8 439542-56-0
RL: PRP (Properties)

(unclaimed nucleotide sequence; fusion proteins of protease inhibitors and their use in treatment of inflammatory disease)
IT 439542-30-0 439542-32-2 439542-34-4 439542-43-5 439542-45-7 439542-47-9 439542-49-1 439542-51-5 439542-53-7 439542-55-9 439542-57-1

RL: PRP (Properties)
(unclaimed protein sequence; fusion proteins of protease inhibitors and their use in treatment of inflammatory disease)

IT 439542-52-6
RL: PRP (Properties)
(unclaimed sequence; fusion proteins of protease inhibitors and their use in treatment of inflammatory disease)

IT 9041-92-3DP, α 1-Antitrypsin, fusion proteins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fusion proteins of protease inhibitors and their use in treatment of inflammatory disease)

RN 9041-92-3 HCAPLUS
CN Trypsin inhibitor, α 1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 9004-06-2, Elastase 146480-36-6, Matrix metalloproteinase 9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic inhibition of; fusion proteins of protease inhibitors and their use in treatment of inflammatory disease)

RN 9004-06-2 HCAPLUS
CN Elastase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 146480-36-6 HCAPLUS
CN Gelatinase B (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L77 ANSWER 7 OF 15 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:628010 HCAPLUS
DN 133:217681
ED Entered STN: 10 Sep 2000
TI Inhibitors of serine protease activity, and methods and compositions for treatment of herpes virus infections
IN Shapiro, Leland
PA The Trustees of University Technology Corporation, USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K038-08
ICS A61K038-57; A61P031-22

CC 1-5 (Pharmacology)

Section cross-reference(s): 63

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000051625	A1	20000908	WO 2000-US5557	20000303 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1999-123167P	P	19990305 <--		
	US 1999-153942P	P	19990915 <--		

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	WO 2000051625	ICM	A61K038-08
		ICS	A61K038-57; A61P031-22
	WO 2000051625	ECLA	A61K038/08; A61K038/57 <--
OS	MARPAT 133:217681		
AB	<p>Comps. and methods of treating and preventing a viral infection are provided. A method of blocking a viral infection facilitated by a serine proteolytic (SP) activity is disclosed, which involves administering to a subject suffering or about to suffer from a viral infection a therapeutically effective amount of a substance having serine protease inhibitory activity or serpin activity. Among the substances found to be useful are .alpha.1-antitrypsin (AAT), peptide derivs. from the carboxy terminal end of AAT and synthetic drugs mimicking the action of such substances. The invention is particularly well suited for checking a viral infection mediated by members of herpesviridae family.</p>		
ST	antiviral herpes serine protease inhibitor; antitrypsin alphas1 antiviral herpes; peptide antitrypsin alphas1 antiviral herpes		
IT	AIDS (disease) (AIDS-related lymphoma; serine protease inhibitors and methods and comps. for treatment of herpes virus infections)		
IT	Antitumor agents (B-cell lymphoma; serine protease inhibitors and methods and comps. for treatment of herpes virus infections)		
IT	Antitumor agents (Burkitt's lymphoma; serine protease inhibitors and methods and comps. for treatment of herpes virus infections)		
IT	Lymph node (Castleman's disease; serine protease inhibitors and methods and comps. for treatment of herpes virus infections)		
IT	Disease, animal (Gardner's syndrome; serine protease inhibitors and methods and comps. for treatment of herpes virus infections)		
IT	Nervous system (Guillain-Barre syndrome; serine protease inhibitors and methods and comps. for treatment of herpes virus infections)		
IT	Antitumor agents Antitumor agents (Hodgkin's disease inhibitors; serine protease inhibitors and methods and comps. for treatment of herpes virus infections)		
IT	Antitumor agents		

- (Kaposi's sarcoma; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Neoplasm
(Li-Fraumeni syndrome; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Antitumor agents
(T-cell lymphoma; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Sulfones
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amidino; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Hyperplasia
(angiolymphoid; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Mouth
Mouth
(aphthous ulcer, inhibitors; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Antiulcer agents
(aphthous ulcer; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Dermatitis
(atopic; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Skin, neoplasm
(basal cell nevus syndrome; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Antitumor agents
(carcinoma; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Uterus, neoplasm
Uterus, neoplasm
(cervix, inhibitors; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Antitumor agents
(cervix; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Disease, animal
(chills; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Cosmetics
(creams, and ointments; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Carboxylic acids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dicarboxylic, esters, phenylene dialkanoate esters; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Mouth
(disease, idiopathic burning mouth; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Mucous membrane
(disease; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Drugs

- (gastrointestinal; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Gingiva
(gingivitis; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Mouth
(hairy leukoplakia; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Blood vessel, neoplasm
Blood vessel, neoplasm
(hemangiosarcoma, inhibitors; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Antitumor agents
(hemangiosarcoma; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Nucleic acids
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(herpes viral; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Disease, animal
(herpes virus infection-caused; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Digestive tract
Eye, disease
Lung, disease
Mouth
Respiratory tract
Urogenital tract
(infection; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Hodgkin's disease
Hodgkin's disease
(inhibitors; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Eye, disease
(keratoconjunctivitis; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Transplant and Transplantation
Transplant and Transplantation
(kidney, epithelial tumors associated with; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Cosmetics
(lotions, and solns.; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Drug delivery systems
(lotions; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Lymph node
(lymphadenopathy, angioimmunoblastic; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Antitumor agents
(lymphoma; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Disease, animal
(malaise; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Mesothelium
Mesothelium
(mesothelioma, inhibitors; serine protease inhibitors and methods and

compns. for treatment of herpes virus infections)

IT Antitumor agents
(mesothelioma; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)

IT Ear
(middle, infection; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)

IT Erythema
(multiforme; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)

IT Antitumor agents
(multiple myeloma; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)

IT Antitumor agents
(nasopharynx carcinoma; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)

IT Pharynx
Pharynx
(nasopharynx, carcinoma, inhibitors; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)

IT Prostate gland
Prostate gland
(neoplasm, inhibitors; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)

IT Nervous system
(neurofibromatosis type 1; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)

IT Nerve, disease
(neuropathy; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)

IT Drug delivery systems
(ointments, creams; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)

IT Drug delivery systems
(ointments; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)

IT Pharynx
(pharyngitis; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)

IT Neoplasm
(plexopathy from tumor infiltration; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)

IT Nerve, disease
(polyneuropathy; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)

IT Transplant and Transplantation
(post-transplantation lymphoproliferative disease; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)

IT Antitumor agents
(prostate gland; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)

IT Drug delivery systems
(rectal; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)

IT Eye, neoplasm
Eye, neoplasm
(retinoblastoma, inhibitors; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)

IT Antitumor agents

- (retinoblastoma; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Nose
(rhinitis; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Peritoneum
(septic peritonitis; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Antidiarrheals
Antipyretics
Antiviral agents
Behcet's syndrome
Cosmetics
Cytomegalovirus
Drug delivery systems
Encephalitis
Herpesviridae
Human herpesvirus
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 4
Human herpesvirus 5
Human herpesvirus 6
Human herpesvirus 8
Lymphoproliferative disorders
Mononucleosis
Nervous system agents
Sexually transmitted diseases
Skin, disease
Werner syndrome
(serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Peptides, biological studies
Sulfides, biological studies
Sulfoxides
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Analgesics
Anesthetics
Antibiotics
(serine protease inhibitors and methods and compns. for treatment of herpes virus infections, and use with other agents)
- IT Drug delivery systems
(solns.; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Drug delivery systems
(topical; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Kidney
Kidney
(transplant, epithelial tumors associated with; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Drug delivery systems
(unit doses; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Drug delivery systems

- (vaginal; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Human herpesvirus 3
(varicella from, skin sores; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Hepatitis
(viral, herpetic; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Reproductive organ
Reproductive tract
(vulva, neoplasm, inhibitors; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT Antitumor agents
(vulva; serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT 37259-58-8, Serine protease
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT 9041-92-3, α 1 Antitrypsin
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT 145852-04-6 145852-05-7 145852-06-8 145852-07-9 145852-08-0
145852-14-8 145852-15-9 180526-15-2 291296-75-8 291296-76-9
291296-77-0 291296-78-1 291296-79-2 291296-80-5 291296-81-6
291296-82-7 291296-83-8 291296-84-9 291296-85-0 291296-86-1
291296-87-2 291296-88-3 291296-89-4 291296-90-7 291296-91-8
291296-92-9 291296-93-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT 98-10-2D, Benzenesulfonamide, derivs. 289-06-5D, Thiadiazole, derivs.
11120-54-0D, Oxadiazole, derivs. 27988-97-2D, Tetrazole, derivs.
37306-44-8D, Triazole, peptoid derivs. 179752-50-2 179752-51-3
179752-52-4 179752-53-5 179752-54-6 179752-55-7 179752-56-8
179752-57-9 179752-58-0 179752-59-1 179752-60-4 179752-61-5
179752-62-6 179752-64-8 179752-65-9 208840-11-3 208840-12-4
208840-13-5 208840-14-6 208840-18-0 208840-19-1 208840-20-4
208840-21-5 208840-22-6 208840-24-8 208840-25-9 208840-27-1
208840-28-2 208840-39-5 208845-34-5 208845-35-6 208845-38-9
208845-39-0 208845-40-3 208845-43-6 208845-56-1 208845-62-9
208845-63-0 208845-65-2 208845-66-3 208845-77-6 208845-85-6
208846-02-0 208846-03-1 208846-13-3 208847-42-1 208847-55-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(serine protease inhibitors and methods and compns. for treatment of herpes virus infections)
- IT 9004-06-2, Elastase 56645-49-9, Cathepsin G 128028-50-2,
Proteinase-3 186322-81-6, Caspase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(serine protease inhibitors and methods and compns. for treatment of

herpes virus infections)
 IT 292094-96-3
 RL: PRP (Properties)
 (unclaimed protein sequence; inhibitors of serine protease activity,
 and methods and compns. for treatment of herpes virus infections)
 RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE
 (1) Cortech; WO 9824806 A 1998 HCAPLUS
 (2) Emory University; WO 9846597 A 1998 HCAPLUS
 (3) Lezdey, J; WO 9407525 A 1994 HCAPLUS
 IT 9041-92-3, α 1 Antitrypsin
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological
 process); BSU (Biological study, unclassified); THU (Therapeutic use);
 BIOL (Biological study); PROC (Process); USES (Uses)
 (serine protease inhibitors and methods and compns. for treatment of
 herpes virus infections)
 RN 9041-92-3 HCAPLUS
 CN Trypsin inhibitor, α 1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 9004-06-2, Elastase
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
 (Biological study); PROC (Process)
 (serine protease inhibitors and methods and compns. for treatment of
 herpes virus infections)
 RN 9004-06-2 HCAPLUS
 CN Elastase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L77 ANSWER 8 OF 15 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2000:628008 HCAPLUS
 DN 133:217724
 ED Entered STN: 10 Sep 2000
 TI Inhibitors of serine protease activity, and methods and compositions for
 treatment of nitric oxide-induced clinical conditions
 IN Shapiro, Leland
 PA The Trustees of University Technology Corp., USA
 SO PCT Int. Appl., 50 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K038-00
 CC 1-12 (Pharmacology)
 Section cross-reference(s): 63

FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000051623	A2	20000908	WO 2000-US5556	20000303 <--
WO 2000051623	A3	20001214		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG US 6489308 B1 20021203 US 2000-518097 20000303 <--				

PRAI US 1999-123167P P 19990305 <--
 US 1999-156523P P 19990929 <--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000051623	ICM	A61K038-00
WO 2000051623	ECLA	A61K038/08; A61K038/57 <--
US 6489308	NCL	514/045.000; 514/423.000; 514/454.000; 514/613.000
	ECLA	A61K038/57+M <--
AB	A method of treating and preventing diseases is provided. In particular, compns. and methods of blocking diseases associated with aberrant levels of nitric oxide and facilitated by a serine proteolytic activity are disclosed, which consist of administering to a subject a therapeutically effective amount of a compound having a serine protease inhibitory activity. Among effective compds. are .alpha.1-antitrypsin and synthetic drugs mimicking some or all of the actions of .alpha.1-antitrypsin .	
ST	serine protease inhibitor NO assocd disease; nitric oxide assocd disease	
IT	Intestine, disease (Hirschsprung's disease; serine protease inhibitors for treatment of NO-induced diseases)	
IT	Transcription factors RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (NF-κB (nuclear factor κB); serine protease inhibitors for treatment of NO-induced diseases)	
IT	Receptors RL: BSU (Biological study, unclassified); BIOL (Biological study) (PAR (proteinase-activated receptors), inhibitors; serine protease inhibitors for treatment of NO-induced diseases)	
IT	Pancreas, disease (acute pancreatitis; serine protease inhibitors for treatment of NO-induced diseases)	
IT	Respiratory distress syndrome (adult; serine protease inhibitors for treatment of NO-induced diseases)	
IT	Aging, animal (age-associated memory impairment; serine protease inhibitors for treatment of NO-induced diseases)	
IT	Nervous system (amyotrophic lateral sclerosis; serine protease inhibitors for treatment of NO-induced diseases)	
IT	Artery (angioplasty; serine protease inhibitors for treatment of NO-induced diseases)	
IT	Antiartherosclerotics (antiatherosclerotics; serine protease inhibitors for treatment of NO-induced diseases)	
IT	Heart, disease (autoimmune myocarditis; serine protease inhibitors for treatment of NO-induced diseases)	
IT	Antibodies RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (blocking; serine protease inhibitors for treatment of NO-induced diseases)	
IT	Drug delivery systems (buccal; serine protease inhibitors for treatment of NO-induced	

diseases)

IT Development, mammalian postnatal
(child; pediatric respiratory failure; serine protease inhibitors for treatment of NO-induced diseases)

IT Lung, disease
(chronic obstructive; serine protease inhibitors for treatment of NO-induced diseases)

IT Liver, disease
Lung, disease
(chronic; serine protease inhibitors for treatment of NO-induced diseases)

IT Artery
(coronary, ectasia; serine protease inhibitors for treatment of NO-induced diseases)

IT Artery, disease
(coronary; serine protease inhibitors for treatment of NO-induced diseases)

IT Nervous system
(degeneration; serine protease inhibitors for treatment of NO-induced diseases)

IT Nerve, disease
(diabetic neuropathy; serine protease inhibitors for treatment of NO-induced diseases)

IT Uterus, disease
(dysfunctional bleeding; serine protease inhibitors for treatment of NO-induced diseases)

IT Kidney, disease
(end-stage; serine protease inhibitors for treatment of NO-induced diseases)

IT Drug delivery systems
(epidural; serine protease inhibitors for treatment of NO-induced diseases)

IT Heart, disease
(failure; serine protease inhibitors for treatment of NO-induced diseases)

IT Stomach, disease
(gastritis; serine protease inhibitors for treatment of NO-induced diseases)

IT Drugs
(gastrointestinal; serine protease inhibitors for treatment of NO-induced diseases)

IT Stress, animal
(heat; serine protease inhibitors for treatment of NO-induced diseases)

IT Hypoxia, animal
(hypoxemia, hypoxemic respiratory failure; serine protease inhibitors for treatment of NO-induced diseases)

IT Heart, disease
(infarction; serine protease inhibitors for treatment of NO-induced diseases)

IT Joint, anatomical
Respiratory tract
(inflammation; serine protease inhibitors for treatment of NO-induced diseases)

IT Intestine, disease
(inflammatory; serine protease inhibitors for treatment of NO-induced diseases)

IT Stomach, neoplasm
Stomach, neoplasm
(inhibitors; serine protease inhibitors for treatment of NO-induced diseases)

- IT Drug delivery systems
(injections, i.m.; serine protease inhibitors for treatment of NO-induced diseases)
- IT Drug delivery systems
(injections, i.v.; serine protease inhibitors for treatment of NO-induced diseases)
- IT Drug delivery systems
(injections, s.c.; serine protease inhibitors for treatment of NO-induced diseases)
- IT Reperfusion
(injury; serine protease inhibitors for treatment of NO-induced diseases)
- IT Drug delivery systems
(intracerebrovascular; serine protease inhibitors for treatment of NO-induced diseases)
- IT Drug delivery systems
(intrathecal; serine protease inhibitors for treatment of NO-induced diseases)
- IT Brain, disease
Heart, disease
Kidney, disease
Liver, disease
Lung, disease
(ischemia; serine protease inhibitors for treatment of NO-induced diseases)
- IT Apparatus
(mech. device for reestablishment of blood flow; serine protease inhibitors for treatment of NO-induced diseases)
- IT Circulation
(mech. device for reestablishment of; serine protease inhibitors for treatment of NO-induced diseases)
- IT Drug delivery systems
(nasal; serine protease inhibitors for treatment of NO-induced diseases)
- IT Newborn
(neonatal respiratory failure; serine protease inhibitors for treatment of NO-induced diseases)
- IT Toxicity
(nephrotoxicity; serine protease inhibitors for treatment of NO-induced diseases)
- IT cDNA
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(of inhibitory kinases; serine protease inhibitors for treatment of NO-induced diseases)
- IT Drug delivery systems
(oral; serine protease inhibitors for treatment of NO-induced diseases)
- IT Drug delivery systems
(osmotic pumps; serine protease inhibitors for treatment of NO-induced diseases)
- IT Ear
(otitis, otitis media, chronic; serine protease inhibitors for treatment of NO-induced diseases)
- IT Drug delivery systems
(parenterals; serine protease inhibitors for treatment of NO-induced diseases)
- IT Antioxidants
(pharmaceutical; serine protease inhibitors for treatment of NO-induced diseases)

IT Pleura
(pleurisy; serine protease inhibitors for treatment of NO-induced diseases)

IT Fatty acids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyunsatd., omega-3, and complexes; serine protease inhibitors for treatment of NO-induced diseases)

IT Fatty acids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyunsatd., omega-6, and complexes; serine protease inhibitors for treatment of NO-induced diseases)

IT Disease, animal
(primary ciliary dyskinesia; serine protease inhibitors for treatment of NO-induced diseases)

IT Antihypertensives
(pulmonary; serine protease inhibitors for treatment of NO-induced diseases)

IT Drug delivery systems
(rectal; serine protease inhibitors for treatment of NO-induced diseases)

IT Breathing (animal)
(respiratory failure, acute; serine protease inhibitors for treatment of NO-induced diseases)

IT Eye, disease
(retinopathy; serine protease inhibitors for treatment of NO-induced diseases)

IT Shock (circulatory collapse)
(septic; serine protease inhibitors for treatment of NO-induced diseases)

IT Animal tissue culture
Anti-AIDS agents
Anti-Alzheimer's agents
Anti-inflammatory agents
Anti-ischemic agents
Antiarthritics
Antiasthmatics
Antidiabetic agents
Antiglaucoma agents
Antihypertensives
Antimalarials
Antimigraine agents
Antiparkinsonian agents
Antirheumatic agents
Antitumor agents
Antiviral agents
Autoimmune disease
Blood vessel, disease
Bone, disease
Cardiovascular agents
Cirrhosis
Cognition enhancers
Cytomegalovirus
Dysmenorrhea
Human herpesvirus 1
Ischemia
Liver, disease

Lung, disease
 Lyme disease
 Nervous system agents
 Organ, animal
 Oxidative stress, biological
 Preeclampsia
 Protozoacides
 Radical scavengers
 Sick cell anemia
 Thrombolytics
 (serine protease inhibitors for treatment of NO-induced diseases)
 IT Cytokines
 Lipopolysaccharides
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (serine protease inhibitors for treatment of NO-induced diseases)
 IT Hemoglobins
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (serine protease inhibitors for treatment of NO-induced diseases)
 IT Myoglobins
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (serine protease inhibitors for treatment of NO-induced diseases)
 IT Reactive oxygen species
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (serine protease inhibitors for treatment of NO-induced diseases)
 IT Antitumor agents
 Antitumor agents
 (stomach; serine protease inhibitors for treatment of NO-induced diseases)
 IT Brain, disease
 (stroke; serine protease inhibitors for treatment of NO-induced diseases)
 IT Lupus erythematosus
 (systemic; serine protease inhibitors for treatment of NO-induced diseases)
 IT Multiple sclerosis
 (therapeutic agents; serine protease inhibitors for treatment of NO-induced diseases)
 IT Kidney
 (toxicity; serine protease inhibitors for treatment of NO-induced diseases)
 IT Drug delivery systems
 (transdermal; serine protease inhibitors for treatment of NO-induced diseases)
 IT Brain, disease
 (trauma; serine protease inhibitors for treatment of NO-induced diseases)
 IT Kidney, disease
 (tubulointerstitial, acquired; serine protease inhibitors for treatment of NO-induced diseases)
 IT Drug delivery systems
 (vaginal; serine protease inhibitors for treatment of NO-induced diseases)
 IT Interferons

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(γ; serine protease inhibitors for treatment of NO-induced diseases)

IT Headache

('hot dog headache'; serine protease inhibitors for treatment of NO-induced diseases)

IT 56-86-0, L-Glutamic acid, biological studies

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(glutamate-induced asthma and glutamate-induced Chinese restaurant syndrome; serine protease inhibitors for treatment of NO-induced diseases)

IT 289-06-5D, Thiadiazole, derivs. 11120-54-0D, Oxadiazole, derivs.

37306-44-8D, Triazole, peptoid derivs.

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(inhibitors; serine protease inhibitors for treatment of NO-induced diseases)

IT 9004-06-2, Elastase 125978-95-2, Nitric oxide synthase

128028-50-2, Proteinase-3

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitors; serine protease inhibitors for treatment of NO-induced diseases)

IT 9001-92-7, Protease 9031-44-1, Kinase

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(inhibitory; serine protease inhibitors for treatment of NO-induced diseases)

IT 50-81-7, Vitamin C, biological studies 50-81-7D, Vitamin C, complexes

52-90-4, Cysteine, biological studies 52-90-4D, Cysteine, complexes

55-63-0, Nitroglycerine 56-06-4, 2,4-Diamino-6-hydroxypyrimidine

71-44-3, Spermine 79-17-4, Aminoguanidine 100-33-4 124-20-9,

Spermidine 140-64-7, Pentamidine isethionate 151-16-6 298-83-9,

p-Nitroblue tetrazolium chloride 432-70-2, α-Carotene 432-70-2D,

α-Carotene, complexes 458-37-7, Curcumin 458-37-7D, Curcumin,

complexes 616-91-1, N-Acetylcysteine 616-91-1D, N-Acetylcysteine,

complexes 867-44-7 1071-37-0, 2-Ethyl-2-thiopseudourea hydrobromide

1190-74-5, Mercaptoethylguanidine 1406-18-4, Vitamin E 1406-18-4D,

Vitamin E, complexes 2149-70-4 2751-09-9, Troleandomycin 2942-42-9,

7-Nitroindazole 2986-19-8, S-Methylisothiurea 2986-20-1,

S-Ethylisothiurea 4673-26-1 7235-40-7, β-Carotene 7235-40-7D,

β-Carotene, complexes 7782-49-2, Selenium, biological studies

7782-49-2D, Selenium, complexes, biological studies 8001-27-2, Hirudin

9041-92-3, α 1-Antitrypsin

9054-89-1, Superoxide dismutase 9054-89-1D, Superoxide dismutase,

complexes 11103-57-4, Vitamin A 11103-57-4D, Vitamin A, complexes

13395-35-2, 2-Iminobiotin 17035-90-4 18144-22-4 20933-81-7

21835-19-8 22722-03-8, S-Ethylisothiurea sulfate 25769-03-3,

1-Pyrrolidinecarbodithioic acid 30344-00-4 33876-97-0 36889-13-1

50912-92-0 53774-63-3 57564-91-7, S-Nitroso-glutathione 66036-77-9,

NG-Nitro-D-arginine 74209-34-0, 3-Bromo-7-nitroindazole 75830-53-4

79032-48-7, S-Nitroso-N-acetylpenicillamine 112229-23-9 133587-00-5,

NG-Monomethyl-L-arginine acetate 137694-74-7 150403-88-6

156719-37-8, L-Thiocitrulline 156719-41-4, S-Methyl-L-thiocitrulline

179752-50-2 179752-51-3 179752-52-4 179752-53-5 179752-54-6

179752-55-7 179752-56-8 179752-57-9 179752-58-0 179752-59-1
179752-60-4 179752-61-5 179752-62-6 179752-64-8 179752-65-9
208840-11-3 208840-12-4 208840-13-5 208840-14-6 208840-18-0
208840-19-1 208840-20-4 208840-21-5 208840-22-6 208840-24-8
208840-25-9 208840-27-1 208840-28-2 208840-39-5 208845-34-5
208845-35-6 208845-38-9 208845-39-0 208845-40-3 208845-43-6
208845-56-1 208845-62-9 208845-63-0 208845-65-2 208845-66-3
208845-77-6 208845-85-6 208846-02-0 208846-03-1 208846-13-3
208847-42-1 208847-55-6 209248-80-6 209248-86-2 209589-59-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(serine protease inhibitors for treatment of NO-induced diseases)

IT 7782-44-7D, Oxygen, reactive species, biological studies 10102-43-9,
Nitric oxide, biological studies 137632-07-6, p44 MAP kinase
137632-08-7, p42 MAP kinase

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(serine protease inhibitors for treatment of NO-induced diseases)

IT 292094-95-2

RL: PRP (Properties)

(unclaimed protein sequence; inhibitors of serine protease activity, and methods and compns. for treatment of nitric oxide-induced clin. conditions)

IT 9004-06-2, Elastase

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; serine protease inhibitors for treatment of NO-induced diseases)

RN 9004-06-2 HCAPLUS

CN Elastase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 9041-92-3, α 1-Antitrypsin

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(serine protease inhibitors for treatment of NO-induced diseases)

RN 9041-92-3 HCAPLUS

CN Trypsin inhibitor, α 1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L77 ANSWER 9 OF 15 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1994:587340 HCAPLUS

DN 121:187340

ED Entered STN: 15 Oct 1994

TI Treatment of inflammation with serine protease inhibitors

IN Lezdey, John; Wachter, Allan

PA USA

SO U.S., 4 pp. Cont.-in-part of U.S. 5,217,951.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K037-64

INCL 514008000

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI	US 5290762	A	19940301	US 1993-18888	19930217 <--
	US 5008242	A	19910416	US 1989-445005	19891204 <--
	CA 2019974	AA	19910604	CA 1990-2019974	19900627 <--
	CA 2019974	C	20020122		
	EP 432117	A1	19910612	EP 1990-850286	19900829 <--
	EP 432117	B1	19940622		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	ES 2055406	T3	19940816	ES 1990-850286	19900829 <--
	JP 03181422	A2	19910807	JP 1990-238844	19900906 <--
	US 5114917	A	19920519	US 1990-591630	19901002 <--
	US 5166134	A	19921124	US 1991-710055	19910604 <--
	US 5217951	A	19930608	US 1991-781003	19911018 <--
PRAI	US 1986-946445	B2	19861224	<--	
	US 1988-181707	A2	19880414	<--	
	US 1988-242735	B2	19880909	<--	
	US 1989-445005	A2	19891204	<--	
	US 1990-591630	A2	19901002	<--	
	US 1990-598241	B2	19901016	<--	
	US 1991-643727	B2	19910118	<--	
	US 1991-781003	A2	19911018	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 5290762	ICM	A61K037-64
	INCL	514008000
US 5290762	NCL	514/008.000; 514/002.000; 514/012.000; 514/021.000 <--
US 5008242	NCL	514/008.000; 514/021.000; 530/380.000; 530/395.000; 530/397.000 <--
EP 432117	ECLA	A61K009/127; A61K038/57 <--
US 5114917	NCL	514/008.000; 514/002.000; 514/012.000; 514/021.000; 530/397.000 <--
US 5166134	NCL	514/008.000; 514/002.000; 514/012.000; 514/021.000 <--
US 5217951	NCL	514/008.000; 514/002.000; 514/021.000; 530/395.000 <--
AB	A method for the prophylaxis or direct treatment of inflammatory diseases or injuries comprises administering to the site of the disease or injury an effective amount of at least one serine protease inhibitor, its salts, derivs. or analogs which bind with the mast cell mediators, T-cell mediators or kallikrein. For example, a topical cream contained α -2 macroglobulin 1.0, olive oil 5.0, cetanol 2.0, stearic acid 5.0, glyceride 12.0, Tween-60 0.5, propylene glycol 0.5, methylparaben 0.1, propylparaben 0.02, and purified water to 100 g.	
ST	antiinflammatory serine protease inhibitor topical prepn	
IT	Mast cell (mediators; treatment of inflammation with serine protease inhibitors)	
IT	Antihistaminics Basophil Eosinophil Neutrophil Psoriasis Virucides and Virustats (treatment of inflammation with serine protease inhibitors)	
IT	Kinins (animal hormones) RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (treatment of inflammation with serine protease inhibitors)	
IT	Proteins, specific or class RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (C-reactive, treatment of inflammation with serine protease inhibitors)	

IT Immunoglobulins
 RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (E, treatment of inflammation with serine protease inhibitors)

IT Proteins, specific or class
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (SAA (serum amyloid A), treatment of inflammation with serine protease inhibitors)

IT Lymphocyte
 (T-cell, mediators; treatment of inflammation with serine protease inhibitors)

IT Ear
 (disease, otitis, treatment of inflammation with serine protease inhibitors)

IT Eye, disease
 (inflammation, treatment of inflammation with serine protease inhibitors)

IT Pharmaceutical dosage forms
 (ointments, treatment of inflammation with serine protease inhibitors)

IT Pharmaceutical dosage forms
 (ointments, creams, treatment of inflammation with serine protease inhibitors)

IT Pharmaceutical dosage forms
 (solns., treatment of inflammation with serine protease inhibitors)

IT Macroglobulins
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (α 2-, treatment of inflammation with serine protease inhibitors)

IT 122320-05-2, Secretory leukocyte protease inhibitor 138757-15-0
 139691-92-2, Serine protease inhibitor
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (treatment of inflammation with serine protease inhibitors)

IT 9004-06-2, Elastase 56645-49-9, Cathepsin G
 RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (treatment of inflammation with serine protease inhibitors)

IT 9004-06-2, Elastase
 RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (treatment of inflammation with serine protease inhibitors)

RN 9004-06-2 HCAPLUS
 CN Elastase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L77 ANSWER 10 OF 15 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1992:123636 HCAPLUS
 DN 116:123636
 ED Entered STN: 03 Apr 1992
 TI ELISA to determine immunoreactive Pseudomonas aeruginosa elastase in chronic suppurative otitis media
 AU Jin, Chun Shun; Hamaguchi, Yukiyo; Sakakura, Yasuo
 CS Sch. Med., Mie Univ., Tsu, 514, Japan
 SO International Archives of Allergy and Applied Immunology (1991), 96(3), 193-8

CODEN: IAAAAAM; ISSN: 0020-5915
DT Journal
LA English
CC 7-1 (Enzymes)
Section cross-reference(s): 14
AB A sensitive sandwich ELISA was developed to measure the levels of *P. aeruginosa* elastase (PE) in ear discharges from chronic suppurative otitis media (CSOM) patients. Preincubation of the sample with EDTA before ELISA was employed to inhibit PE activity which hydrolyzes the anti-PE IgG antibody into a smaller mol. form. The PE levels of 10 middle ear effusions (MEE) from chronic otitis media with effusion were also measured. In CSOM, 9 of 10 samples had significant PE levels, ranging from 6.8 to 62.1 µg/mL, which were significantly higher than those in MEE, the majority of which was below the detection limit. Two samples of CSOM with the *P. aeruginosa* infection showed high PE levels. This sandwich ELISA for the measurement of PE is a very sensitive method requiring only a small sample amount
ST elastase Pseudomonas detn ELISA otitis media
IT Pseudomonas aeruginosa
(elastase of, determination of immunoreactive, in ear discharges of humans with chronic suppurative otitis media, ELISA for)
IT Ear
(disease, otitis media, elastase of Pseudomonas aeruginosa in ear discharges of humans with chronic suppurative, ELISA for determination of immunoreactive)
IT 9004-06-2, Elastase
RL: ANST (Analytical study)
(determination of immunoreactive, of Pseudomonas aeruginosa in ear discharges of humans with chronic suppurative otitis media, ELISA for)
IT 9004-06-2, Elastase
RL: ANST (Analytical study)
(determination of immunoreactive, of Pseudomonas aeruginosa in ear discharges of humans with chronic suppurative otitis media, ELISA for)
RN 9004-06-2 HCAPLUS
CN Elastase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L77 ANSWER 11 OF 15 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1991:245275 HCAPLUS
DN 114:245275
ED Entered STN: 28 Jun 1991
TI Neutrophil elastase in ear discharges of chronic suppurative otitis media
AU Hamaguchi, Yukiyoshi; Jin, Chun Shun; Suzumura, Hidehisa; Sakakura, Yasuo
CS Sch. Med., Mie Univ., Tsu, 514, Japan
SO Ear Research Japan (1990), 21(1), 15-16
CODEN: ERJAEA; ISSN: 0288-9781
DT Journal
LA Japanese
CC 14-3 (Mammalian Pathological Biochemistry)
AB Neutrophil elastase (NE) levels in ear discharges from chronic suppurative otitis media (CSOM) patients were measured by ELISA. Levels of NE complexed with .alpha.1-antitrypsin were higher in CSOM than in middle ear effusions from

chronic **otitis media** with effusion (OME). Total NE levels in CSOM were significantly higher than in chronic OME.

ST suppurative **otitis media** pus neutrophil elastase
IT Neutrophil
 (elastase of, α 1-**antitrypsin**
 complexes with, in pus, in chronic suppurative **otitis media**, of humans)

IT Pus
 (neutrophil elastase complexes with α 1-**antitrypsin** in, in chronic suppurative **otitis media**, of humans)

IT Ear
 (disease, **otitis media**, with effusion, neutrophil elastase complexes with α 1-**antitrypsin** in, of humans)

IT Ear
 (disease, suppurative **otitis media**, neutrophil elastase complexes with α 1-**antitrypsin** in pus in, of humans)

IT 9004-06-2, Elastase 9004-06-2D, Elastase, α 1-**antitrypsin** complexes
9041-92-3D, Trypsin, elastase complexes
RL: BIOL (Biological study)
 (neutrophil, of pus, in chronic suppurative **otitis media**, of humans)

IT 9004-06-2, Elastase 9004-06-2D, Elastase, α 1-**antitrypsin** complexes
9041-92-3D, Trypsin, elastase complexes
RL: BIOL (Biological study)
 (neutrophil, of pus, in chronic suppurative **otitis media**, of humans)

RN 9004-06-2 HCAPLUS
CN Elastase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9004-06-2 HCAPLUS
CN Elastase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9041-92-3 HCAPLUS
CN Trypsin inhibitor, α 1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L77 ANSWER 12 OF 15 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1990:16407 HCAPLUS
DN 112:16407
ED Entered STN: 21 Jan 1990
TI Antiinflammatory effects of a corticosteroid and protease inhibitor agents on antigen-induced **otitis media** in chinchillas
AU Hamaguchi, Yukiyoshi; Sakakura, Yasuo; Juhn, Steven K.
CS Fac. Med., Mie Univ., Tsu, 514, Japan
SO Ear Research Japan (1989), 20(1), 165-6
CODEN: ERJAEA; ISSN: 0288-9781
DT Journal
LA Japanese
CC 2-4 (Mammalian Hormones)
Section cross-reference(s): 14
AB The effects of a glucocorticoid, triamcinolone acetate, and of a kallikrein inhibitor, aprotinin, were examined on levels of .alpha

.1-antitrypsin and total protein concentration in the middle ear fluid and on leukocyte infiltration into the middle ear fluid of chinchillas. These drugs were injected into the middle ear with an antigen, human serum albumin. Both vascular permeability and leukocyte infiltration were suppressed by treatment with triamcinolone acetate or aprotinin. Apparently the kallikrein-kinin system is related to the early stage of antigen-induced **otitis media**.

ST corticosteroid protease inhibitor **otitis media**;
inflammation inhibition corticosteroid aprotinin

IT Corticosteroids, biological studies
RL: BIOL (Biological study)
(ear **otitis media** treatment by protease inhibitor and)

IT Leukocyte
(infiltration of, in ear **otitis media**,
corticosteroid and protease inhibitor suppression of)

IT **Inflammation**
(inhibition of, by corticosteroid and protease inhibitor, in ear **otitis media**)

IT Blood vessel, metabolism
(permeability of, in ear **otitis media**,
corticosteroid and protease inhibitor in decrease of)

IT Kinins (animal hormones)
RL: BIOL (Biological study)
(-kallikrein system, in ear **otitis media**
pathogenesis)

IT **Ear**
(disease, **otitis media**, treatment of,
with corticosteroid and protease inhibitor)

IT Biological transport
(permeation, of blood vessels, in ear **otitis media**,
corticosteroids and protease inhibitor decrease of)

IT 9087-70-1, Aprotinin
RL: BIOL (Biological study)
(ear **otitis media** treatment by corticosteroid and)

IT 67-78-7
RL: BIOL (Biological study)
(ear **otitis media** treatment by protease inhibitor and)

L77 ANSWER 13 OF 15 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1989:452922 HCAPLUS
DN 111:52922
ED Entered STN: 20 Aug 1989
TI Purification and properties of Streptococcus pneumoniae neuraminidase
AU Scanlon, K. Lenia; Diven, Warren F.; Glew, Robert H.
CS Sch. Med., Univ. Pittsburgh, Pittsburgh, PA, 15261, USA
SO Enzyme (1989), 41(3), 143-50
CODEN: ENZYBT; ISSN: 0013-9432
DT Journal
LA English
CC 7-2 (Enzymes)
AB To study the role of neuraminidase of S. pneumoniae in the pathol. of **otitis media** a method for its purification was developed. The enzyme was purified >5,800-fold by removing the organism and passing the culture broth through a series of affinity and ion-exchange columns. The overall yield was 2 mg enzyme protein and the final specific activity was 1.8 + 106 units/mg protein. A mol. weight of 65,000 was estimated by SDS-PAGE and gel-filtration chromatog. The Stokes radius of neuraminidase was calculated to be 32 Å, its isoelec. point was 7.2, and its pH optimum

was 6.0. In terms of specificity, the enzyme catalyzed the hydrolysis of sialic acid linkages in mucin, glycoproteins, and gangliosides: bovine submaxillary mucin supported the highest catalytic efficiency, and .
alpha.-1-antitrypsin the lowest.

Neuraminidase acted on ≥ 3 linkage classes of substrates, α -2,6 and α -2,3 linkages of N-acetylneuraminic acid to galactose, and α -2,6 linkages to N-acetylgalactosamine.

ST neuraminidase Streptococcus; **otitis media**

neuraminidase Streptococcus

IT Streptococcus pneumoniae

(neuraminidase of, purification and properties of)

IT Michaelis constant

(of neuraminidase, of Streptococcus pneumoniae)

IT Fetus

Transferrins

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, with neuraminidase of Streptococcus pneumoniae, kinetics of)

IT Molecular structure-biological activity relationship

(neuraminidase substrate, of carbohydrates and gangliosides and glycoproteins)

IT Mucins

RL: RCT (Reactant); RACT (Reactant or reagent)

(sialo-, reaction of, with neuraminidase of Streptococcus pneumoniae, kinetics of)

IT 9001-67-6P, Neuraminidase

RL: PREP (Preparation)

(of Streptococcus pneumoniae, purification and properties of)

IT 9041-92-3, α 1-Antitrypsin

12707-58-3, Ganglioside GD1a 35890-38-1, Neuramin lactose 59322-44-0

93230-05-8, Ganglioside GT1

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, with neuraminidase of Streptococcus pneumoniae, kinetics of)

IT 9041-92-3, α 1-Antitrypsin

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, with neuraminidase of Streptococcus pneumoniae, kinetics of)

RN 9041-92-3 HCAPLUS

CN Trypsin inhibitor, α 1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L77 ANSWER 14 OF 15 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1979:133539 HCAPLUS

DN 90:133539

ED Entered STN: 12 May 1984

TI Alpha1-antitrypsin in the inner ear perilymph and other body fluids

AU Opolska, Barbara; Trela, Franciszek

CS Zakl. Med. Sadowej, Akad. Med., Krakow, Pol.

SO Folia Medica Cracoviensia (1978), 20(1), 135-7

CODEN: FMCRAW; ISSN: 0015-5616

DT Journal

LA Polish

CC 4-2 (Toxicology)

AB .alpha.1-Antitrypsin [9041-92-3]

was detected in 89.0% of inner ear perilymph and in 62.13% of the cerebrospinal fluid samples examined, but not in vitreous fluid. The samples were all taken from human cadavers. .alpha.1-Antitrypsin anal. may be useful in the identification of corpses.

ST antitrypsin body fluid forensic analysis
IT Legal chemistry and medicine
 (antitrypsin detection in body fluids in)
IT Body fluid
 (antitrypsin detection in, in forensic anal.)
IT Cerebrospinal fluid
 (fluid of, antitrypsin detection in, in forensic anal.)
IT Ear
 (labyrinth, fluid of, antitrypsin detection in, in forensic anal.)
IT 9041-92-3
 RL: BIOL (Biological study)
 (of body fluids, forensic anal. in relation to)
IT 9041-92-3
 RL: BIOL (Biological study)
 (of body fluids, forensic anal. in relation to)
RN 9041-92-3 HCAPLUS
CN Trypsin inhibitor, α 1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L77 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1977:403911 HCAPLUS
DN 87:3911
ED Entered STN: 12 May 1984
TI Complement C3 proactivator as an acute phase reactant
AU Ota, Hisahiro
CS Nagasaki City Hosp., Nagasaki, Japan
SO Igaku no Ayumi (1977), 100(12), 866-8
 CODEN: IGAYAY; ISSN: 0039-2359
DT Journal
LA Japanese
CC 15-13 (Immunochemistry)
AB The increased levels of serum C3 proactivator in infections (e.g. acute
 otitis media, leg abscess) approx. paralleled that of
 alpha.1-antitrypsin and C-reactive protein.
ST complement C3 proactivator inflammation
IT Inflammation
 (complement in)
IT Complement
 (C3 proactivator, acute phase reactant activity of)

=>. => fil medline

FILE 'MEDLINE' ENTERED AT 15:31:40 ON 21 JUN 2005

FILE LAST UPDATED: 18 JUN 2005 (20050618/UP). FILE COVERS 1950 TO DATE.

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP
RLOAD at an arrow prompt (=>). See also:

<http://www.nlm.nih.gov/mesh/>
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the
MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all tot

L113 ANSWER 1 OF 19 MEDLINE on STN
 AN 2002258084 MEDLINE
 DN PubMed ID: 11997781
 TI Inhibition of **matrix metalloproteinases** in gerbil
 cholesteatoma: preliminary findings.
 AU Lehman David A; Wilmoth Jason G; Prevatt Angela R; Schultz Gregory S;
 Antonelli Patrick J
 CS Department of Otolaryngology, University of Florida, Gainesville
 32610-0264, USA.
 SO Otolaryngology--head and neck surgery : official journal of American
 Academy of Otolaryngology-Head and Neck Surgery, (2002 Apr) 126
 (4) 404-8.
 Journal code: 8508176. ISSN: 0194-5998.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200206
 ED Entered STN: 20020509
 Last Updated on STN: 20020611
 Entered Medline: 20020606
 AB OBJECTIVES: This study was conducted to examine the role of **matrix
 metalloproteinases (MMPs)** and the impact of a topical
MMP inhibitor, ilomostat, on the development of tympanic membrane
 (TM) atelectasis in the gerbil model. METHODS: Eustachian tubes were
 cauterized bilaterally in 19 gerbils. Thereafter, both TMs received
 once-daily topical treatment for 8 weeks with ilomostat or vehicle or no
 treatment (n = 6 or 7 per group). TM atelectasis was serially graded, and
 TMs were harvested at 8 weeks. Gelatin zymograms were performed to
 determine **MMP** activity. RESULTS: The mean activity levels of
 proenzyme and active **MMP-9** and **MMP-2** and degree of
 atelectasis did not differ between groups. TM atelectasis did not
 correlate to levels of enzymes across individual samples. CONCLUSIONS:
 Topical application of an **MMP** inhibitor did not significantly
 prevent the development of TM atelectasis. It remains to be determined
 whether the use of **MMP** inhibitors may prevent the progression of
 atelectasis in humans.
 CT Check Tags: Male
 Animals
 *Cholesteatoma, Middle Ear: PC, prevention & control
 *Dipeptides: TU, therapeutic use
 Gelatinase A: ME, metabolism
 Gelatinase B: ME, metabolism
 Gerbillinae
 *Matrix Metalloproteinases: AI, antagonists & inhibitors
 *Matrix Metalloproteinases: PH, physiology
 *Protease Inhibitors: TU, therapeutic use
 Tympanic Membrane: DE, drug effects
 CN 0 (Dipeptides); 0 (GM 6001); 0 (Protease Inhibitors);
 EC 3.4.24.- (Matrix Metalloproteinases); EC 3.4.24.24
 (Gelatinase A); EC 3.4.24.35 (Gelatinase B)

L113 ANSWER 2 OF 19 MEDLINE on STN
 AN 2002110540 MEDLINE
 DN PubMed ID: 11843930

TI **Matrix metalloproteinases 2 and 9 in otitis media with effusion.**

AU Jennings C R; Guo L; Collins H M; Birchall J P

CS Department of Otorhinolaryngology and Head and Neck Surgery, Queen's Medical Centre, University Hospital, Nottingham, UK.

SO Clinical otolaryngology and allied sciences, (2001 Dec) 26 (6) 491-4.

Journal code: 7701793. ISSN: 0307-7772.

CY England: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200203

ED Entered STN: 20020215

Last Updated on STN: 20020314

Entered Medline: 20020313

AB A qualitative and quantitative study of the presence of **matrix metalloproteinase 2 (MMP 2)** and **matrix metalloproteinase 9 (MMP 9)**, in the effusions of otitis media with effusion (OME), was performed. The activity of the above enzymes was compared in thick and thin effusions, and concentrations compared in samples from children with one, two, three and four sets of ventilation tubes. The activity of both **MMP 2** and **MMP 9** was higher in thick than thin effusions, $P = 0.07$ and $P = 0.04$, respectively. The concentrations of **MMP 9** did not vary with the number of tube insertions but those of **MMP 2** did (ANOVA $P < 0.05$). **MMPs** may be involved in tympanic membrane damage and prognosis of OME.

CT Check Tags: Female; Male

Child

Child, Preschool

Electrophoresis, Agar Gel

Enzyme-Linked Immunosorbent Assay

*Exudates and Transudates: EN, enzymology

*Gelatinase A: ME, metabolism

*Gelatinase B: ME, metabolism

Humans

Middle Ear Ventilation

*Otitis Media with Effusion: EN, enzymology

Otitis Media with Effusion: SU, surgery

Research Support, Non-U.S. Gov't

Viscosity

CN EC 3.4.24.24 (Gelatinase A); EC 3.4.24.35 (Gelatinase B)

L113 ANSWER 3 OF 19 MEDLINE on STN

AN 1998453249 MEDLINE

DN PubMed ID: 9781988

TI Analysis of protease activity in human otitis media.

AU Avidano M A; Cotter C S; Stringer S P; Schultz G S

CS Department of Otolaryngology-Head and Neck Surgery, University of Florida College of Medicine, Gainesville, USA.

SO Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, (1998 Oct) 119 (4) 346-51.

Journal code: 8508176. ISSN: 0194-5998.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199811

ED Entered STN: 19990106
Last Updated on STN: 20000303
Entered Medline: 19981103

AB Chronic otitis media is a common problem associated with a nonintact tympanic membrane frequently involving *Staphylococcus aureus* and *Pseudomonas aeruginosa*. The virulence of *Pseudomonas* bacteria is related to the production of two **matrix metalloproteinases**, elastase and alkaline **protease**. Serine **proteases**, such as neutrophil elastase, are produced by the host inflammatory response. These **proteases** are thought to contribute to tissue destruction and assist bacterial invasion during infection. This preliminary study was done to identify **protease** activity in otorrhea samples from patients with otitis media and a nonintact tympanic membrane and to examine the ability of selective **protease** inhibitors to decrease **protease** activity. Ilomostat (galardin) is a synthetic, specific inhibitor of **matrix metalloproteinases** including *P. aeruginosa* elastase and alkaline **protease**, whereas alpha1-antitrypsin inhibits serine **proteases** including neutrophil elastase. Samples were collected and cultured from 20 patients with otorrhea resulting from tympanic membrane perforations or pressure-equalization tubes. A **protease** assay that used azocasein as the substrate was used to quantify **protease** activity, with and without addition of selective **protease** inhibitors. Cultures revealed *P. aeruginosa* alone in 7 samples, *P. aeruginosa* plus other organisms in 10, and *S. aureus* alone in 3. **Protease** activity was detected in 15 (75%) of the samples. A statistically significant ($p < 0.05$) decrease in **protease** activity was seen with the addition of alpha1-antitrypsin or Ilomostat plus alpha1-antitrypsin, but not with Ilomostat alone. Analyzing the 10 samples with the highest **protease** activity, a statistically significant decrease in activity was seen with Ilomostat or alpha1-antitrypsin alone and with both Ilomostat and alpha1-antitrypsin together. Bacteriologic type, source of sample, age and gender of the subject, and duration of infection were not significantly related to **protease** activity. This is the first study to quantify **protease** activity and inhibition by selective **protease** inhibitors in human otorrhea. **Protease** inhibitors effectively decrease **protease** activity in most cases and in addition to standard antibiotic therapy might prove beneficial in the treatment of otitis media with a nonintact tympanic membrane. This study supports future clinical investigations into the role of **proteases** and inhibition of **protease** activity in the treatment of otitis media.

CT Check Tags: Female; Male
Anti-Bacterial Agents: TU, therapeutic use
Bacterial Proteins: AN, analysis
Bacterial Proteins: AI, antagonists & inhibitors
Bacterial Proteins: BI, biosynthesis
Caseins: DU, diagnostic use
Child
Child, Preschool
Chronic Disease
Dipeptides: PD, pharmacology
*Endopeptidases: AN, analysis
Humans
Leukocyte Elastase: AN, analysis
Leukocyte Elastase: AI, antagonists & inhibitors
Leukocyte Elastase: BI, biosynthesis
*Membrane Transport Proteins
Metalloendopeptidases: AN, analysis

protease

Metalloendopeptidases: AI, antagonists & inhibitors

Metalloendopeptidases: BI, biosynthesis

Middle Ear Ventilation

Otitis Media: DT, drug therapy

*Otitis Media: EN, enzymology

Otitis Media: MI, microbiology

Pancreatic Elastase: AN, analysis

Pancreatic Elastase: AI, antagonists & inhibitors

Pancreatic Elastase: BI, biosynthesis

Protease Inhibitors: PD, pharmacology

Protease Inhibitors: TU, therapeutic use

Pseudomonas Infections: DT, drug therapy

Pseudomonas Infections: EN, enzymology

Pseudomonas aeruginosa: EN, enzymology

Pseudomonas aeruginosa: PY, pathogenicity

Serine Endopeptidases: AN, analysis

Serine Endopeptidases: BI, biosynthesis

Serine Proteinase Inhibitors: PD, pharmacology

Staphylococcal Infections: DT, drug therapy

Staphylococcal Infections: EN, enzymology

Subtilisins: AN, analysis

Subtilisins: AI, antagonists & inhibitors

Subtilisins: BI, biosynthesis

Tympanic Membrane Perforation: EN, enzymology

Virulence

alpha 1-Antitrypsin: PD, pharmacology

CN 0 (Anti-Bacterial Agents); 0 (AprE protein, Bacteria); 0 (Bacterial Proteins); 0 (Caseins); 0 (Dipeptides); 0 (GM 6001); 0 (Membrane Transport Proteins); 0 (Protease Inhibitors); 0 (Serine Proteinase Inhibitors); 0 (alpha 1-Antitrypsin); 0 (azocasein); EC 3.4.- (Endopeptidases); EC 3.4.21 (Serine Endopeptidases); EC 3.4.21.- (Subtilisins); EC 3.4.21.36 (Pancreatic Elastase); EC 3.4.21.37 (Leukocyte Elastase); EC 3.4.24 (Metalloendopeptidases)

L113 ANSWER 4 OF 19 MEDLINE on STN

AN 1998319699 MEDLINE

DN PubMed ID: 9657594

TI Psychological change over 54 months of cochlear implant use.

AU Knutson J F; Murray K T; Husarek S; Westerhouse K; Woodworth G; Gantz B J; Tyler R S

CS Department of Psychology, The University of Iowa, Iowa City 52242, USA.

NC 2 P50 DC 00242 (NIDCD)

RR00059 (NCRR)

SO Ear and hearing, (1998 Jun) 19 (3) 191-201.

Journal code: 8005585. ISSN: 0196-0202.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199810

ED Entered STN: 19981029

Last Updated on STN: 19981029

Entered Medline: 19981022

AB OBJECTIVE: To determine the long-term psychological outcome of postlingually deafened adults who received multichannel cochlear implants and to relate the psychological outcome to audiological outcome. DESIGN: Thirty-seven recipients of multichannel cochlear implants who participated in a prospective clinical trial completed psychological assessments before implantation and at regularly scheduled follow-ups through 54 mo of

implant use. Standardized measures of affect, social function, and personality were used, and scores on these measures were correlated with asymptotic scores on several audiological measures. RESULTS: Evidence of significant improvement on measures of loneliness, social anxiety, and distress were obtained within a year after implantation and throughout the duration of the follow-up period. For measures of assertiveness and marital satisfaction, improvement was apparent only after long-term implant use. Although favorable changes on the Minnesota Multiphasic Personality Inventory (MMPI) Depression Scale were evidenced only in the initial follow-up period, improvements on the MMPI Paranoia and Social Introversion Scales persisted throughout the 54 mo follow-up. CONCLUSION: Multichannel cochlear implant use is associated with long-term psychological benefit. Correlations between audiological outcome and psychological outcome, however, suggested that the relation between audiological benefit and psychological benefit is not simple.

CT Check Tags: Female; Male
Adult
Aged
*Cochlear Implantation
*Deafness: PX, psychology
*Deafness: SU, surgery
Depression: DI, diagnosis
Follow-Up Studies
Humans
MMPI
Middle Aged
Prospective Studies
Research Support, U.S. Gov't, P.H.S.
Time Factors

L113 ANSWER 5 OF 19 MEDLINE on STN
AN 96047567 MEDLINE
DN PubMed ID: 7554333
TI Neutrophil elastase-**alpha 1-antitrypsin** in
middle ear fluid in chronic otitis media with effusion.
AU Tierney P; Chan B; Samuel D; Thomas M; Patel K
CS Department of Otolaryngology-Head & Neck Surgery, St Mary's Hospital,
London, UK.
SO Clinical otolaryngology and allied sciences, (1995 Jun) 20 (3)
230-3.
Journal code: 7701793. ISSN: 0307-7772..
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199511
ED Entered STN: 19951227
Last Updated on STN: 20000303
Entered Medline: 19951114
AB Neutrophil elastase-**alpha 1-antitrypsin** was
quantified in samples taken from middle ear effusions collected at
operation from 17 children attending for elective myringotomy and grommet
insertion. At the time of surgery the effusion was classified as serous
or mucoid. Children with a recent history of infection or antimicrobial
therapy were excluded. The quantification of immunoreactive neutrophil
elastase was by means of enzyme-linked immunosorbant assay (ELISA). The
mean value of neutrophil elastase-**alpha 1-antitrypsin** was 50.6 +/- 38.3 (SD) micrograms/ml in mucoid
effusions, which was significantly higher (P < 0.05) than that in serous
effusions (5.3 +/- 4.8 micrograms/ml). These results indicate that a

mucoid effusion may reflect a more severe inflammatory response and that persistence of neutrophil activity in the middle ear mucosa may contribute to the persistence of at least one group of middle ear effusions.

CT Child
Child, Preschool
Chronic Disease
*Ear, Middle: EN, enzymology
*Ear, Middle: PP, physiopathology
Enzyme-Linked Immunosorbent Assay
Humans
*Leukocyte Elastase: AN, analysis
Middle Ear Ventilation
*Neutrophils: CH, chemistry
*Otitis Media with Effusion: PP, physiopathology
Otitis Media with Effusion: TH, therapy
*Pancreatic Elastase: AN, analysis
*alpha 1-Antitrypsin: AN, analysis
CN 0 (alpha 1-Antitrypsin); EC 3.4.21.36
(Pancreatic Elastase); EC 3.4.21.37 (Leukocyte Elastase)

L113 ANSWER 6 OF 19 MEDLINE on STN

AN 94234651 MEDLINE

DN PubMed ID: 8179269

TI Determining otitis media severity from middle ear fluid analysis.

AU Juhn S K; Garvis W J; Lees C J; Le C T; Kim C S

CS Otitis Media Research Center, University of Minnesota School of Medicine, Minneapolis.

NC P01-DC00133 (NIDCD)

SO Annals of otology, rhinology & laryngology. Supplement, (1994 May)
163 43-5.

Journal code: 1256156. ISSN: 0096-8056.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199406

ED Entered STN: 19940620

Last Updated on STN: 19940620

Entered Medline: 19940609

AB Otitis media has a complex multifactorial pathogenesis, and the middle ear inflammatory response is typified by the accumulation of cellular and chemical mediators in middle ear effusion. However, specific biochemical and immunochemical factors that may be responsible for the severity or chronicity of otitis media have not been identified. Identification of factors involved in chronicity appears to be an essential step in the treatment and ultimate prevention of chronic otitis media. We analyzed 70 effusion samples from patients 1 to 10 years of age who had chronic otitis media with effusion for two cytokines (interleukin-1 beta and tumor necrosis factor alpha) and total collagenase. The highest concentrations of all three inflammatory mediators were found in purulent otitis media, and concentrations were higher in younger than in older patients. Mediator concentrations were similar in samples obtained from patients having their first myringotomy for otitis media with effusion and in those who had had multiple previous myringotomies. The multiresponse star, which incorporates several biochemical parameters in one graphic illustration, may best characterize the complex nature of middle ear inflammation.

CT Child
Child, Preschool
Chronic Disease

*Collagenases: AN, analysis
 Collagenases: ME, metabolism
 *Ear, Middle: CH, chemistry
 Ear, Middle: EN, enzymology
 Ear, Middle: IM, immunology

*Exudates and Transudates: CH, chemistry

Humans

Infant

*Interleukin-1: AN, analysis

Interleukin-1: IM, immunology

*Otitis Media with Effusion: DI, diagnosis

Otitis Media with Effusion: IM, immunology

Otitis Media with Effusion: PP, physiopathology

Research Support, U.S. Gov't, P.H.S.

*Tumor Necrosis Factor-alpha: AN, analysis

Tumor Necrosis Factor-alpha: IM, immunology

Tympanic Membrane: SU, surgery

CN 0 (Interleukin-1); 0 (Tumor Necrosis Factor-alpha); EC 3.4.24.-
 (Collagenases)

L113 ANSWER 7 OF 19 MEDLINE on STN

AN 93037039 MEDLINE

DN PubMed ID: 1416649

TI Neutrophil elastase and its complex with **alpha 1-antitrypsin** in the pathogenesis of chronic suppurative otitis media.

AU Hamaguchi Y; Sakakura Y

CS Department of Otorhinolaryngology, Mie University School of Medicine, Tsu, Japan.

SO Annals of otology, rhinology & laryngology. Supplement, (1992 Oct) 157 26-31.

Journal code: 1256156. ISSN: 0096-8056.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199211

ED Entered STN: 19930122

Last Updated on STN: 20000303

Entered Medline: 19921119

AB Neutrophil elastase (NE) and its complex with **alpha 1-antitrypsin** were quantified in ear discharges from 15 patients with chronic suppurative otitis media (CSOM), and their levels were compared to those in middle ear effusions from 10 pediatric patients with chronic otitis media with effusion (OME). The localization of immunoreactive NE was also examined by immunocytologic study. The mean value of total NE was 161.8 +/- 29.5 micrograms/mL in CSOM, which was significantly higher than that in OME (16.5 +/- 6.7 micrograms/mL). The mean value of NE-**alpha 1-antitrypsin** complex was 13.7 +/- 8.8 micrograms/mL in CSOM and 7.8 +/- 4.0 micrograms/mL in OME. There was no significant difference between culture-positive and culture-negative samples in CSOM. Immunoreactive NE could be observed in the neutrophils of ear discharges, and extracellular release of NE was also observed. Ear discharges in CSOM contain a considerable amount of uncomplexed NE, of which the level does not depend on active bacterial infections. Uncomplexed NE seems to play a role in the chronicity of CSOM.

CT Check Tags: Female; Male
 Adolescent
 Adult

Aged
 Child
 Chronic Disease
 Exudates and Transudates: EN, enzymology
 Exudates and Transudates: IM, immunology
 Humans
 Infant
 Leukocyte Count
 Leukocyte Elastase
 Middle Aged
 Otitis Media with Effusion: EN, enzymology
 Otitis Media with Effusion: IM, immunology
 *Otitis Media, Suppurative: EN, enzymology
 Otitis Media, Suppurative: IM, immunology
 *Pancreatic Elastase: ME, metabolism
 Research Support, Non-U.S. Gov't
 *alpha 1-Antitrypsin: ME, metabolism

CN 0 (alpha 1-Antitrypsin); EC 3.4.21.36
 (Pancreatic Elastase); EC 3.4.21.37 (Leukocyte Elastase)

L113 ANSWER 8 OF 19 MEDLINE on STN

AN 89298305 MEDLINE

DN PubMed ID: 2544990

TI Microvascular response to locally injected collagenase. An experimental investigation in hamsters and rabbits.

AU Rydevik B; Ehira T; Linder L; Olmarker K; Romanus M; Branemark P I

CS Department of Orthopaedics, Gothenburg University, Sweden.

SO Scandinavian journal of plastic and reconstructive surgery and hand surgery / Nordisk plastikkirurgisk forening [and] Nordisk klubb for handkirurgi, (1989) 23 (1) 17-21.

Journal code: 8707869. ISSN: 0284-4311.

CY Sweden

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 198908

ED Entered STN: 19900309

Last Updated on STN: 19900309

Entered Medline: 19890803

AB Collagenase was injected into the ears of rabbits and the cheek-pouches of hamsters. The acute and long-term microvascular effects were studied by vital microscopy and microangiography. The enzyme was injected at three different concentrations: 120 units/ml, 600 units/ml and 3,000 units/ml. The medium (600 units/ml) and high (3,000 units/ml) concentrations induced effects on the microcirculation such as blood flow impairment and microbleedings. The magnitude of these effects was related to the concentration of the enzyme. Generally, these microvascular effects were of low magnitude as compared with other substances tested using the same experimental models.

CT Animals

Cheek: BS, blood supply

Cheek: DE, drug effects

Cicatrix

 Ear, External: BS, blood supply

 Ear, External: DE, drug effects

Hamsters

Injections, Subcutaneous

Mesocricetus

 *Microbial Collagenase: AD, administration & dosage

 Microbial Collagenase: PD, pharmacology

*Microcirculation: DE, drug effects
 Rabbits
 Regional Blood Flow
 Research Support, Non-U.S. Gov't
 CN EC 3.4.24.3 (Microbial Collagenase)

L113 ANSWER 9 OF 19 MEDLINE on STN
 AN 89206052 MEDLINE
 DN PubMed ID: 2468303
 TI Protease inhibitors in middle ear effusions from experimental otitis media with effusion: kinetics of **alpha 1-antitrypsin** and alpha 2-macroglobulin levels.
 AU Hamaguchi Y; Juhn S K; Sakakura Y
 CS Department of Otolaryngology, University of Minnesota, Minneapolis.
 NC NS 14538 (NINDS)
 SO Annals of otology, rhinology, and laryngology, (1989 Apr) 98 (4 Pt 1) 287-92.
 Journal code: 0407300. ISSN: 0003-4894.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 198905
 ED Entered STN: 19900306
 Last Updated on STN: 20000303
 Entered Medline: 19890512
 AB **Alpha 1-antitrypsin** (alpha 1-AT) and alpha 2-macroglobulin (alpha 2-M) were measured by both immunochemical and functional assays in paired plasma and middle ear effusions (MEEs) from experimental otitis media models (serous otitis media [SOM], purulent otitis media [POM], and SOM + POM). The MEE/plasma ratio of **alpha 1-AT** in SOM was significantly higher than that in POM (p less than .01) because of the high **alpha 1-AT** level in POM plasma. The ratio of both antitryptic activity and **trypsin**-binding activity in POM was significantly higher than that in SOM + POM (p less than .01, less than .05), and significantly lower than that in SOM (p less than .01). The majority of both **inhibitors** in SOM exists as the free state, and the reaction between proteases and **inhibitors** in POM and SOM + POM is more active than that in SOM. It is concluded that both **alpha 1-AT** and alpha 2-M appear to play an important role in the protection of middle ear mucosa by forming protease-**inhibitor** complexes to reduce proteolytic damage in POM and SOM + POM models.
 CT Animals
 Chinchilla
 Disease Models, Animal
 Ear, Middle: PP, physiopathology
 Endopeptidases: ME, metabolism
 Mucous Membrane: PP, physiopathology
 *Otitis Media: PP, physiopathology
 *Otitis Media with Effusion: PP, physiopathology
 *Otitis Media, Suppurative: PP, physiopathology
 Research Support, U.S. Gov't, P.H.S.
 *alpha 1-Antitrypsin: PK, pharmacokinetics
 *alpha-Macroglobulins: PK, pharmacokinetics
 CN 0 (alpha 1-Antitrypsin); 0
 (alpha-Macroglobulins); EC 3.4.- (Endopeptidases)

L113 ANSWER 10 OF 19 MEDLINE on STN
 AN 89023753 MEDLINE

DN PubMed ID: 2459981
 TI Antiinflammatory effects of a corticosteroid and protease inhibitor agents on antigen-induced otitis media in chinchillas.
 AU Hamaguchi Y; Juhn S K; Sakakura Y
 CS Department of Otolaryngology, University of Minnesota Medical School, Minneapolis.
 NC NS-14538 (NINDS)
 SO American journal of otolaryngology, (1988 May-Jun) 9 (3) 142-8.
 Journal code: 8000029. ISSN: 0196-0709.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 198811
 ED Entered STN: 19900308
 Last Updated on STN: 19970203
 Entered Medline: 19881115
 AB Using an antigen-induced otitis media (OM) model in chinchillas sensitized with human serum albumin (HSA), we studied the antiinflammatory effect of a corticosteroid (triamcinolone) and a protease (kallikrein) inhibitor (aprotinin) by conducting both biochemical and cytologic analyses of middle ear fluid (MEF). The levels of HSA, **alpha 1-antitrypsin**, **alpha 2-macroglobulin**, and total protein concentration were measured in the MEF to evaluate the degree of OM. Both vascular leakage and leukocyte infiltration were significantly reduced by corticosteroid and inhibitor treatments. HSA levels in the MEF were markedly reduced after HSA challenge, and both treatments reduced the drop in HSA levels. In conclusion, the kallikrein-kinin system is related to the early stage of antigen-induced OM. Both corticosteroid and inhibitor treatments effectively reduce the degree of antigen-induced OM in chinchillas, suggesting that both may be useful local therapeutic agents in the treatment of human OM.
 CT Animals
 Aprotinin: ME, metabolism
 *Aprotinin: TU, therapeutic use
 Chinchilla
 *Otitis Media with Effusion: DT, drug therapy
 Otitis Media with Effusion: ME, metabolism
 Research Support, U.S. Gov't, P.H.S.
 Serum Albumin: ME, metabolism
 *Triamcinolone: TU, therapeutic use
alpha 1-Antitrypsin: ME, metabolism
alpha-Macroglobulins: ME, metabolism
 RN 124-94-7 (Triamcinolone); 9087-70-1 (Aprotinin)
 CN 0 (Serum Albumin); 0 (**alpha 1-Antitrypsin**);
 0 (**alpha-Macroglobulins**)
 L113 ANSWER 11 OF 19 MEDLINE on STN
 AN 88268548 MEDLINE
 DN PubMed ID: 2455499
 TI Biochemical and cytological studies of immune-complex-induced otitis media in the chinchilla.
 AU Hamaguchi Y; Juhn S K; Sakakura Y
 CS Department of Otolaryngology, University of Minnesota, Minneapolis 55414.
 NC NS14538 (NINDS)
 SO Archives of oto-rhino-laryngology, (1988) 245 (2) 77-81.
 Journal code: 0414105. ISSN: 0302-9530.
 CY GERMANY, WEST: Germany, Federal Republic of
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English

FS Priority Journals
EM 198808
ED Entered STN: 19900308
Last Updated on STN: 19970203
Entered Medline: 19880811

AB The pathogenesis of immune complex (IC)-induced otitis media in the chinchilla was studied through cytological and biochemical analyses of middle ear fluid (MEF) recovered after instillation of premade IC. The number to total leukocytes was $3.03 \pm 2.13 \times 10^6/\text{cm}^3$, and mainly involved neutrophils (72.3%) and macrophages (22.7%). The mean value of total protein, **alpha 1-antitrypsin** (**alpha 1-AT**) and **alpha 2-macroglobulin** (**alpha 2-M**) was 27.1 mg/ml, 189.5 and 75.2 mg/dl. The number of leukocytes had a significant correlation with the levels of total protein, **alpha 1-AT** and **alpha 2-M** (P less than 0.01). The inflammatory reaction induced by premade IC is characterized by an increased vascular leakage and an infiltration of leukocytes into the locus. The percentage of macrophages in the total leukocytes was larger in IC-induced otitis media than that in antigen-induced otitis media. These findings suggest that cellular events in the early stage of IC-induced otitis media may be different from antigen-induced otitis media.

CT Check Tags: Comparative Study
Animals
*Chinchilla: IM, immunology
Disease Models, Animal
Exudates and Transudates: CY, cytology
Exudates and Transudates: IM, immunology
Immune Complex Diseases: BL, blood
*Immune Complex Diseases: CO, complications
Immune Complex Diseases: IM, immunology
Leukocyte Count
Macrophages
Neutrophils
Otitis Media with Effusion: BL, blood
*Otitis Media with Effusion: ET, etiology
Otitis Media with Effusion: IM, immunology
Proteins: AN, analysis
Research Support, U.S. Gov't, P.H.S.
Tympanic Membrane
alpha 1-Antitrypsin: AN, analysis
alpha-Macroglobulins: AN, analysis

CN 0 (Proteins); 0 (**alpha 1-Antitrypsin**); 0
(alpha-Macroglobulins)

L113 ANSWER 12 OF 19 MEDLINE on STN
AN 87323796 MEDLINE
DN PubMed ID: 2443031
TI Kinetics of lysosomal protease activity in human otitis media with effusion.
AU Hamaguchi Y; Sakakura Y; Majima Y; Juhn S K
SO American journal of otolaryngology, (1987 Jul-Aug) 8 (4) 194-8.
Journal code: 8000029. ISSN: 0196-0709.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198710
ED Entered STN: 19900305
Last Updated on STN: 20000303
Entered Medline: 19871022

AB Hydrolytic activity of various lysosomal proteases--elastase, collagenase, and cathepsins B and H--were measured in 125 middle ear effusions from patients with chronic (serous and mucoid) and acute otitis media with effusion (OME). The levels of cathepsin B activity and alpha-2-macroglobulin during the course of clinical therapies (myringotomy and tympanostomy tubing) were analyzed in 10 chronic OME cases where follow-up evaluation was possible. It is found that the level of lysosomal protease activity (elastase, collagenase and cathepsin B) was higher in acute OME than that in chronic OME; the hydrolytic activity of cathepsin B in middle ear effusions could be used as an indicator to reflect the level of lysosomal proteases activity in the middle ear; in chronic OME, inflammatory reaction including lysosomal protease activity of the middle ear mucosa at the time of the first myringotomy appeared to be more active than that at the time of the final myringotomy, but less than that in acute OME; and the proteolytic damage of lysosomal thiol proteases to the middle ear mucosa, which may be related to the chronicity of OME, could be reduced by both therapeutic myringotomy and tympanostomy.

CT Check Tags: Female; Male
 Cathepsin B: ME, metabolism
 Cathepsins: ME, metabolism
 Child
 *Cysteine Endopeptidases
 Follow-Up Studies
 Humans
 Kinetics
 *Lysosomes: EN, enzymology
 Microbial Collagenase: ME, metabolism
 Middle Ear Ventilation
 *Otitis Media with Effusion: EN, enzymology
 Pancreatic Elastase: ME, metabolism
 *Peptide Hydrolases: ME, metabolism
 alpha-Macroglobulins: ME, metabolism
 CN 0 (alpha-Macroglobulins); EC 3.4.- (Cathepsins); EC 3.4.- (Peptide Hydrolases); EC 3.4.21.36 (Pancreatic Elastase); EC 3.4.22 (Cysteine Endopeptidases); EC 3.4.22.1 (Cathepsin B); EC 3.4.22.16 (cathepsin H); EC 3.4.24.3 (Microbial Collagenase)

L113 ANSWER 13 OF 19 MEDLINE on STN

AN 86241753 MEDLINE

DN PubMed ID: 3835890

TI The significance of protease inhibitors in the pathogenesis of otitis media with effusion.

AU Hamaguchi Y; Majima Y; Ukai K; Sakakura Y; Miyoshi Y

SO Auris, nasus, larynx, (1985) 12 Suppl 1 S145-7.

Journal code: 7708170. ISSN: 0385-8146.

CY Japan

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 198607

ED Entered STN: 19900321

Last Updated on STN: 19900321

Entered Medline: 19860707

AB Concentration of alpha 1-antitrypsin (alpha 1-AT), alpha 1-antichymotrypsin (alpha 1-AChyT), inter-alpha-trypsin inhibitor (I-alpha-I), and alpha 2-macroglobulin (alpha 2-M) was measured in 27 serous middle ear effusions (MEEs) from 24 adult patients. The presence of protease-inhibitor complex was analyzed by crossed immunoelectrophoresis (CIEP). Mean concentration of

alpha 1-AT was 361 +/- 90.0 mg/dl and was higher than that of other **inhibitors: alpha 1-AChyT**, 80.6 +/- 40.7; **I-alpha-I**, 21.3 +/- 21.5; **alpha 2-M**, 59.5 +/- 57.1. Molar concentration of **alpha 2-M** was the lowest. Most of **alpha 1-AT** and **alpha 1-AChyT** in MEEs were unsaturated; free **inhibitors. Alpha-1-AT** could be saturated by **trypsin** and elastase immediately, and only **alpha 2-M** could be saturated by papain (classical thiol protease). Serous MEEs have high **anti-trypsin** activity attributed to mainly free **alpha 1-AT**. Since level of **alpha 2-M** was very low, lysosomal thiol proteases could be one of the major proteases inducing proteolytic damage to middle ear mucosa.

CT Adult

Ear, Middle

*Exudates and Transudates: AN, analysis

Humans

Mucous Membrane: ME, metabolism

*Otitis Media with Effusion: ME, metabolism

*Protease Inhibitors: AN, analysis

CN 0 (Protease Inhibitors)

L113 ANSWER 14 OF 19 MEDLINE on STN

AN 83229348 MEDLINE

DN PubMed ID: 6602580

TI Middle ear disorders in patients with **alpha 1-antitrypsin** deficiency.

AU Carlsson B

SO Annals of otology, rhinology, and laryngology, (1983 May-Jun) 92 (3 Pt 1) 300-4.

Journal code: 0407300. ISSN: 0003-4894.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 198307

ED Entered STN: 19900319

Last Updated on STN: 19900319

Entered Medline: 19830715

AB As it is not known whether individuals with **alpha 1-antitrypsin** deficiency show increased sequelae following otitis media, 52 patients with **alpha 1-antitrypsin** deficiency were studied with respect to history of middle ear disease, presence of irreversible pathologic changes of the tympanic membranes, and hearing ability. The middle ear status was determined on otomicroscopy, tympanometry, and pure-tone audiometry. The frequency of individuals with a history of otitis media was 50%. The frequency of individuals with pathologic tympanic membrane changes was no different from that shown in the results obtained in a Swedish normal population study. Minor conductive hearing losses were found in three patients of which only one was related to a history of middle ear disease. However, the history of acute severe complications from otitis media revealed a higher frequency in those individuals with **alpha 1-antitrypsin** deficiency as compared to normals.

CT Check Tags: Female; Male

Adolescent

Adult

Aged

Ear Diseases: ET, etiology

Hearing Disorders: ET, etiology

Hearing Tests

Humans
 Middle Aged
 *Otitis Media: CO, complications
 Otitis Media: PA, pathology
 Phenotype
 Risk
 Tympanic Membrane: PA, pathology
 *alpha 1-Antitrypsin Deficiency

L113 ANSWER 15 OF 19 MEDLINE on STN
 AN 82203720 MEDLINE
 DN PubMed ID: 6177249
 TI The enzymatic mechanism of the otospongiotic disease and NaF action on the enzymatic balance.
 AU Causse J R; Uriel J; Berges J; Shambaugh G E Jr; Bretlau P; Causse J B
 SO American journal of otology, (1982 Apr) 3 (4) 297-314.
 Journal code: 7909513. ISSN: 0192-9763.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 198207
 ED Entered STN: 19900317
 Last Updated on STN: 19900317
 Entered Medline: 19820719
 AB Extensive research on enzymes led to the discovery of the innermost mechanism of the otospongiotic disease. The authors present the results of multiple correlations made from February 1976 to September 1980 on 648 samples of perilymph taken during stapedectomies performed on otosclerotic patients. We studied microdosages of three selected enzymes--**trypsin**, **alpha 1 antitrypsin**, and **alpha 2 macroglobulin**--in each of the samples and their relationship with cochlear deterioration expressed in dBs of bone conduction decrease in pure-tone audiometry testing. This study allowed us a better knowledge of the enzymatic mechanism of the otospongiotic disease, based on the previously reported **trypsin-alpha 1 antitrypsin** balance, but in which **alpha 2 macroglobulin** appears to play a role as essential as that of **alpha 1 antitrypsin**. This enzymatic mechanism explains NaF efficiency, which is due in fact to a double action: not only direct **trypsin inhibition**, but also an overall reduction in enzymatic values in the perilymph of otospongiotic/otosclerotic patients. Current studies could lead to the possibility of future NaF replacement by proteinase **inhibitors** either of microbial origin, under study by Japanese researchers, or even of synthetic origin, which should be investigated. In fact, the role of NaF therapy could already be taken over by diphosphonates currently under study.
 CT Audiometry, Pure-Tone
 Bone Conduction
 *Cochlea: PA, pathology
 *Fluorides: TU, therapeutic use
 Humans
 Labyrinth Diseases: EN, enzymology
 *Otosclerosis: EN, enzymology
 Perilymph: EN, enzymology
 *Sodium Fluoride: TU, therapeutic use
 Stapes Surgery
 Trypsin: ME, metabolism
 Trypsin Inhibitors: ME, metabolism
 alpha-Macroglobulins: ME, metabolism

RN 7681-49-4 (Sodium Fluoride)
 CN 0 (Fluorides); 0 (Trypsin Inhibitors); 0 (alpha-Macroglobulins); EC 3.4.21.4 (Trypsin)

L113 ANSWER 16 OF 19 MEDLINE on STN
 AN 82133477 MEDLINE
 DN PubMed ID: 6174065
 TI [Enzymatic mechanism of otosclerosis. Action of NaF].
 Mechanisme enzymatique de l'otospongiose. Action du NaF.
 AU Causse J R; Uriel J; Berges J; Bretlau P; Causse J B
 SO Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Societe d'oto-laryngologie des hopitaux de Paris, (1981) 98 (6) 269-97.
 Journal code: 9431026. ISSN: 0003-438X.
 CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 LA French
 FS Priority Journals
 EM 198204
 ED Entered STN: 19900317
 Last Updated on STN: 19900317
 Entered Medline: 19820420

AB The authors present the conclusions they reached after more than four years of multiple correlations made from february 1976 to september 1980. 648 perilymph samples were selected from a total number of 811 samples taken during stapedectomies on otosclerotic patients. These multiple correlations were based on micro-dosages of three selected enzymes (**trypsin-alpha 1 antitrypsin** and **alpha 2 macroglobulin**, the fourth cathepsin B having not been found, even in perilymph pools) in each of the selected samples, and on their relationship with the cochlear deterioration expressed in dBs of B.C. decrease and in audiometric stages corrected with reference to the patients' age. This study leads to an enzymatic mechanism, based on the previously reported **trypsin-alpha 1 antitrypsin** balance, but in which **alpha 2 macroglobulin** appears to play as essential a role as that of **alpha 1 A**. This enzymatic mechanism explains NaF efficiency, due in fact to a double action, not only to direct **trypsin inhibition**, but also to an overall reduction in enzymatic levels in the perilymph of otosclerotic patients. The authors conclude by suggesting the possibility of future NaF replacement by proteinase inhibitors, either of microbial origin currently under study by Japanese researchers, or even of synthetic origin.

CT Check Tags: Comparative Study
 Adult
 Aged
 Audiometry
 English Abstract
 *Fluorides: PD, pharmacology
 Humans
 Middle Aged
 Otosclerosis: DT, drug therapy
 *Otosclerosis: EN, enzymology
 Perilymph: EN, enzymology
 *Sodium Fluoride: PD, pharmacology
 Sodium Fluoride: TU, therapeutic use
 Stapes Surgery
 Trypsin: AN, analysis
 Trypsin Inhibitors
 alpha 1-Antitrypsin: AN, analysis

alpha-Macroglobulins: AN, analysis
 RN 7681-49-4 (Sodium Fluoride)
 CN 0 (Fluorides); 0 (Trypsin Inhibitors); 0 (alpha 1-Antitrypsin); 0 (alpha-Macroglobulins); EC 3.4.21.4 (Trypsin)

L113 ANSWER 17 OF 19 MEDLINE on STN
 AN 77191566 MEDLINE
 DN PubMed ID: 140959
 TI [The investigation of a low molecular acid stable proteinase inhibitor in the middle ear secretion (author's transl)].
 Der Nachweis eines niedermolekularen saurestabilen Proteinaseninhibitors im Ohrsekret bei chronischer Mittelohreiterung.
 AU Kastenbauer E R; Hochstrasser K; Reichert R; Brohr T
 SO Laryngologie, Rhinologie, Otologie, (1977 Mar) 56 (3) 201-6.
 Journal code: 7513628. ISSN: 0340-1588.
 CY GERMANY, WEST: Germany, Federal Republic of
 DT Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS Priority Journals
 EM 197707
 ED Entered STN: 19900314
 Last Updated on STN: 19900314
 Entered Medline: 19770723

AB The proteolytic activity of different proteinases during chronic otitis media can be inhibited by alpha-2-macroglobulin and alpha-1-antitrypsin. A new low molecular (13,000) acid stable and polyvalent proteinase inhibitor could be investigated in the middle ear secretion from patients with cholesteatoma and chronic otitis media. We believe that this inhibitor is identical with the low molecular inhibitor of bronchial mucus and the nasal fluid. This inhibitor shows a high anti proteolytic capacity and can inactivate trypsin, chymotrypsin, pronase and leucocytic preproteinases. The inhibitor is not detectable in any case. We could find it in 55 cases, three specimens of middle ear secretions obtained no acid stable inhibitor. It is present in the secretion in a masked form by in situ-reaction with leucocytic proteinases. By denaturing deproteinizing it is liberated out of the complex with proteinases and can be measured. The investigations demonstrate that the level of the inhibitor varies during the course of a chronic otitis media. In the postoperative phase the inhibitor concentrations were clearly higher than preoperatively. A steep drop of inhibitor can be observed in cases of chronic otitis with the symptomatology of an acute inflammation. In cases with a chronic inflammation the inhibitor level seems to remain low. The decrease of the inhibitor is explained as a using up effect during reaction between inhibitor and leucocytic proteinases. We believe that this inhibitor in the middle ear secretion results from a limited proteolysis and splitting of inter-alpha-trypsin inhibitor by a proteolytic enzyme, possibly by kallikrein.

CT Ear, Middle: EN, enzymology
 *Ear, Middle: SE, secretion
 English Abstract
 Humans
 Molecular Weight
 *Otitis Media: EN, enzymology
 Otitis Media: PP, physiopathology
 *Protease Inhibitors
 CN 0 (Protease Inhibitors)

L113 ANSWER 18 OF 19 MEDLINE on STN
 AN 77055330 MEDLINE
 DN PubMed ID: 63098
 TI [The effect of ear surgery to the immunologic defense system of the middle ear during chronic otitis media (author's transl)].
 Der Operationseffekt auf das immunologische Abwehrsystem des Mittelohres bei der chronischen Ohreiterung.
 AU Kastenbauer E R; Hochstrasser K; Brohr T
 SO Laryngologie, Rhinologie, Otologie, (1976 Oct) 55 (10) 804-12.
 Journal code: 7513628. ISSN: 0340-1588.
 CY GERMANY, WEST: Germany, Federal Republic of
 DT Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS Priority Journals
 EM 197701
 ED Entered STN: 19900313
 Last Updated on STN: 19900313
 Entered Medline: 19770125
 AB **Alpha-1-antitrypsin** and alpha-2-macroglobuline are very important proteinase inhibitors for the healing process in chronic otitis media, because they can inhibit numerous bacterial and leukocytic proteinases: Alpha-2-macroglobuline can block the malignant proteinases of pseudomonas aeruginosa, staphylococcus aureus and proteus vulgaris. In 58 cases in the middle ear secretion was examined and the level of **alpha-1-antitrypsin** and alpha-2-macroglobulin investigated pre- and postoperatively. By these investigations we could demonstrate that the postoperative level of these two inhibitors is higher than preoperatively. In a couple of cases with cholesteatoma the postoperative concentration of alpha-2-macroglobuline was nearly three times higher than prior to the tympanoplasty. We believe that one of the causes for this high inhibitor level is the liberation of alpha-2-macroglobuline by injuring blood vessels during a tympanoplasty. It is our opinion that the increase of the inhibitor level in the postoperative phase is one of the prerequisites for the healing process in chronic otitis media.
 CT Antibody Formation
 Chronic Disease
 *Ear, Middle: IM, immunology
 English Abstract
 Humans
 Immunoglobulins
 *Otitis Media: SU, surgery
 Postoperative Complications: BL, blood
 Postoperative Complications: IM, immunology
 alpha 1-Antitrypsin: ME, metabolism
 alpha-Macroglobulins: ME, metabolism
 CN 0 (Immunoglobulins); 0 (**alpha 1-Antitrypsin**); 0 (alpha-Macroglobulins)

L113 ANSWER 19 OF 19 MEDLINE on STN
 AN 74043966 MEDLINE
 DN PubMed ID: 4758137
 TI Management of general anesthesia for mastoid-tympanoplasty: anesthesia and surgical considerations.
 AU Snow J C; Kripke B J; Strong M S
 SO Laryngoscope, (1973 Nov) 83 (11) 1786-93.
 Journal code: 8607378. ISSN: 0023-852X.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English

FS Priority Journals
EM 197401
ED Entered STN: 19900310
Last Updated on STN: 19990129
Entered Medline: 19740130
CT Adolescent
Adult
Aged
Alanine Transaminase: BL, blood
*Anesthesia, Inhalation
Bicarbonates: BL, blood
Carbon Dioxide: BL, blood
Child
Electrocardiography
*Halothane
Halothane: AE, adverse effects
Humans
Hydrogen-Ion Concentration
*Hypotension, Controlled
Isoenzymes
L-Lactate Dehydrogenase: BL, blood
Leucyl Aminopeptidase: BL, blood
Liver: DE, drug effects
Liver Function Tests
*Mastoid: SU, surgery
Middle Aged
Oxygen: BL, blood
Trimethaphan: DU, diagnostic use
*Tympapanoplasty
RN 124-38-9 (Carbon Dioxide); 151-67-7 (Halothane); 7187-66-8 (Trimethaphan);
7782-44-7 (Oxygen)
CN 0 (Bicarbonates); 0 (Isoenzymes); EC 1.1.1.27 (L-Lactate Dehydrogenase);
EC 2.6.1.2 (Alanine Transaminase); EC 3.4.11.1 (Leucyl Aminopeptidase)

=> => fil wpix

FILE 'WPIX' ENTERED AT 15:48:50 ON 21 JUN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 16 JUN 2005 <20050616/UP>
MOST RECENT DERWENT UPDATE: 200538 <200538/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
GUIDES, PLEASE VISIT:
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
FIRST VIEW - FILE WPIFV.
FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.

PLEASE CHECK:

<http://thomsonderwent.com/support/dwpioref/reftools/classification/code-revision/>
FOR DETAILS. <<<

=> d all abeq tech abex tot

L151 ANSWER 1 OF 20 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2005-182067 [19] WPIX

DNC C2005-058121

TI New peptide compounds useful in the treatment of e.g. central and peripheral nervous system disorders, muscles disorders, diseases of various organs such as gonads and pancreas, cancer, and prion diseases.

DC B04.D16

IN ALBRECHTSEN, M; BEREZIN, V; BOCK, E; HOLM, A

PA (ENKA-N) ENKAM PHARM AS

CYC 108

PI WO 2005014623 A2 20050217 (200519)* EN 195 C07K007-00

RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE

LS LU MC MW MZ NA NL OA PL PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE

DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG

KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ

OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG

US UZ VC VN YU ZA ZM ZW

ADT WO 2005014623 A2 WO 2004-DK527 20040806

PRAI DK 2004-814 20040525; DK 2003-1141 20030807

IC ICM C07K007-00

AB WO2005014623 A UPAB: 20050321

NOVELTY - Peptide compounds comprising two individual peptide sequences, are new.

DETAILED DESCRIPTION - Peptide compounds comprising two individual peptide sequences. At least one of the peptide sequences is a sequence of formula L1-A-L2-B-L3-C-L4-D-L5 (I). The peptide sequences are connected to each other through linker of formula X((A1)nCOOH)((B1)mCOOH) (II).

A - D = hydrophobic amino acid residue, basic amino acid residue, Asn, Gln, acidic amino acid residue, Asn, Gln, Gly or Ala;

L1 - L5 = chemical bond or an amino acid sequence having n1 amino acid residues;

n1 = 0 - 5;

n, m and p = 1 - 20;

X = HN, H2N(CR2)pCR, RHN(CR2)pCR, HO(CR2)pCR, HS(CR2)pCR, halogen(CR2)pCR, HOOC(CR2)pCR, ROOC(CR2)pCR, HCO(CR2)pCR, RCO(CR2)pCR, (HOOC(A1)n)(HOOC(B1)m)CR(CR2)pCR, H2N(CR2)p, RHN(CR2)p, HO(CR2)p, HS(CR2)p, halogen(CR2)p, HOOC(CR2)p, ROOC(CR2)p, HCO(CR2)p, RCO(CR2)p, or (HOOC(A1)n)(HOOC(B1)m)(CR2)p;

R and R2 = not defined;

A1 and B1 = 1-10C alkyl, 2-10C alkenyl, cyclic moiety, heterocyclic moiety or aromatic moiety (all optionally substituted);

A1+B1 = cyclic, heterocyclic, or aromatic moiety.

An INDEPENDENT CLAIM is included for preparation of the peptide compounds by ligand presenting assembly method.

ACTIVITY - CNS-Gen.; Cerebroprotective; Antiparkinsonian; Neuroprotective; Nootropic; Anticonvulsant; Antidiabetic; Antimanic; Antidepressant; Neuroleptic; Muscular-Gen.; Nephrotropic; Cardiant; Hepatotropic; Gastrointestinal-Gen.; Cytostatic; Vulnerary; Vasotropic; Antialcoholic; Ophthalmological; Auditory; Respiratory-Gen.; Antiarrhythmic.

The Neuroprotective efficacy of a peptide compound of formula T1-CO-CH2-NH-CH2-CO-T1 (FGL-L) (where T1 is -Glu-Val-Tyr-Val-Val-Ala-Glu-Asn-Gln-Gln-Gly-Lys-Ser-Lys-Ala-NH2) (IIa) was evaluated by analyzing

behavior and memory of rats in which cognitive impairment was induced by beta -amyloid fragment. (IIa) Was administered sub-occipitally at days 7, 10, and 13 following intracerebroventricular administration of the beta -amyloid fragment. Administration of beta -amyloid fragment caused significant increase in the time spent by the rat exploring a juvenile animal at a second meeting as well as amyloid burden and neuronal cell death. However treatment with (IIa) significantly reduced significant increase in the time spent by the rat exploring a juvenile animal at a second meeting. In rats treated/untreated with (IIa), the amyloid burden (%) in cingulated cortex was found to be 39/100; and density of neurons (neurons/mcm2 multiply 10-4) in hippocampus zone was found to be 22/15. (IIa) Was found to prevent short-term memory deficit and ameliorate neuropathological changes in the brain tissue.

MECHANISM OF ACTION - Fibroblast growth factor receptor (FGFR) modulator.

USE - In the manufacture of medicament for the treatment of conditions of the central and peripheral nervous system associated with postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic damage, e.g. resulting from stroke, Parkinson's disease, Alzheimer's disease, Huntington's disease, dementias (e.g. multiinfarct dementia), sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, schizophrenia, and mood disorders such as manic depression; diseases or conditions of the muscles including conditions with impaired function of neuro-muscular connections, such as after organ transplantation, and genetic or traumatic atrophic muscle disorders; diseases or conditions of various organs, such as degenerative conditions of the gonads, of the pancreas such as diabetes mellitus Type I and II, of the kidney such as nephrosis and of the heart, liver and bowel; also for the treatment of cancer (e.g. solid tumors requiring neoangiogenesis); for the promotion of wound-healing; for the prevention of death of heart muscle cells, such as after acute myocardial infarction, or after angiogenesis; for revascularisation; for the stimulation of the ability to learn and the short as well as long-term memory; for the prevention of cell death due to ischemia, and body damages due to alcohol consumption; for the treatment of prion diseases (all claimed). Also for the treatment of epilepsy, amyotrophic lateral sclerosis, disorders affecting multiple structures of eyes and ears, arrhythmia and diseases in pulmonary system.

ADVANTAGE - The compounds are capable of low affinity binding to fibroblast growth factor receptor (FGFR); exhibit excellent FGFR modulatory activity; and thus are important in treatment and prevention of different pathological conditions.

Dwg.0/28

FS CPI

FA AB; DCN

MC CPI: B04-C01; B04-C01H; B14-E10C; B14-F01A; B14-F01B; B14-F02; B14-G02C; B14-H01; B14-J01; B14-J05; B14-J07; B14-K01; B14-M01A; B14-N02; B14-N03; B14-N07; B14-N10; B14-N12; B14-N13; B14-N16; B14-N17B; B14-S04; D05-H17A

TECH UPTX: 20050321

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preparation (claimed): Preparation of the peptide compounds by ligand presenting assembly method involves:
 (1) providing ligands comprising desired sequence(s) by solid phase synthesis or fragment coupling, where the ligands are attached to a solid phase;
 (2) optionally deprotecting N-terminal amino acid groups while the ligands are still attached to the solid phase;
 (3) reacting the ligand(s) having unprotected N-terminal groups with an achiral di-, tri- or tetracarboxylic acid so as to provide a construct

having a ring structure; and

(4) cleaving the construct from the solid phase so as to provide an LPA comprising ligands having free C-terminal groups.

TECHNOLOGY FOCUS - BIOLOGY - Preferred Components: At least one of the peptide sequences is capable of binding to a functional cell surface receptor. The functional cell surface receptor is a receptor selected from the family of fibroblast growth factor receptors (FGFRs) (e.g. FGFR1, FGFR2, FGFR3, FGFR4, or their functional homologues).

The peptide sequence is derived from the sequence of a polypeptide selected from cell adhesion molecule, cell-surface receptor, heparan sulfate proteoglycans, **metalloprotease**, extracellular **matrix** molecule and growth factor (preferably the peptide sequence is selected from 146 sequences as given in the specification, e.g. Glu-Val-Tyr-Val-Val-Ala-Glu-Asn-Gln-Gln-Gly-Lys-Ser-Lys-Ala, Asn-Ile-Glu-Val-Trp-Val-Glu-Ala-Glu-Asn-Ala-Leu-Gly-Lys-Lys-Val, their fragments, variants or homologues).

The cell adhesion molecule is selected from 24 molecules, their fragments and variants as given in the specification, e.g. Neural Cell Adhesion Molecule (NCAM) (Swiss-Prot Ass. Nos: P13591, P13595-01, P13595), Axonin-1/TAG-1 (Swiss-Prot Ass. Nos: Q02246, P22063, P28685), and Cadherin (Swiss-Prot Ass. No: Q9VW71). The cell-surface receptor is selected from 30 receptors as given in the specification, e.g. Fibroblast Growth Factor Receptor 1 (FGFR1) (Swiss-Prot Ass. Nos: Q9QZM7, Q99AVV7, Q9UD50, Q63827), Fibroblast Growth Factor Receptor 2 (FGFR2) (Swiss-Prot Ass. Nos: Q96KM2, P21802, Q63241), Leukocyte Antigen Related Protein-Tyrosine Phosphatase (LAR-PTPRF) (Swiss-Prot Ass. Nos: Q9EQ17, Q64605, Q64604, Q9QW67, Q9VIS8, P10586), Insulin Receptor (IR) (Swiss-Prot Ass. No: Q9PWN6), and Interleukin-6 Receptor (IL-6R) (Swiss-Prot Ass. No: Q00560). The heparan sulfate proteoglycan is perlecan (Swiss-Prot Ass. No: P98160), its fragment or variant. The **metalloprotease** is selected from 12 **metalloproteases** as given in the specification, e.g. ADAM-8 (Swiss-Prot Ass. No: Q05910), ADAM-19 (Swiss-Prot Ass. No: Q9H013, Q35674). The extracellular **matrix** molecule is collagen type VII (Swiss-Prot Ass. No: Q63870), Fibronectin (Swiss-Prot Ass. Nos: Q95KV4, Q95KV5, P07589, Q28377, U42594, Q95609, P11276), or Tenascin-R (Swiss-Prot Ass. Nos: Q15568, Q00531, Q90995, P10039), their fragments or variants. The growth factor is cytokine-like factor-1 (CLF-1) (Swiss-Prot Ass. No: Q75462), its fragment or variant.

ABEX

UPTX: 20050321

ADMINISTRATION - Dosage (mg/kg) of the peptide compounds is 0.1 - 5000 (preferably 0.1 - 1000) or 0.1 - 1000 (preferably 0.1 - 250) when administered in monomeric or multimeric forms respectively. Administration is by oral, percutaneous, intramuscular, intravenous, intracranial, intrathecal, intracerebroventricular, intranasal, rectal, nasal, or pulmonary route.

EXAMPLE - A peptide compound of formula T1-CO-CH2-NH-CH2-CO-T1 (FGL-L) (where T1 is -Glu-Val-Tyr-Val-Val-Ala-Glu-Asn-Gln-Gln-Gly-Lys-Ser-Lys-Ala-NH2) was made by coupling N-tert-butyl oxycarbonyl-iminodiacetic acid to the peptide on the resin using O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate/1-hydroxybenzotriazol as described in WO 00/18791. The peptide was cleaved from the resin and simultaneously deprotected on the side chains on TFA in the presence of TES and water. The resultant LPA-type dimmer (0.5 mg/ml) was purified by reverse phase HPLC.

L151 ANSWER 2 OF 20 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2005-132500 [14] WPIX

DNC C2005-043705

TI New tetracycline compounds useful to treat e.g. bacterial, viral and

parasitic infections, cancer, bone mass disorders and neurological disorders.

DC B03 B05
IN AMOO, V; ASSEFA, H; BERNIAC, J; BHATIA, B; BOWSER, T; CHEN, J; GRIER, M;
HONEYMAN, L; KIM, O; MECHICHE, R; OHMEMENG, K; PAN, J

PA (PARA-N) PARATEK PHARM INC

CYC 108

PI WO 2005009944 A1 20050203 (200514)* EN 45 C07C237-26
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE
LS LU MC MW MZ NA NL OA PL PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE
DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG
KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ
OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG
US UZ VC VN YU ZA ZM ZW

ADT WO 2005009944 A1 WO 2004-US20305 20040625

PRAI US 2004-566150P 20040427; US 2003-486017P 20030709;

US 2003-525287P 20031125; US 2003-530123P 20031216

IC ICM C07C237-26

ICS A61K031-65

AB WO2005009944 A UPAB: 20050228

NOVELTY - Tetracycline compounds (A) and their salts are new.

DETAILED DESCRIPTION - Tetracycline compounds (A) of formulae (I)-(IV) and their salts are new.

E = O, N or a covalent bond;

G = alkyl, heterocyclicalkyl, aryl, alkylcarbonyloxyalkyl, arylcarbonyloxyalkyl or alkoxyalkoxyalkyl;

Q1 = a prodrug moiety and its salts (preferably (C=O)-E1-G1);

E1 = O, N or a covalent bond (preferably O);

G1 = alkyl, heterocyclicalkyl, aryl, alkylcarbonyloxyalkyl, arylcarbonyloxyalkyl, alkyloxyalkyl, arylalkylcarbonyloxyalkyl, alkyloxyalkylcarbonyloxyalkyl or alkoxyalkoxyalkyl (especially alkylcarbonyloxyalkyl, most preferably (CH₂)_m-O-(C=O)-R7);

m = 1-5 (preferably 1);

R7 = alkyl (preferably methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, (CH₂)₁₀-CH₃ or (CH₂)₁₁-CH₃);

Q2 = a prodrug moiety or its salt (preferably (C=O)-G2);

G2 = alkyloxyalkyl or alkyl;

Q3 = a prodrug moiety or its salt (preferably (C=O)-E3-G3);

E3 = O, N or a covalent bond (preferably O); and

G3 = alkyl, heterocyclicalkyl, aryl, alkylcarbonyloxyalkyl, arylcarbonyloxyalkyl, alkyloxyalkyl, arylalkylcarbonyloxyalkyl, alkyloxyalkylcarbonyloxyalkyl or alkoxyalkoxyalkyl (preferably aryl or alkyl (both optionally substituted)).

ACTIVITY - Antibacterial; Virucide; Antiparasitic; Fungicide; Cytostatic; Antiarthritic; Osteopathic; CNS-Gen.; Respiratory-Gen.; Antidiarrheic; Uropathic; Dermatological; Auditory; Vulnerary; Antiinflammatory; Antimalarial; Vasotropic; Cerebroprotective; Ophthalmological; Antiulcer; Antidiabetic; Neuroprotective; Nootropic.

An assay to determine the efficacy of tetracycline compounds (A) against common bacteria is described, but no results are given.

MECHANISM OF ACTION - None given.

USE - (A) are useful to treat tetracycline responsive states (bacterial infections, viral infections or parasitic infections; where the bacterial infection (gram positive or gram negative) is associated with E. coli, S. aureus or E. faecalis; and the infection is resistant to other tetracycline antibiotics) in subjects (preferably humans) (claimed). (A) are useful to treat fungal infections, cancer (e.g. prostate cancer and melanoma), neoplasms, arthritis, osteoporosis, cystic fibrosis, diarrhea, urinary tract infections, infections of skin and skin structure,

ear, nose and throat infections, wound infection, mastitis, inflammatory process associated states (e.g. osteoarthritis and upper respiratory infections), nitric oxide associated states (e.g. malaria and vascular stroke), **matrix metalloproteinase** associated states (e.g. corneal ulceration and emphysema), acute lung injury, diabetes (e.g. juvenile diabetes), bone mass disorders (e.g. osteoporosis and Paget's disease), chronic lung disorders, ischemia, stroke, ischemic stroke, skin wound, neurological disorders (e.g. Alzheimer's disease and dementias), aortic or vascular aneurysm in vascular tissue and other states for which (A) have been found to be active.

ADVANTAGE - (A) is substantially non-toxic when compared to other cancer treatments.

Dwg.0/0

FS

CPI

FA

AB; GI; DCN

MC

CPI: B02-T; B14-A01; B14-A01A; B14-A01A3; B14-A01B; B14-A01B4; B14-A02; B14-A03B; B14-A04; B14-B02; B14-C03; B14-C09; B14-C09A; B14-D07C1; B14-E02; B14-E08; B14-F01; B14-F02; B14-F02D; B14-F02D1; B14-H01; B14-H01B; B14-J01; B14-J01A4; B14-K01; B14-N01; B14-N01A; B14-N02; B14-N04; B14-N05B; B14-N07; B14-N16; B14-N17; B14-N17B; B14-N18; B14-S04; B14-S16

TECH

UPTX: 20050228

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preparation: Disclosed preparation of (I) comprises:

(a) reaction of a tetracycline compound of formula (a) with N-hydroxy benzopyrole-2,7-dione in the presence of methylamine, methanol and hydrochloric acid; and

(b) reaction of the obtained amino tetracycline compound of formula (b) with 3,3-dimethyl-butylaldehyde in the presence of sodiumhypoboroacetate and dimethylformamide to give a tetracycline compound of formula (c) (representative compound of (I)).

Preferred Method: For the treatment of diseases, (A) is administered with a pharmaceutically acceptable carrier; and (A) is metabolized in vivo to tetracycline compounds of formulae (1)-(4).

ABEX

UPTX: 20050228

SPECIFIC COMPOUNDS - 33 compounds (A) are specifically claimed e.g. N-t-butylcarbonyloxymethyl (9-((2,2-dimethyl-propylamino)-methyl)-minocycline) carbamate of formula (Ia).

ADMINISTRATION - Administration of (A) is 0.01-100 (preferably 1-20) mg/kg/day, orally, parenterally or topically.

EXAMPLE - A mixture of sodium bicarbonate (3.21 g), tetrabutylammonium sulfate (6.49 g), pentanoic acid (1.95 g), water (38.5 ml) and dichloromethane (38.5 ml) was stirred for 1 hour. A solution of crude thiocarbonic acid O-iodomethyl ester S-ethyl ester (3.5 g) in dichloromethane (7 ml) was added over a 0.5 hour period and the temperature was maintained below 30degreesC. The mixture was then stirred for further 1.5 hours at room temperature. The reaction mixture was worked up to give 2,2-dimethyl propionic acid ethylsulfanylcabonyl oxymethyl ester (i). Sulfuryl chloride (0.68 ml) was added to (i) (1.84 g) at 0-5degreesC with stirring over 5 minutes. The solution was worked up to give t-butylcarbonyloxymethyl chloroformate (ii). To a mixture of 9-((2,2-dimethyl-propyl amino)-methyl)-minocycline (0.1 g), sodium bicarbonate (63 mg) in water (1 ml) and dichloromethane (20 ml) was added the t-butylcarbonyloxymethyl chloroformate (44 mg). The reaction mixture was worked up to give N-t-butylcarbonyloxymethyl (9-((2,2-dimethyl-propylamino)-methyl)-minocycline) carbamate (25 mg).

DEFINITIONS - Preferred Definitions: In (I),

E = either a covalent bond (where G is alkyl); or a nitrogen (where G is aryl; preferably substituted phenyl); or an oxygen (where G is alkylcarbonyloxyalkyl (preferably (CH₂)_g-O-(C=O)-R₁), alkyloxycarbonyloxyalkyl (preferably (CH₂)-O-(C=O)-O-R₃), arylcarbonyloxyalkyl (preferably (CH₂)_f-O-(C=O)-R₂), alkyl (preferably methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, (CH₂)₁₀-CH₃ or (CH₂)₁₁-CH₃), alkyloxycarbonyloxyalkyl (preferably (CH₂)-O-(C=O)-O-R₃), arylalkylcarbonyloxyalkyl (preferably (CH₂)-O-(C=O)-(CH₂)_h-R₄), alkyloxyalkylcarbonyloxyalkyl (preferably (CH₂)-O-(C=O)-(CH₂)_i-R₅), alkoxyalkoxyalkylcarbonyloxyalkyl (preferably (CH₂)-O-(C=O)-(CH₂)_j-O-(CH₂)_k-O-R₆));

g = 1-5 (preferably 1, where R₁ is alkyl (preferably methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, (CH₂)₁₀-CH₃, (CH₂)₁₁-CH₃ or cycloalkyl); or 2 (where R₁ is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, (CH₂)₁₀-CH₃ or (CH₂)₁₁-CH₃));

f = 1-5 (preferably 1);

R₂ = aryl (preferably phenyl optionally substituted with halo, alkoxy and/or alkyl);

R₃ = alkyl (preferably methyl, ethyl, propyl, butyl or pentyl);

h = 1-5 (preferably 1-2);

R₄ = aryl (preferably phenyl);

i = 1-5 (preferably 1-3);

R₅ = methyl;

j and k = 1-5; and

R₆ = alkyl (preferably methyl; where j is 1 and k is 2).

L151 ANSWER 3 OF 20 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2004-794473 [78] WPIX

CR 2004-783852 [77]; 2004-794491 [78]

DNC C2004-277232

TI Sparing tissue levels of **alpha-1-antitrypsin** in animal for treatment of inflammatory diseases or disorders, or hypotension, comprises administering nitric oxide synthase inhibitor.

DC B05

IN SHAPIRO, L

PA (SHAP-I) SHAPIRO L

CYC 1

PI US 2004220113 A1 20041104 (200478)* 22 A61K038-04

ADT US 2004220113 A1 Div ex US 2003-427929 20030502, US 2003-669250 20030925

PRAI US 2003-427929 20030502; US 2003-669250 20030925

IC ICM A61K038-04

ICS A61K031-4245

AB US2004220113 A UPAB: 20041206

NOVELTY - Sparing tissue levels of **alpha 1-antitrypsin** in animal, comprises administering nitric oxide synthase inhibitor.

ACTIVITY - Vasotropic; Hypertensive; Respiratory-Gen.; Anti-HIV; Neuroprotective; Nootropic; Antiasthmatic; Antiarteriosclerotic; Immunosuppressive; Cardiant; Cytostatic; Antiinflammatory; Cerebroprotective; Cardiovascular-Gen.; Antidiabetic; Analgesic; Gynecological; Antibacterial; Nephrotropic; Ophthalmological; Gastrointestinal-Gen.; Hypotensive; Antiulcer; Hepatotropic; Antimigraine; Antiarthritic; Osteopathic; Antiparkinsonian; Protozoacide; Antianemic; Antisickling; Antirheumatic; Dermatological.

MECHANISM OF ACTION - Serine protease inhibitor; Antagonist.

USE - For sparing tissue levels of **alpha 1-antitrypsin** in animal, e.g. human, and for treatment of inflammatory diseases or disorders, or hypotension, acquired tubulointerstitial disease, acute pancreatitis, acute respiratory failure,

acute respiratory distress syndrome (ARDS), age-associated memory impairment, AIDS, airway inflammation, Alzheimer's disease, amyotrophic lateral sclerosis, asthma, atherosclerosis, autoimmune disease, myocarditis, carcinogenesis, cerebral ischemia, cerebrovascular disease, chronic liver disease, chronic lung disease, chronic obstructive pulmonary disease, chronic otitis media, congestive heart failure, coronary artery disease, coronary artery ectasia, diabetes mellitus, diabetic neuropathy, dysfunctional uterine bleeding, dysmenorrhea, endotoxic shock, end-stage renal disease falciparum malaria, gastric carcinogenesis, gastrointestinal pathophysiology, glaucoma, glutamate-induced asthma, glutamate induced Chinese restaurant syndrome, heart failure, heat stress, gastritis, 'hotdog headache', Hirschprung's disease, HIV infection, hypertension, hypoxemic respiratory failure, inflammatory arthritis, inflammatory bowel disease (Crohn's disease and ulcerative colitis), inflammatory joint disease, liver cirrhosis, liver disease, Lyme neuroborreliosis, migraine, multiple sclerosis, neonatal and pediatric respiratory failure, nephrotoxicity, neurodegenerative diseases, orthopedic disease, osteoarthritis, oxidant stress, Parkinson's disease, pediatric pulmonary disease, pleural inflammation, preeclampsia, primary ciliary dyskinesia, primary pulmonary hypertension, protozoan infections, pugilistic Alzheimer's disease, pulmonary hypertension, retinal disease, septic shock, sickle cell anemia, rheumatoid arthritis, stroke, systemic lupus erythematosus, traumatic brain injury, tumor progression, or vascular disease.

ADVANTAGE - The method provides for treatment of diseases dependent on the action of NO and proteases. The serine protease inhibitors exhibit high activity at low concentrations.

Dwg.0/7

FS

CPI

FA

AB; DCN

MC

CPI: B02-T; B04-B04D2; B06-D05; B06-F03; B07-D03; B07-D12; B07-D13; B10-A03; B10-A05; B10-A13A; B10-A17; B10-B01B; B14-A02B1; B14-A03; B14-A03B; B14-C01; B14-C03; B14-C04; B14-C09; B14-D01C; B14-D07C; B14-E10; B14-F01B; B14-F01E; B14-F02; B14-F03; B14-F07; B14-F08; B14-G01B; B14-G02D; B14-H01; B14-J01; B14-K01; B14-L06; B14-N01; B14-N03; B14-N10; B14-N12; B14-N13; B14-N14; B14-N16; B14-N17; B14-S01; B14-S04; B14-S06; B14-S08

TECH

UPTX: 20041206

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Compounds: The nitric oxide (NO) synthase inhibitor comprises N-G-nitro-L-arginine methyl ester, N-G-nitro-L-arginine N,N'-dimethylarginine, N-G-monoethyl-L-arginine acetate, N-G-monomethyl-L-arginine acetate, N-G-monomethyl-D-arginine, N-G-monomethyl-L-homoarginine acetate, N-G-nitro-D-arginine, N-G-nitro-D-arginine methyl ester hydrochloride, omega-nitro-arginine, L-N6-(1-iminoethyl)lysine, aminoguanidine, S-methylisothiourea sulfate, S-ethylisothiourea sulfate, S-aminoethylisothiourea sulfate, mercaptoethylguanidine, 2,4-diamino-6-hydroxypyrimidine, diphenyleneiudonium chloride, 2-ethyl-2-thiopseudourea hydrobromide, 2-iminobiotin, L-N-5-(1-iminoethyl)ornithine hydrochloride, S-methyl-L-thiocitrulline dihydrochloride, p-nitroblue tetrazolium chloride, 3-bromo-7-nitroindazole, pentamidine isethionate, 1-pyrrolidinecarbodithioic acid, spermidine, spermine-NO, 3-morpholinonydonimine-N-ethyl-carbamide, L-thiocitrulline, troleandomycin, 7-nitroindazole, hemoglobin, myoglobin, cytochrome V, A-nitroso-N-acetylpenicillamine S-nitrosoglutathione, or nitroglycerine, or their free bases or salts.

ABEX

UPTX: 20041206

ADMINISTRATION - Doses are administered at 0.01-20 mg/ml biologic fluid of treated patient, by injection, continuous intravenous infusion, transdermally, or orally.

L151 ANSWER 4 OF 20 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2004-783852 [77] WPIX

CR 2004-794473 [78]; 2004-794491 [78]

DNC C2004-274208

TI Use of **alpha-1-antitrypsin**, **alpha-1-antitrypsin-like agent**, antielastase, antiproteinase-3 agent and/or serine protease inhibitor for the treatment of ischemia reperfusion injury.

DC B05

IN SHAPIRO, L

PA (SHAP-I) SHAPIRO L

CYC 1

PI US 2004220239 A1 20041104 (200477)* 22 A61K031-433

ADT US 2004220239 A1 Div ex US 2003-427929 20030502, US 2003-669251 20030925

PRAI US 2003-427929 20030502; US 2003-669251 20030925

IC ICM A61K031-433

ICS A61K031-4245

AB US2004220239 A UPAB: 20041206

NOVELTY - Treatment of ischemia reperfusion injury involves administration of at least one of **alpha 1-antitrypsin**, **alpha 1-antitrypsin-like agent**, antielastase, antiproteinase-3 agent and/or serine protease inhibitor.

ACTIVITY - Vasotropic; Cerebroprotective; Nephrotropic; Nootropic; Neuroprotective; Respiratory-Gen.; Antiinflammatory; Hepatotropic; Anti-HIV; Virucide; Immunosuppressive; Antidiabetic; Auditory; Cardiant; Gynecological; Analgesic; Antibacterial; Ophthalmological; Antimalarial; Gastrointestinal-Gen.; Osteopathic; Antiasthmatic; Antiarteriosclerotic; Protozoacide; Dermatological; Cytostatic; Hypotensive; Antiulcer; Antimigraine; Antianemic; Antisickling; Antirheumatic; Tranquilizer; Vulnerary; Antiarthritic; Antiparkinsonian.

MECHANISM OF ACTION - Nitric oxide synthesis inhibitor. The efficacy of **alpha 1-antitrypsin** (Ia) to inhibit nitric oxide synthesis was evaluated in macrophages. RAW 264.5 cell monolayers of macrophages were treated with (Ia) (0.1 - 3 mg/ml), followed by costimulation with interferon- gamma (10 U/ml) and lipopolysaccharide (1 ng/ml) for 18 hours. After incubation aliquots of supernatant were combined with Greiss reagent and incubated at room temperature for 10 minutes and then nitric oxide concentration was measured colorimetrically. The cell layers were treated with costimulants without (Ia) as control. The produced nitric oxide (nmol of NO₂/10⁶ cells) was found to be 1, 2, 4.5 and 8 in the cell supernatant treated with 3, 1 and 0.1 mg/ml of (Ia) and control respectively.

USE - For the treatment of ischemia reperfusion injury associated with heart, brain, lung, kidneys or liver (claimed). Also for the treatment of acute pancreatitis, acute respiratory failure, acute respiratory distress syndrome (ARDS), age-associated memory impairment, AIDS, cytomegalovirus infection, Herpes simplex infection, airway inflammation, Alzheimer's disease, amyotrophic lateral sclerosis, asthma, atherosclerosis, autoimmune disease, myocarditis, carcinogenesis, cerebral ischemia, cerebrovascular disease, chronic liver disease, chronic lung disease, chronic obstructive pulmonary disease, chronic otitis media, congestive heart failure, coronary artery disease, diabetes mellitus, diabetic neuropathy, dysfunctional uterine bleeding, dysmenorrhea, endotoxic shock, end-stage renal disease, falciparum malaria, gastrointestinal pathophysiology, glaucoma, glutamate-induced asthma, heart failure, heat stress, gastritis, hypertension, inflammatory arthritis, inflammatory bowel disease (Crohn's disease and ulcerative colitis), inflammatory joint diseases, liver cirrhosis, liver disease, migraine, multiple sclerosis, neonatal and pediatric respiratory failure,

nephrotoxicity, neurodegenerative diseases, orthopedic disease, osteoarthritis, oxidant stress, Parkinson's disease, pediatric pulmonary disease, preeclampsia, primary ciliary dyskinesia, protozoan infections, pulmonary hypertension, retinal disease, septic shock, sickle cell anemia, rheumatoid arthritis, stroke, systemic lupus erythematosus, traumatic brain injury, tumor progression, and vascular disease.

ADVANTAGE - The method is safe and effective for amelioration of many diseases related to nitric oxide-caused damage. The therapeutic agents used exhibit significant potential as nitric oxide synthesis inhibitor, and high activity at relatively low concentration.

Dwg.0/7

FS CPI

FA AB; DCN

MC CPI: B04-C01A; B04-M01; B04-N02; B04-N04A; B07-D03; B07-E04; B14-A02A3; B14-A03; B14-C01; B14-C03; B14-C04; B14-C09; B14-D01C; B14-D07C; B14-E08; B14-E10; B14-F01B; B14-F01E; B14-F02; B14-F03; B14-F05; B14-F07; B14-F08; B14-G01B; B14-G02D; B14-H01; B14-J01; B14-K01; B14-N02; B14-N03; B14-N10; B14-N12; B14-N13; B14-N14; B14-N16; B14-N17; B14-S01; B14-S04; B14-S06; B14-S08

TECH UPTX: 20041203

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Method: The method further involves administration of a thrombolytic agent; and using a mechanical device to reestablish blood flow. The mechanical device involves angioplasty or percutaneous transluminal coronary angioplasty. Preferred Component: The alpha1-antitrypsin-like agent is a form of alpha1-antitrypsin resistant to inactivation by reactive oxygen intermediates.

ABEX UPTX: 20041203

ADMINISTRATION - Dosage of the compounds is 0.01 - 20 mg/ml of biological fluid of treated patient. Administration is by oral, topical, transdermal, parenteral (including subcutaneous, intravenous, intraarterial, intranasal, intraperitoneal, intramuscular), transbronchial, transalveolar, or rectal route.

EXAMPLE - No relevant example given.

L151 ANSWER 5 OF 20 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2004-765487 [75] WPIX

CR 2003-342643 [32]; 2004-329624 [30]

DNN N2004-603924 DNC C2004-268299

TI New triazine compounds are smooth muscle proliferation inhibitor useful for treating inflammation mediated disease and hyperproliferative disease.

DC B03 B04 D22 S05 T01

IN ALEXANDER, C W; KRISHNA, R V V; KUMAR, P R; PAL, M; PILLARISETTI, S; REDDY, G O; REDDY, J T; SAXENA, U; SRIDEVI, B S; TIMMER, R T; YELESWARAPU, K R

PA (ALEX-I) ALEXANDER C W; (KRIS-I) KRISHNA R V V R M; (KUMA-I) KUMAR P R; (PALM-I) PAL M; (PILL-I) PILLARISETTI S; (REDD-I) REDDY G O; (REDD-I) REDDY J T; (SAXE-I) SAXENA U; (SRID-I) SRIDEVI B S; (TIMM-I) TIMMER R T; (YELE-I) YELESWARAPU K R

CYC 1

PI US 2004209881 A1 20041021 (200475)* 254 A61K031-53

ADT US 2004209881 A1 US 2003-400134 20030326

PRAI US 2003-400134 20030326

IC ICM A61K031-53

ICS C07D251-48; C07D403-02

AB US2004209881 A UPAB: 20050603

NOVELTY - Triazine compounds (I) are new.

DETAILED DESCRIPTION - Triazine compounds of formula (I) are new.

R1b = e.g. 4-fluoro-5-methoxy-pyridin-2-yl, 3-fluoro-2-methoxy-

pyridin-5-yl, 3-fluoro-4-(Na+ O-)-phenyl, 3-fluoro-4-(K+ O-)-phenyl, 3-(trifluoromethyl)-4-methoxyphenyl or 4-methoxy-3-carboxy-phenyl (or its sodium salt);

R2b = e.g. hexahydro-pyrrolo(1,2-c)imidazol-2-yl, hexahydro-pyrrolo(1,2-c)imidazol-3-on-2-yl, 2,3-dihydro-1H-indol-1-yl or 1H-indol-1-yl;

R4b = H, CH₃, CH₂CH₃ or CH₂CH₂CH₃;

R5b = e.g. cycloheptane, cyclohepten-4-yl, azepan-4-yl or 1-methyl-azepan-4-yl;

R6b = O, NH, NCH₃, NCH₂CH₃ or N-C=N; and

R7b = cycloheptanyloxy, cyclopropyloxy, cyclopentanyloxy, cyclohexanyloxy or -N(R4b)R5b.

NB: Full definitions are given in the Definitions (Full Definitions) field.

INDEPENDENT CLAIMS are included for the following:

- (1) a composition (C1) comprising (I);
- (2) a medical device comprising a drug delivering or eluting member and (C1) disposed on or in the drug delivering or eluting member;
- (3) a microarray comprising a gene expression profile generated from a cell type treated with (I); and
- (4) an expression profile database comprising a patient identifying reference; and an expression profile for the patient generated by administering (I).

ACTIVITY - Cytostatic; Antiinflammatory; Vasotropic; Antiarteriosclerotic; Antidiabetic; Cardiovascular-Gen.; Immunosuppressive; Antiarteriosclerotic; Antiarthritic; Antirheumatic; Antiulcer; Gastrointestinal-Gen.; Osteopathic; Dermatological; Ophthalmological; Neuroprotective; Respiratory-Gen.; Vasotropic; Antiallergic; Antiasthmatic; Antipsoriatic; Antibacterial; Fungicide; Virucide; Vulnerary; Cerebroprotective; Hemostatic; Nephrotropic; Hepatotropic; Muscular-Gen.

MECHANISM OF ACTION - Glycated protein inhibitor/blocker; Smooth muscle proliferation inhibitor; Heparanase activity modulator/inhibitor.

(I) was tested for smooth muscle proliferation inhibition (SMC) activity using human aortic smooth muscle cells and smooth muscle cell proliferation assay. (I) showed SMC inhibition of greater than 70%.

USE - For treating unwanted cellular proliferation, inflammation mediated disease, hyperproliferative disease, modulating a glycosidase enzyme in a human or an animal (claimed). Also useful for treating pathophysiological conditions arising from inflammatory responses and vascular occlusive conditions characterized by smooth muscle proliferation e.g. restenosis and atherosclerosis, and diabetes, cardiovascular diseases, organ transplant sequelae, neointimal hyperplasia, transplant vasculopathy, cardiac allograft vasculopathy and arteriosclerosis; for treating and preventing cancer, autoimmune diseases, arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, gastric ulcer, seronegative arthropathies, osteoarthritis, inflammatory bowel disease, ulcerative colitis, systemic lupus erythematosus, antiphospholipid syndrome, iridocyclitis/uveitis/optic neuritis, idiopathic pulmonary fibrosis, systemic vasculitis/wegener's granulomatosis, sarcoidosis, orchitis/vasectomy reversal procedures, allergic/atopic diseases, asthma, allergic rhinitis, eczema, allergic contact dermatitis, allergic conjunctivitis, hypersensitivity pneumonitis, transplants, organ transplant rejection, graft-versus-host disease, systemic inflammatory response syndrome, sepsis syndrome, gram positive sepsis, gram negative sepsis, culture negative sepsis, fungal sepsis, neutropenic fever, urosepsis, meningococemia, trauma/hemorrhage, burns, ionizing radiation exposure, acute pancreatitis, adult respiratory distress syndrome, alcohol-induced hepatitis, chronic inflammatory pathologies, Crohn's pathology, sickle cell anemia, diabetes, nephrosis,

atopic diseases, hypersensitivity reactions, perennial rhinitis, conjunctivitis, endometriosis, asthma, urticaria, systemic anaphylaxis, dermatitis, pernicious anemia, hemolytic disease, thrombocytopenia, graft rejection of any organ or tissue, kidney transplant rejection, heart transplant rejection, liver transplant rejection, pancreas transplant rejection, lung transplant rejection, bone marrow transplant (BMT) rejection, skin allograft rejection, cartilage transplant rejection, bone graft rejection, small bowel transplant rejection, fetal thymus implant rejection, parathyroid transplant rejection, xenograft rejection of any organ or tissue, allograft rejection, anti-receptor hypersensitivity reactions, Graves disease, Raynaud's disease, type B insulin-resistant diabetes, myasthenia gravis, -mediated cytotoxicity, type III hypersensitivity reactions, POEMS syndrome, polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes syndrome, anti-phospholipid syndrome, pemphigus, scleroderma, mixed connective tissue disease, idiopathic Addison's disease, autoimmune hemolytic anemia, autoimmune hepatitis, idiopathic pulmonary fibrosis, scleroderma, diabetes mellitus, chronic active hepatitis, vitiligo, vasculitis, post-MI cardiotomy syndrome, contact dermatitis, hypersensitivity pneumonitis, granulomas due to intracellular organisms, drug sensitivity, metabolic/idiopathic, Wilson's disease, hemochromatosis, **alpha-1-antitrypsin** deficiency, diabetic retinopathy, hashimoto's thyroiditis, osteoporosis, hypothalamic-pituitary-adrenal axis evaluation, primary biliary cirrhosis, thyroiditis, encephalomyelitis, cachexia, cystic fibrosis, neonatal chronic lung disease, chronic obstructive pulmonary disease (COPD), familial hemophagocytic lymphohistiocytosis, dermatologic conditions, psoriasis, alopecia, nephrotic syndrome, nephritis, glomerular nephritis, acute renal failure, hemodialysis, uremia, toxicity, preeclampsia, ankylosing spondylitis, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, CREST syndrome, cold agglutinin disease, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia-fibromyositis, Graves' disease, Guillain-Barré, idiopathic thrombocytopenia purpura (ITP), IgA nephropathy, insulin dependent diabetes, lichen planus, meniere's disease, multiple sclerosis, pemphigus vulgaris, polyarteritis nodosa, Cogan's syndrome, polycondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobulinemia, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, stiff-man syndrome, Takayasu arteritis and temporal arteritis/giant cell arteritis.

Dwg.0/86

FS

CPI EPI

FA

AB; GI; DCN

MC

CPI: B05-B01M; B06-H; B07-D13; B11-C04; B11-C08E6; B11-C09; B12-K04; B14-C03; B14-C04; B14-C06; B14-C09; B14-D01; B14-D07B; B14-E08; B14-E10C; B14-E11; B14-F01; B14-F02; B14-F03; B14-F07; B14-F08; B14-G02; B14-H01; B14-J01; B14-J05; B14-K01; B14-L06; B14-M01; B14-N01; **B14-N02**; B14-N03; B14-N04; B14-N07; B14-N10; B14-N11; B14-N12; B14-N13; B14-N14; B14-N16; B14-N17; B14-R02; B14-S01; B14-S04; B14-S06; D08-B; D09-C01

EPI: S05-G02G1; T01-J05B4P; T01-J06A1

TECH

UPTX: 20041122

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preparation: No general method for preparation of (I) is given.

TECHNOLOGY FOCUS - BIOLOGY - Preferred Cell: The cell type is coronary artery, umbilical artery, umbilical vein, aortic, dermal microvascular, pulmonary artery or myometrium microvascular endothelium, keratinocyte, bronchial, mammary, prostate, renal cortical, renal proximal tubule, small

airway or renal epithelium, umbilical artery smooth muscle, neonatal dermal fibroblast, pulmonary artery smooth muscle, dermal fibroblast, neural progenitor cells, skeletal muscle, astrocytes, aortic smooth muscle, mesangial cells, coronary artery, bronchial or uterine smooth muscle, lung fibroblast, osteoblasts or prostate stromal cells.

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: (C1) Further comprises a carrier and optionally auxiliary, preservative and excipient. (C1) further comprising an agent selected from a chemotherapeutic agent, immunosuppressive agent, cytokine, cytotoxic agent, nucleolytic compound, radioactive isotope, receptor, pro-drug activating enzyme, anti-inflammatory agent, antirheumatic agent, cardiovascular agent and/or toxin.

ABEX

UPTX: 20041122

WIDER DISCLOSURE - Triazine compounds of formula (II) are also disclosure as new.

Na, Nb and Nc = pendant substituted amino group.

SPECIFIC COMPOUNDS - 162 Compounds are specifically claimed as (I) e.g. N-(3-chloro-4-methoxy-phenyl)-N'-cycloheptyl-N''-(1-ethyl-pyrrolidin-2-ylmethyl)-(1,3,5)triazine-2,4,6-triamine.

ADMINISTRATION - The drug delivering or eluting member is selected from a shunt, colostomy bag attachment device, ear drainage tube, lead for a pace maker, lead for an implantable defibrillator, suture, staple, anastomosis device, vertebral disk, bone pin, suture anchor, hemostatic barrier, clamp, screw, plate, clip, vascular implant, tissue adhesive, tissue sealant, tissue scaffold, bone substitute, intraluminal device, stent or vascular support (preferably stent). (C1) Is in the form of tablet, capsule, cachet, powder, granule, solution, suspension, emulsion, bolus, lozenge, suppository, pessary, tampon, cream, gel, paste, foam, spray, aerosol, microcapsule, liposome, transdermal patch, pastille, paste or mouthwash (claimed). Dosage of (I) is 0.1 - 100 mg and administered orally, corneal, conjunctivally, buccally, sublingually, nasally, vaginally, pulmonary, abdominally, intestinally, rectally or suppository.

EXAMPLE - To 6-chloro-N-(3-chloro-4-methoxy-phenyl)-N'-cycloheptyl-(1,3,5)triazine-2,4-diamine (0.1257 g) dissolved in acetonitrile (3 ml) was added N,N-diisopropylethylamine (DIEA) (0.07 ml) followed by 2-(aminomethyl)-1-ethyl pyrrolidine (0.06 ml). The mixture was refluxed overnight under a nitrogen atmosphere. After work-up N-(3-chloro-4-methoxy-phenyl)-N'-cycloheptyl-N-(1-ethyl-pyrrolidin-2-ylmethyl)-(1,3,5)triazine-2,4,6-triamine (77 mg) was obtained.

DEFINITIONS - Full Definitions:

R1b = 3-X-4-methoxy-phenyl, 4-fluoro-5-methoxy-pyridin-2-yl, 3-fluoro-2-methoxy-pyridin-5-yl, 3-fluoro-4-(Na⁺ O⁻)-phenyl, 3-fluoro-4-(K⁺ O⁻)-phenyl, 3-(trifluoromethyl)-4-methoxyphenyl, 3-(trifluoromethyl)-4-(trifluoromethoxy)phenyl, 3-(trifluoromethyl)-4-hydroxyphenyl, 3-fluoro-4-Y-phenyl or 4-methoxy-3-carboxy-phenyl (or its sodium salt);

X = fluoro, chloro, bromo or iodo;

Y = methoxymethoxy, methylthiomethoxy, cyclopropyloxy, PO₃-O-methoxy, di(tert-butoxy)-P(O)-O-methoxy, di(benzyloxy)-P(O)-O-methoxy, PO₄, methoxyethoxyethoxyethoxyethylcarbonyloxy, hydroxyethoxyethoxyethoxyethylcarbonyloxy, hydroxyethoxyethoxyethoxyethoxy or methoxyethoxyethoxyethoxyethoxy;

R2b = hexahydro-pyrrolo(1,2-c)imidazol-2-yl, hexahydro-pyrrolo(1,2-c)imidazol-3-on-2-yl, 2,3-dihydro-1H-indol-1-yl, 1H-indol-1-yl, -NH-R3b, -N(CH₃)-R3b or -O-R3b;

R3b = 1-Ra-pyrrolidin-2-ylmethyl, 1-Rb-piperidin-4-yl, tetrahydrofuran-2-

yl, 1-ethyl-pyrrolidin-2-yl oxide, hexahydropyran-4-yl, 1-ethylpyrrolidinium-2-ylmethyl bromide, chloride, iodide, fumarate or succinate, 1-ethyl-1-methylcarbonylpyrrolidinium-2-ylmethyl chloride, 1-methyl-1-PO₄CH₂-pyrrolidinium-2-ylmethyl chloride or trifluoroacetate, 1-ethyl-1-(di(tert-butoxy or benzyloxy)P(O)-OCH₂)-pyrrolidinium-2-yl methyl chloride, 1-methylpyrrol-2-ylmethyl, thiphen-2-ylmethyl, 1,1-dioxothiophen-2-ylmethyl, furan-2-yl, 2-ethyl, methyl, amino or hydroxy-cyclopentyl, 3-hydroxycyclopentyl, imidazol-4-yl or pyridin-2 or 3-yl;

Ra = H, methyl, ethyl, C(O)H, COOH, C(O)NH₂, hydroxyethoxyethoxyethoxyethoxyethylcarbonyl, methoxyethoxyethoxyethoxyethoxyethylcarbonyl, hydroxyethoxyethoxyethoxyethoxymethyl, methoxyethoxyethoxyethoxyethoxymethyl or PO₄-CH₂-;

Rb = COOH, C(O)NH₂, C(O)CH₃, H, methyl, amino, dimethylamino, ethylcarbonyl, propylcarbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, hydroxy, methylcarbonylmethyl, ethylcarbonylmethyl, propylcarbonylmethyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, propoxycarbonylmethyl or phenoxycarbonyl;

R4b = H, CH₃, CH₂CH₃ or CH₂CH₂CH₃;

R5b = cycloheptane, cyclohepten-4-yl, azepan-4-yl, 1-methyl-azepan-4-yl, thiepan-4-yl, thiepane 1,1-dioxid-4-yl, oxepan-2-yl, azepan-2-yl, thiepan-2yl, thiepan-3-yl, thiepane 1,1-dioxid-3-yl, azepan-1-yl, cyclohepten-3-yl, azepan-3-yl, oxepan-3-yl, azepan-2-on-3-yl, -CH(CH₂CH₃)CH₂CH₃, cyclopenten-3-yl, pyrrolidin-1-yl, pyrrolidin-3-yl, tetrahydro-furan-3-yl, pyrrolidin-2-on-3-yl, cyclohexen-3-yl, tetrahydro-pyran-3-yl, piperidin-1-yl, piperidin-2-on-3-yl, -C=N, -C(O)CH₃, -C(O)OH, -C(O)NH₂, -CH₂-C(O)CH₃, -CH₂-C(O)-CH₂CH₃, indo-1-aza-bicyclo(2.2.1)heptan-3-yl, exo-1-aza-bicyclo(2.2.1)heptan-3-yl or bicyclo(2.2.1)heptan-2-yl;

R6b = O, NH, NCH₃, NCH₂CH₃ or N-C=N; and

R7b = cycloheptanyloxy, cyclopropyloxy, cyclopentanyloxy, cyclohexanyloxy or -N(R4b)R5b.

L151 ANSWER 6 OF 20 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2004-542624 [52] WPIX

CR 2003-067606 [06]; 2003-606116 [57]; 2003-830575 [77]; 2003-830978 [77]; 2003-830979 [77]; 2003-899131 [82]; 2004-032631 [03]; 2004-059437 [06]; 2004-069282 [07]; 2004-551748 [53]; 2004-652054 [63]; 2004-708482 [69]

DNC C2004-199091

TI Use of an atomically disordered crystalline material or a nanocrystalline material comprising a metal and an element for the treatment of e.g., tuberculosis, pneumonia and cystic fibrosis.

DC B06

IN GILLIS, S H; SCHECHTER, P; STILES, J A R

PA (GILL-I) GILLIS S H; (SCHE-I) SCHECHTER P; (STIL-I) STILES J A R

CYC 1

PI US 2004131698 A1 20040708 (200452)* 42 A61K033-24

ADT US 2004131698 A1 CIP of US 2000-628735 20000727, CIP of US 2001-840637 20010423, CIP of US 2001-916757 20010727, CIP of US 2002-128208 20020423, CIP of US 2002-131509 20020423, CIP of US 2002-131511 20020423, CIP of US 2002-131568 20020423, CIP of US 2002-159587 20020530, CIP of US 2002-277298 20021022, CIP of US 2002-277320 20021022, CIP of US 2002-277356 20021022, CIP of US 2002-277358 20021022, CIP of US 2002-277362 20021022, CIP of US 2002-277673 20021022, US 2003-690724 20031022

FDT US 2004131698 A1 CIP of US 6692773

PRAI US 2003-690724 20031022; US 2000-628735 20000727;
US 2001-840637 20010423; US 2001-916757 20010727;
US 2002-128208 20020423; US 2002-131509 20020423;
US 2002-131511 20020423; US 2002-131568 20020423;

US 2002-159587	20020530; US 2002-277298	20021022;
US 2002-277320	20021022; US 2002-277356	20021022;
US 2002-277358	20021022; US 2002-277362	20021022;
US 2002-277673	20021022	

IC ICM A61K033-24

AB US2004131698 A UPAB: 20041109

NOVELTY - Treatment of a condition comprises contacting an area of the condition with an atomically disordered crystalline material or a nanocrystalline material (I) (that contains at least one atomic percent of the element) comprising a metal and an element such as oxygen, nitrogen, carbon, boron, sulfur, halo, phosphorus, silicon and/or hydrogen.

ACTIVITY - Antibacterial; Antiinflammatory; Fungicide; Virucide; Immunosuppressive; Hemostatic; Cytostatic; Respiratory-Gen.; Antiasthmatic; Antimicrobial; Antitubercular; Tuberculostatic; Antiallergic; CNS-Gen.; Antiarthritic; Antiarteriosclerotic; Vasotropic; Antiangiogenic; Gastrointestinal-Gen.; Auditory; Ophthalmological; Dermatological; Vulnerary; Antiseborrheic; Antipsoriatic; Uropathic; Antipruritic.

(I) was assessed for its ability to control Propionibacterium acne by in vitro test. The results showed that (I) at 10 micro g/ml, gave 4.3 logarithm reduction in viable Propionibacterium acne counts in two hours.

MECHANISM OF ACTION - **Matrix metalloproteinases** modulator.

USE - (I) is useful to treat bacterial conditions, biofilm conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, idiopathic conditions, hyperproliferative conditions, noncancerous growths and/or cancerous conditions of respiratory conditions (preferably asthma, emphysema, bronchitis, pulmonary edema, acute respiratory distress syndrome, bronchopulmonary dysplasia, fibrotic conditions, pulmonary atelectasis, tuberculosis, pneumonia, sinusitis, allergic rhinitis, pharyngitis, mucositis, stomatitis, chronic obstructive pulmonary disease, bronchiectasis and/or cystic fibrosis), a musculo-skeletal condition (preferably tendonitis, osteomyelitis, fibromyalgia, bursitis and/or arthritis), circulatory condition (preferably arteriosclerosis, lymphoma, septicemia, leukemia, ischemic vascular disease, lymphangitis and/or atherosclerosis), mucosal conditions and/or serosal conditions (preferably pericarditis, Bowen's disease, stomatitis, prostatitis, digestive disorders, peptic ulcers, esophageal ulcers, gastric ulcers, duodenal ulcer, esophagitis, gastritis, enteritis, enterogastric intestinal hemorrhage, toxic epidermal necrolysis syndrome, Stevens Johnson syndrome, fibrotic conditions, bronchitis, pharyngitis, common cold, ear infections, sore throat, sexually transmitted diseases, inflammatory bowel disease, colitis, hemorrhoids, thrush, dental conditions, oral conditions, conjunctivitis and/or periodontal conditions), cancer (particularly tumors and/or hematologic malignancies), skin conditions and integument conditions (preferably burn, eczema, erythroderma, an insect bite, mycosis fungoides, pyoderma gangrenosum, erythema multiforme, rosacea, onychomycosis, acne, psoriasis, Reiter's syndrome, pityriasis rubra pilaris, hyperpigmentation, vitiligo, hypertrophic scarring, keloid, lichen planus, age related skin disorders and/or hyperproliferative variants of the disorders of keratinization) (claimed.)

Dwg.0/9

FS CPI

FA AB; DCN

MC CPI: B05-A03B; B05-C02; B14-A01; B14-A02; B14-A04; B14-C01; B14-C03; B14-C09; B14-D07; B14-E04; B14-E08; B14-E10; B14-F01; B14-F02; B14-F07; B14-F08; B14-G02D; B14-H01; B14-H01A; B14-J05; B14-K01; B14-L01; B14-N01; B14-N02; B14-N03; B14-N04; B14-N05; B14-N06B; B14-N17; B14-S06

TECH UPTX: 20040813
 TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Method: The area of contact of (I), where apoptosis has to be induced is a hyperplastic tissue, a tumor tissue and/or a cancerous lesion. Apoptosis is induced by modulating **matrix metalloproteinases** at the area of the subject.

ABEX UPTX: 20040813
 SPECIFIC COMPOUNDS - Silver is specifically disclosed as the metal. Silver nitrate is specifically disclosed as the crystalline material (I).

ADMINISTRATION - Administration of (I) is oral, parenteral, topical or by inhalation. No dosage is given.

L151 ANSWER 7 OF 20 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2004-480798 [45] WPIX

DNN N2004-379260 DNC C2004-178833

TI Treatment of **otitis media** involves administration of protease inhibitor such as alpha one-antitrypsin.

DC B02 P32

IN ANTONELLI, P J; BARR, P J; PEMBERTON, P A; SCHULTZ, G S; SUNDIN, D J

PA (ANTO-I) ANTONELLI P J; (BARR-I) BARR P J; (PEMB-I) PEMBERTON P A; (SCHU-I) SCHULTZ G S; (SUND-I) SUNDIN D J; (ARRI-N) ARRIVA PHARM INC

CYC 107

PI WO 2004052236 A2 20040624 (200445)* EN 33 A61F000-00
 RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE
 LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE
 DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG
 KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM
 PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US
 UZ VC VN YU ZA ZM ZW

US 2004175383 A1 20040909 (200459) A61K039-395

AU 2003296378 A1 20040630 (200472) A61F000-00

ADT WO 2004052236 A2 WO 2003-US39053 20031208; US 2004175383 A1 Provisional US 2002-431286P 20021206, Provisional US 2002-435985P 20021220, US 2003-731375 20031208; AU 2003296378 A1 AU 2003-296378 20031208

FDT AU 2003296378 A1 Based on WO 2004052236

PRAI US 2002-435985P 20021220; US 2002-431286P 20021206;
 US 2003-731375 20031208

IC ICM A61F000-00; A61K039-395

ICS A61K031-56

AB WO2004052236 A UPAB: 20040716

NOVELTY - Treatment of **otitis media** in a mammal involves administering alpha one-antitrypsin (AAT).

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a kit comprising AAT and instructions for its use in the treatment of **otitis media**.

ACTIVITY - Auditory.

MECHANISM OF ACTION - Protease inhibitor.

The utility of recombinant alpha one-antitrypsin (rAAT) and **ilomastat** in treating **otitis media** was determined by measuring human neutrophil elastase activity using a standard technique in middle ear effusion samples. rAAT was expressed in recombinant yeast cells as described in Travis et. al., J. Biol. Chem 260:4384;4389(1985) and purified by column chromatography. The results showed inhibition (greater than 30% reduction) in 82% of the samples.

USE - The method is useful for treating **otitis media** (e.g. recurrent acute **otitis media** (RAOM), chronic **otitis media** with effusion (COME), acute post-tympanostomy otorrhea (APTO), chronic suppurative **otitis media** (CSOM) or choleostoma) in mammal (preferably human) having perforated tympanic membrane due to

tympanostomy (all claimed).

ADVANTAGE - The lack of toxicity of AAT and ilomastat allows direct application to the site of infection. The method reduces the risk, severity and/or increase the time to possible consequences of tube insertion, including post-tympanostomy tube otorrhea and/or the necessity of tube replacement.

Dwg.0/0

FS CPI GMPI

FA AB; DCN

MC CPI: B04-J02; B04-N06; B06-D01; B14-A01; B14-C03; B14-D07C;
B14-N02

TECH UPTX: 20040716

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Method: The method additionally involves administering antibiotic, steroid or ilomastat.

ABEX UPTX: 20040716

ADMINISTRATION - Dosage is 0.1 - 50 mg. Administration is in the form of liquid or dry powder (claimed), topical, by insufflation, otical, oral, simultaneous or nasal.

EXAMPLE - No relevant example given.

L151 ANSWER 8 OF 20 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2004-440892 [41] WPIX

DNC C2004-165261

TI Composition useful for treating and preventing inflammatory or hyperproliferative mucocutaneous disorder comprises protease inhibitor and gelling agent.

DC A96 B04 D16

IN ANGEL, A J; BARR, P J; BATHURST, I C; MAYHEW, J W; PEMBERTON, P A; SUNDIN, D J

PA (ARRI-N) ARRIVA-PROMETIC INC

CYC 107

PI WO 2004045634 A1 20040603 (200441)* EN 51 A61K038-00

RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE

LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE

DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG

KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM

PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US

UZ VC VN YU ZA ZM ZW

AU 2003286258 A1 20040615 (200470) A61K038-00

ADT WO 2004045634 A1 WO 2003-GB5049 20031120; AU 2003286258 A1 AU 2003-286258 20031120

FDT AU 2003286258 A1 Based on WO 2004045634

PRAI US 2002-427702P 20021120

IC ICM A61K038-00

AB WO2004045634 A UPAB: 20040629

NOVELTY - A composition (C1) comprises protease inhibitor (a) and gelling agent (b).

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for preparation (M1) of a protease inhibitor gel composition involving:
(1) mixing a powdered gelling agent with an aqueous solution to form a gel;

(2) adjusting pH of the gel to 5.5 - 9;

(3) sterilizing the gel; and

(4) combining a protease inhibitor with the gel to form the protease inhibitor gel.

ACTIVITY - Cytostatic; Antiinflammatory; Dermatological; Antiulcer; Antiseborrheic; Antipsoriatic; Antilichen; Anti-HIV; Keratolytic;

Ophthalmological; Gastrointestinal-Gen.; Auditory; Antiasthmatic; Vulnerary.

MECHANISM OF ACTION - Protease inhibitor.

USE - For treating or preventing inflammatory or hyperproliferative mucocutaneous disorder; dermatological disorder (e.g. atopic dermatitis, skin photodamage, extrinsic skin aging, skin irritation, chronic, burn and ulcer wounds, acne, psoriasis, lichen (particularly lichen planus), basal or squamous cell carcinoma (Bowen's disease), Kaposi's sarcoma, keratosis, disorder of keratinization such as ichthyosis (particularly lamellar ichthyosis) and keratoderma), disorder of the ear and ocular disorder such as otitis, conjunctivitis, disorders of the gastrointestinal tract and urinary tract such as colitis and interstitial cystitis (claimed); disorder of lung e.g. inflammation of the lung mucosa such as asthma.

ADVANTAGE - The gel formulations maintain a uniform pH and have demonstrated improved protease inhibitor solubility, gel consistency, sterility and an unexpectedly superior therapeutic activity and stability with no undesirable side effects.

Dwg.0/2

FS CPI

FA AB; DCN

MC CPI: A12-V01; B04-N02; B12-M07; B14-C03; B14-D07C; B14-E10C; B14-H01; B14-K01A; B14-N02; B14-N03; B14-N07B; B14-N17; D05-C12

TECH UPTX: 20040629

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Method: The aqueous solution is a physiological buffer. (M1) Further involves adjusting the pH of the protease inhibitor gel from 5.5 - 9 and lyophilizing the protease inhibitor gel. The sterilizing involves irradiation.

Preferred Composition: (C1) Further comprises a physiological buffer at pH of 6 - 9 (preferably 6.5 - 7.5) and at least one agent.

Preferred Components: (a) Is an **alpha 1-antitrypsin** (preferably natural, synthetic or recombinant **alpha 1-antitrypsin**, modified peptide, biologically active fragment, substantially homologous polypeptide, oligopeptide, homodimer, heterodimer, variant, derivative and/or **alpha 1-antitrypsin** analog).

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Components: (b) Is hydroxyethyl cellulose, hydroxypropyl cellulose, polyacrylic acid and/or polyoxyethylene-polyoxypropylene block copolymer.

ABEX UPTX: 20040629

ADMINISTRATION - Dosage is 0.5 - 100 mg/kg. The sterile composition may be administered by transdermal, intraperitoneal, intracranial, intravaginal, intrauterine, oral, rectal, ophthalmic (including intravitreal or intracameral), nasal, topical (including subcutaneous, intraperitoneal, intramuscular, intradermal, intratracheal or epidural).

EXAMPLE - A composition comprised (weight/weight%): antitrypsin (10), benzyl alcohol (1), hydroxyethyl cellulose (2) and purified water (97). The composition was tested after two weeks and was found to be clear and had pH of 7.45.

L151 ANSWER 9 OF 20 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2004-375816 [35] WPIX

DNC C2004-141291

TI Use of metal containing material for prophylactic treatment of a condition e.g. bacterial, biofilm, microbial, inflammatory and fungal conditions.

DC B05

IN DEMLING, R H; GILLIS, S H; SCHECHTER, P

PA (DEML-I) DEMLING R H; (GILL-I) GILLIS S H; (SCHE-I) SCHECHTER P; (NUCF-N) NUCFRYST PHARM CORP

CYC 106

PI WO 2004037186 A2 20040506 (200435)* EN 73 A61K000-00
 RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS
 LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
 DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
 KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG
 PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ
 VC VN YU ZA ZM ZW
 US 2004110738 A1 20040610 (200438) A61K031-555
 AU 2003286575 A1 20040513 (200468) A61K000-00
 ADT WO 2004037186 A2 WO 2003-US33431 20031022; US 2004110738 A1 Provisional US
 2002-420167P 20021022, US 2003-690710 20031022; AU 2003286575 A1 AU
 2003-286575 20031022
 FDT AU 2003286575 A1 Based on WO 2004037186
 PRAI US 2002-420167P 20021022; US 2003-690710 20031022
 IC ICM A61K000-00; A61K031-555
 ICS A61K031-28; A61K033-24
 AB WO2004037186 A UPAB: 20040603

NOVELTY - Prophylactic treatment comprises contacting a first area (A) of a subject with a metal containing material (I) to reduce the occurrence of a condition at a second area (B). (A) is different from (B).

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a method of prophylactic treatment of a condition comprising contacting an object with (I) to reduce the occurrence of a condition at an area of a subject.

ACTIVITY - Antibacterial; Antimicrobial; Antiinflammatory; Fungicide; Dermatological; Virucide; Immunosuppressive; Cytostatic; Vulnerary; Antiseborrheic; Antipsoriatic; Ophthalmological; Uropathic; Antipruritic; Antiasthmatic; Respiratory-Gen.; Neuroprotective; Antitubercular; Tuberculostatic; CNS-Gen.; Muscular-Gen.; Osteopathic; Antiarthritic; Vasotropic; Antiarteriosclerotic; Antiallergic; Gastrointestinal-Gen.; Antiulcer; Auditory.

Test details are described but no results given.

MECHANISM OF ACTION - **Matrix Metalloproteinase** Modulator.

USE - (I) is useful for the prophylactic treatment of the conditions of bacterial, biofilm, microbial, inflammatory, fungal, viral, autoimmune, hyperproliferative, idiopathic or cancerous conditions (preferably non-bacterial conditions) such as skin, integument conditions (burn, eczema, erythroderma, an insect bite, mycosis fungoides, pyoderma gangrenosum, eythrema multiforme, rosacea, onychomycosis, acne, psoriasis, Reiter's syndrome, pityriasis rubra pilaris, hyperpigmentation, vitiligo, scarring conditions, keloid, lichen planus, age related skin disorders or hyperproliferative variants of the disorders of keratinization), respiratory conditions (asthma, emphysema, bronchitis, pulmonary edema, acute respiratory distress syndrome, bronchopulmonary dysplasia, pulmonary fibrosis, pulmonary atelectasis, tuberculosis, pneumonia, sinusitis, allergic rhinitis, pharyngitis, mucositis, stomatitis, chronic obstructive pulmonary disease, bronchiectasis, lupus pneumonitis, cystic fibrosis or nosocomial or ventilator associated pneumonia), musculo-skeletal condition (tendonitis, osteomyelitis, fibromyalgia, bursitis or arthritis), circulatory condition (arteriosclerosis, lymphoma, septicemia, leukemia, ischemic vascular disease, lymphangitis or atherosclerosis), cancer (tumors or hematologic malignancies) and mucosal conditions or serosal conditions (pericarditis, Bowen's disease, stomatitis, prostatitis, sinusitis, allergic rhinitis, digestive disorders, peptic ulcers, esophageal ulcers, gastric ulcers, duodenal ulcers, toxic epidermal necrolysis syndrome, Stevens Johnson syndrome, bronchitis, pneumonia, pharyngitis, common cold, ear infections, sore throat, sexually

transmitted diseases, inflammatory bowel disease, colitis, hemorrhoids, thrush, dental conditions, oral conditions, conjunctivitis or periodontal conditions) (claimed).

Dwg.0/1

FS CPI

FA AB; DCN

MC CPI: B05-A03B; B05-C02; B05-C04; B05-C08; B07-D12; B10-C02; B10-C04D; B10-C04E; B12-M01B; B12-M01D; B12-M07; B12-M08; B12-M11B; B12-M11C; B12-M11F; B12-M11G; B14-A01; B14-A01B1; B14-A02; B14-A04; B14-C01; B14-C03; B14-C09; B14-D07C; B14-E04; B14-E08; B14-E10; B14-E10C; B14-F01; B14-F02; B14-F02D; B14-F02E; B14-F07; B14-G02D; B14-H01; B14-J05; B14-K01; B14-L01; B14-N02; B14-N03; B14-N04; B14-N06B; B14-N07A; B14-N17; B14-S06

TECH UPTX: 20040603

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Method: The treatment further comprises recognizing a possibility for occurrence of the condition at (B) and selecting (A) (hyperplasic tissue, tumor tissue or cancerous lesion but not the skin and is preferably a portion of the respiratory system, musculo-skeletal system, circulatory system, gastrointestinal system, sublingual area or subdermal area) for contact with the (I) to reduce occurrence of the condition at (B) (hyperplasic tissue, tumor tissue or cancerous lesion). (B) is substantially free of or has the condition when (A) is contacted with the (I). (A) is substantially free of or has the condition when contacted with (I). The treatment prophylactically induces apoptosis and prophylactically modulates **matrix metalloproteinase** at (B). The treatment further comprises the formation of solution containing (I) into an aerosol and inhalation of the solution. (I) has a prophylactic ratio of about 0.95 or less for the condition. (A) and (B) can also be the same area. The treatment with the object after contacting the object with (I) further comprises the contact of the object with the subject (different area of the subject), transferring (I) directly from the object to the subject. The material transferred to the subject comprises a therapeutic agent. Preferred Components: (A) comprises a mucosal membrane (oral or nasal cavity) and (B) comprises the subjects lungs. (I) is a metal (silver (preferred), gold, platinum, palladium and/or combinations) (preferably silver nitrate, silver hydroxide, silver sulfadiazine, colloidal silver, silver carbonate, silver oxide, silver acetate, silver lactate, silver citrate, silver succinate, silver sorbate, silver myristate, silver stearate, silver oleate, silver glutonate, silver adipate or alkali silver thiosulfate) or alloy. (I) comprises an anionic material, atom, molecule, cluster, an atomically disordered crystal containing material or noncrystalline containing material (antimicrobial, anti-biofilm, antibacterial, anti-inflammatory, antifungal, antiviral, anti-autoimmune, anti-cancer or pro-apoptosis metal-containing materials, anti-proliferative materials, **matrix metalloprotienase**, modulating metal-containing materials and/or combinations). (I) (0.001 (preferably 10) wt.% or less) is in a solution comprising a solvent or is in the form of a free standing powder, carrier, powder impregnated material, swab, foam, liposome, tape, pill, capsule, tablet, suppository or lozenge and not in the form of a dressing.

ABEX UPTX: 20040603

ADMINISTRATION - Administration of (I) is by injection or inhalation. No dosage given.

L151 ANSWER 10 OF 20 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2004-203401 [19] WPIX

DNC C2004-080079

TI New tetracycline compounds useful for treatment of bacterial infections and neurodegenerative disorders e.g. Alzheimer's disease and dementia.

DC B02 B05
 IN BANDARAGE, U; CHEN, J; ISMAIL, M Y; NELSON, M L; SIZENSKY, E; CHEMENG, K;
 KIM, O
 PA (PARA-N) PARATEK PHARM INC
 CYC 105
 PI WO 2004006850 A2 20040122 (200419)* EN 43 A61K000-00
 RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS
 LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
 DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
 KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH
 PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN
 YU ZA ZM ZW
 AU 2003261161 A1 20040202 (200450) A61K000-00
 EP 1534300 A2 20050601 (200536) EN A61K031-65
 R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV
 MC MK NL PT RO SE SI SK TR
 ADT WO 2004006850 A2 WO 2003-US21992 20030714; AU 2003261161 A1 AU 2003-261161
 20030714; EP 1534300 A2 EP 2003-764630 20030714, WO 2003-US21992 20030714
 FDT AU 2003261161 A1 Based on WO 2004006850; EP 1534300 A2 Based on WO
 2004006850
 PRAI US 2002-395696P 20020712
 IC ICM A61K000-00; A61K031-65
 AB WO2004006850 A UPAB: 20040318
 NOVELTY - Tetracycline compounds (I) are new.
 DETAILED DESCRIPTION - Tetracycline compounds of formula (I), their
 salts, esters and enantiomers are new.
 X = CHC(R13Y'Y), C=CR13Y, CR6aR6, S, NR6 or O;
 R2b = C(O)NR2R2a or CN;
 R2, R2a = Q1;
 Q1 = H, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl,
 alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclyl, heteroaryl or a
 prodrug group;
 R12a = OR12 or NR12R12b;
 R3, R10, R11, R12, R12b = H, alkyl, alkenyl, aryl, alkynyl, aralkyl,
 acetyl, alkylcarbonyl, alkenylcarbonyl, arylcarbonyl, alkynylcarbonyl,
 alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, aryloxycarbonyl,
 alkylaminocarbonyl, alkenylaminocarbonyl, alkynylaminocarbonyl,
 arylaminocarbonyl, alkylthiocarbonyl, alkenylthiocarbonyl,
 alkynylthiocarbonyl, arylthiocarbonyl, alkyloxythiocarbonyl,
 alkenyloxythiocarbonyl, alkynyloxythiocarbonyl, aryloxythiocarbonyl,
 alkylaminothiocarbonyl, alkenylaminothiocarbonyl,
 alkynylaminothiocarbonyl, arylaminothiocarbonyl, alkylthiothiocarbonyl,
 alkenylthiothiocarbonyl, alkynylthiothiocarbonyl or arylthiothiocarbonyl;
 R4, R4a = NR4OR41, alkyl, alkenyl, alkynyl, hydroxy, halo or H, or
 R4 + R4a = O;
 R5 = OH, H, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic,
 alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl,
 alkylamino, arylalkyl, alkylcarbonyloxy or arylcarbonyloxy;
 R6, R6a = H, methylene, absent, OH, halo, thiol, alkyl, alkenyl,
 alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino
 or arylalkyl;
 R7 = T1 or (CH2)0-3NR7cC(=W')WR7a;
 T1 = H, OH, halo, thiol, nitro, alkyl, alkenyl, alkynyl, aryl,
 alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyl, amino,
 arylalkenyl, arylalkynyl, acyl, aminoalkyl, heterocyclyl or thionitroso;
 R8 = H, OH, halo, thiol, nitro, alkyl, alkenyl, alkynyl, aryl,
 alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, amino,
 arylalkenyl, arylalkynyl, acyl, aminoalkyl, heterocyclyl, thionitroso or
 (CH2)0-3NR8cC(=E')ER8a;

R9 = T1 or (CH₂)₀₋₃NR_{9c}C(=Z')ZR_{9a};
 R13 = H, OH, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, aryl,
 alkylsulfinyl, alkylsulfonyl, alkylamino or arylalkyl;
 E = CR_{8d}R_{8e}, S, NR_{8b} or O;
 E' = O, NR_{8f} or S;
 W = CR_{7d}R_{7e}, S, NR_{7b} or O;
 W' = O, NR_{7f} or S;
 Y', Y = H, OH, halo, CN, sulfhydryl, amino, alkyl, alkenyl, alkynyl,
 alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino or arylalkyl;
 Z = CR_{9d}R_{9e}, S, NR_{9b} or O;
 Z' = O, S or NR_{9f}, and
 R_{7a}-R_{7f}, R_{8a}-R_{8f}, R_{9a}-R_{9e} = Q1 or acyl,
 provided that at least one of R₃, R₁₀, R₁₁ or R₁₂ is not H when R₂ =
 C(=O)NR_{2R2a} and R_{12a} is OR₁₂ (sic).

ACTIVITY - Antiinflammatory; Cytostatic; Ophthalmological;
 Cerebroprotective; Vasotropic; Neuroprotective; Nootropic; Anticonvulsant;
 Antiparkinsonian; Virucide; Fungicide; Antiarthritic; Osteopathic;
 Antidiabetic; Antidiarrheic; Uropathic; Dermatological; Vulnerary;
 Antimalarial; Cardiant; Antiarteriosclerotic; Antiulcer; Ophthalmological;
 Respiratory-Gen.; Antirheumatic; Endocrine-Gen.; Antithyroid;
 Antibacterial; Gastrointestinal-Gen.; Neuroleptic; Hypotensive; Hypnotic;
 Antidepressant; Antimanic; Tranquilizer; Antimigraine; Anorectic;
 Antiasthmatic; CNS-Gen.

Test details are described but no results are given.

MECHANISM OF ACTION - None given.

USE - Used for treating a tetracycline responsive state, particularly
 inflammatory process associated state, cancer, lung injury, eye disorder,
 stroke, neurological disorder (e.g. Alzheimer's disease, Huntington's
 disease, Parkinson's disease, amyotrophic lateral sclerosis and multiple
 sclerosis) (all claimed), viral and fungal infections (including those
 which are resistant to other tetracycline compounds), arthritis,
 osteoporosis, diabetes (e.g. diabetes I and diabetes II), diarrhea,
 urinary tract infections, infections of skin and skin structure, ear, nose
 and throat infections, wound infections, mastitis, nitric oxide associated
 states, particularly malaria, senescence, diabetes, vascular stroke,
 cardiac disease (reperfusion-associated injury following infarction),
 juvenile diabetes, matrix metalloproteinase states, particularly
 arteriosclerosis, corneal ulceration, emphysema, osteoarthritis, multiple
 sclerosis, osteosarcoma, osteomyelitis, bronchiectasis, chronic pulmonary
 obstructive disease, skin and eye disease, periodontitis, osteoporosis,
 rheumatoid arthritis, ulcerative colitis, inflammatory disorders, tumor
 growth and invasion, metastasis, acute and chronic lung injury, stroke,
 ischemia, ischemic stroke, diabetes, aortic or vascular aneurysms, skin
 tissue wounds, dry eye, bone and cartilage degradation), bone mass
 disorder, particularly osteoporosis, bone fractures, bone formation
 associated with surgical procedures such as facial reconstruction,
 osteogenesis imperfecta, hypophosphatasia, Paget's disease, fibrous
 dysplasia, osteopetrosis, myeloma bone disease and the depletion of
 calcium in bone such as that which is related to primary
 hyperparathyroidism, aortic or vascular aneurysm in vascular tissue and
 bacterial infections caused by e.g. *Klebsiella pneumoniae*.

The inflammatory disorders include osteoarthritis, acute and chronic
 infections (bacterial and fungal infections including diphtheria and
 pertussis), acute and chronic bronchitis, sinusitis, upper respiratory
 infections (e.g. common cold), acute and chronic gastroenteritis and
 colitis, acute and chronic cystitis and urethritis, acute and chronic
 dermatitis, acute and chronic conjunctivitis, acute and chronic serositis
 , particularly pericarditis, peritonitis, synovitis, pleuritis and
 tendonitis, uremic pericarditis, acute and chronic cholecystitis, acute and
 chronic vaginitis, acute and chronic uveitis, drug reactions, insect

bites, burns (e.g. thermal, chemical and electrical) and sunburn.

The neurological disorders include Pick's disease, Lewy diffuse body diseases, senile dementia, Gilles de la Tourette's syndrome, progressive supranuclear palsy, epilepsy, Creutzfeldt-Jakob disease, autonomic function disorders, particularly hypertension and sleep disorders, neuropsychiatric disorders, particularly depression, schizophrenia, schizoaffective disorders, Korsakoff's psychosis, mania, anxiety disorders or phobic disorders, learning and memory disorders, particularly amnesia or age related memory loss, attention deficit disorder, dysthymic disorder, major depressive disorder, mania, obsessive compulsive disorder, psychoactive substance use disorder, anxiety, phobia, panic disorder, bipolar affective disorder, particularly mood disorder, and bipolar affective neurological disorders, particularly migraine and obesity. The acute lung injury includes adult respiratory distress syndrome, post-pump syndrome and trauma. The chronic lung disorders include asthma, cystic fibrosis and emphysema.

Dwg.0/0

FS CPI

FA AB; GI; DCN

MC CPI: B02-T; B14-A01; B14-A02; B14-C01; B14-C03; B14-C09A; B14-C09B; B14-D02B; B14-E02; B14-E10C; B14-E12; B14-F02B; B14-F02D; B14-F07; B14-G02A; B14-H01; B14-H02; B14-J01A1; B14-J01A3; B14-J01A4; B14-J01B2; B14-J01B3; B14-J01B4; B14-J05; B14-J07; B14-K01A; B14-K01D; B14-K01F; B14-N01; B14-N02; B14-N03; B14-N04; B14-N05; B14-N06B; B14-N07B; B14-N10; B14-N12; B14-N14; B14-N16; B14-N17A; B14-N17B; B14-N17C; B14-S01; B14-S04; B14-S06

TECH UPTX: 20040318

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preparation: No general preparation is given.

ABEX UPTX: 20040318

SPECIFIC COMPOUNDS - 22 Compounds (I) are specifically claimed e.g: 3-benzyloxysancycline (Ia).

ADMINISTRATION - The dosage is 0.01-100 (preferably 0.1-50, especially 1-20) mg/kg/day orally, topically, parenterally (e.g. intraperitoneally, subcutaneously, intravenously, intradermally, intraarticularly or intramuscularly) or enterally.

EXAMPLE - Sodium hydride (60%) in a mineral oil dispersion (100 mg) was added in small portions to a stirred solution of sancycline (0.5 g) in dimethylformamide (5 ml) at room temperature. The resulting suspension was stirred at room temperature for 5 minutes. Benzyl bromide (0.143 ml) was added and heated at 60degreesC for 16 hours. The reaction mixture was then cooled to room temperature and subjected to basic work up to obtain 3-benzyloxysancycline (Ia).

L151 ANSWER 11 OF 20 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2003-830979 [77] WPIX

CR 2002-315278 [35]; 2003-058682 [05]; 2003-058683 [05]; 2003-067606 [06]; 2003-075604 [07]; 2003-140141 [13]; 2003-606116 [57]; 2003-754943 [71]; 2003-830575 [77]; 2003-830978 [77]; 2003-899131 [82]; 2004-032631 [03]; 2004-059437 [06]; 2004-069282 [07]; 2004-542624 [52]; 2004-551748 [53]; 2004-652054 [63]; 2004-708482 [69]

DNC C2003-234116

TI Treatment of a condition e.g. bacterial condition, microbial condition and inflammatory condition, involves contacting the condition with solution containing atomically disordered, nanocrystalline metal-containing compound.

DC B06 D21 D22

IN BURRELL, R E; GILLIS, S H; LAM, K; MOXHAM, P H; NAYLOR, A G; SCHECHTER, P;

WRIGHT, J B; YIN, H Q
 PA (BURR-I) BURRELL R E; (GILL-I) GILLIS S H; (LAMK-I) LAM K; (MOXH-I) MOXHAM
 P H; (NAYL-I) NAYLOR A G; (SCHE-I) SCHECHTER P; (WRIG-I) WRIGHT J B;
 (YINH-I) YIN H Q

CYC 1

PI US 2003180379 A1 20030925 (200377)* 42 A61K033-38

ADT US 2003180379 A1 CIP of US 2000-628735 20000727, CIP of US 2001-840637
 20010423, CIP of US 2001-916757 20010727, CIP of US 2002-128208 20020423,
 CIP of US 2002-131509 20020423, CIP of US 2002-131511 20020423, US
 2002-277673 20021022

PRAI US 2002-277673 20021022; US 2000-628735 20000727;
 US 2001-840637 20010423; US 2001-916757 20010727;
 US 2002-128208 20020423; US 2002-131509 20020423;
 US 2002-131511 20020423

IC ICM A61K033-38

ICS A61K033-24; A61K033-26

AB US2003180379 A UPAB: 20041027

NOVELTY - Treatment of a subject having a condition e.g. bacterial
 condition; microbial condition and inflammatory condition, involves
 contacting an area of the subject having the condition with a solution
 containing an atomically disordered, nanocrystalline metal-containing
 compound.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) a solution, comprising the atomically disordered, nanocrystalline
 metal-containing compound; and a solvent for the metal-containing
 compound. The metal containing compound is at least partially dissolved in
 the solvent (preferably water);

(2) an aerosol comprising a nanocrystalline, metal-containing
 compound;

(3) an aerosol comprising an atomically disordered, metal-containing
 a compound; and

(4) a method (M1) of treating a subject having a condition e.g.
 bacterial condition, microbial condition and inflammatory condition,
 involving contacting an area of the subject having the condition with the
 atomically disordered, crystalline metal-containing compound by injecting
 a solution containing the nanocrystalline metal-containing compound.

ACTIVITY - Dermatological; Antibacterial; Antiinflammatory;
 Fungicide; Virucide; Immunosuppressive; Cytostatic; Vulnerary;
 Insecticide; Antiseborrheic; Antipsoriatic; Ophthalmological; Uropathic;
 Antipruritic; Respiratory-Gen.; Antiasthmatic; Antitubercular;
 Tuberculostatic; CNS-Gen.; Antiarteriosclerotic; Endocrine-Gen.;
 Vasotropic; Cardiovascular-Gen.; Anti-HIV; Osteopathic; Antiarthritic;
 Antirheumatic; Gynecological; Immunomodulator; Gastrointestinal-Gen.;
 Antiulcer.

The antipsoriatic activity of nanocrystalline silver (a) was tested
 by using a female (58 year old) with psoriatic plaques. (a) Was deposited
 on sheets of high density polyethylene (HDPE) using a vapor deposition
 process. Two sheets of this coated HDPE were laminated together around a
 core of non-woven rayon polyester. A piece (50 multiply 50 mm) of this
 composite material was saturated with water and placed centrally on a one
 and a half year old (150 multiply 100 mm) psoriatic plaque on the
 patient's flank. The nanocrystalline silver coated material was covered
 with a piece of low moisture vapor transmission thin polymer film. The
 polymer sheet extended 50 mm beyond the nanocrystalline silver coated HDPE
 to provide control data regarding occlusion of the psoriatic plaque. The
 dressing was removed after three days. There was no discernible change in
 the plaque at this time. Two days later the area that was covered with the
 nanocrystalline silver had the appearance of normal skin while the rest of
 the plaque was still rough and unchanged including the untreated.

MECHANISM OF ACTION - Apoptosis inducer; **Matrix**

metalloproteinases modulator.

USE - The method is used for treating a condition e.g. skin conditions and integument conditions (e.g. bacterial, microbial, inflammatory, fungal, viral, autoimmune, idiopathic, noncancerous growths, cancerous conditions, burn, eczema, erythroderma, an insect bite, mycosis fungoides, pyoderma gangrenosum, eythrema multiforme, rosacea, onychomycosis, acne, psoriasis, Reiter's syndrome, pityriasis rubra pilaris, hyperpigmentation, vitiligo, hypertrophic scarring, keloid, lichen planus, age related skin disorders and hyperproliferative variants of the disorders of keratinization), respiratory condition (e.g. viral respiratory conditions, asthma, emphysema, bronchitis, pulmonary edema, acute respiratory distress syndrome, bronchopulmonary dysplasia, pulmonary fibrosis, pulmonary atelectasis, tuberculosis, pneumonia, sinusitis, pharyngitis, mucositis, stomatitis, chronic obstructive pulmonary disease, bronchiectasis, lupus pneumonitis and cystic fibrosis), musculo-skeletal condition (e.g. tendonitis, osteomyelitis, fibromyalgia, bursitis and arthritis), circulatory condition (e.g. fungal circulatory conditions, arteriosclerosis, septicemia, leukemia, ischemic vascular disease, lymphangitis and atherosclerosis), cancer (e.g. tumors and hematologic malignancies), mucosal conditions and serosal conditions (e.g. pericarditis, Bowen's disease, stomatitis, prostatitis, sinusitis, digestive disorders, toxic epidermal necrolysis syndrome, Stevens Johnson syndrome, common cold, ear infections, sore throat, sexually transmitted diseases, inflammatory bowel disease, colitis, hemorrhoids, thrush, dental conditions, oral conditions, conjunctivitis, and periodontal conditions) (all claimed). Also for treating skin aging, keratoconus, restenosis, osteoarthritis, rheumatoid arthritis, degenerative joint disease, bone disease, wounds, hypovolemic shock, epidermolysis bullosa, scleritis, vascular leakage syndrome, collagenase induced disease, adhesions of the peritoneum, strictures of the esophagus or bowel, cachexia, HIV-infection and cardiovascular conditions, esophageal ulcer, gastric ulcer, duodenal ulcer, esophagitis, gastritis, enteritis, enterogastric intestinal hemorrhage and sexually transmitted disease (e.g. syphilis, gonorrhea, herpes, genital warts and chlamydia).

ADVANTAGE - The method induces apoptosis or modulates **matrix metalloproteinases** at the area of the subject.

Dwg.0/9

FS CPI

FA AB; DCN

MC CPI: B05-A03B; B14-A01; B14-A02; B14-A04; B14-C03; B14-C09; B14-D07C; B14-E08; B14-E10; B14-F01; B14-F02; B14-F07; B14-F08; B14-G02D; B14-H01; B14-H03; B14-J05; B14-K01; B14-N01; B14-N02; B14-N03; B14-N04; B14-N05; B14-N06B; B14-N07C; B14-N17; B14-R01; B14-S06; D08-B09A1; D08-B09A3; D09-A01

TECH UPTX: 20031128

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Method: The method additionally involves forming the solution containing the metal-containing compound; and contacting the solution within at most 1 or after 1.5 minutes of formation, to the area of the subject.

The method additionally involves either forming the solution by combining a powder of the metal-containing compound in a solvent; or forming the solution by disposing an article containing the metal-containing compound in a solvent.

The article comprises a substrate having a coating of the metal-containing compound disposed on it.

The method additionally involves forming the solution into an aerosol; inhaling the aerosol; and contacting the area of the subject includes injecting the solution into the subject.

The solution is injected with a needle less injector or with a needle.

TECHNOLOGY FOCUS - INORGANIC CHEMISTRY - Preferred Components: The metal-containing compound is metal (preferably silver, gold, platinum or palladium; especially silver) or alloy (preferably metal oxide, metal nitride, metal boride, metal halide or metal hydride).
 The metal-containing compound is an ionic compound.
 The metal-containing compound comprises atom, molecule or cluster, or an antimicrobial compound.
 The solution contains metal-containing compound (at least 0.001 or at most 10 wt.%).
 The solution in the treatment additionally comprises a solvent.

TECHNOLOGY FOCUS - BIOLOGY - Preferred Components: The area of the subject is hyperplastic tissue, tumor tissue or cancerous lesion.

ABEX UPTX: 20031128

ADMINISTRATION - The metal-containing compound is administered orally, nasally or by inhalation. No dosage given.

EXAMPLE - No relevant example given.

L151 ANSWER 12 OF 20 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2003-830978 [77] WPIX

CR 2002-315278 [35]; 2003-058682 [05]; 2003-058683 [05]; 2003-067606 [06];
 2003-075604 [07]; 2003-140141 [13]; 2003-606116 [57]; 2003-754943 [71];
 2003-830575 [77]; 2003-830979 [77]; 2003-899131 [82]; 2004-032631 [03];
 2004-059437 [06]; 2004-069282 [07]; 2004-542624 [52]; 2004-551748 [53];
 2004-652054 [63]; 2004-708482 [69]

DNC C2003-234115

TI Use of free standing powder of a nanocrystalline metal-containing compound for the treatment of e.g. burns, acne, arteriosclerosis, asthma, psoriasis, cancer, hemorrhoids, colitis and viral, fungal and bacterial infections.

DC B04 B06 C03 D21 D22

IN BURRELL, R E; GILLIS, S H; SCHECHTER, P; LAM, K; MOXHAM, P H; NAYLOR, A G; WRIGHT, J B; YIN, H Q

PA (BURRELL-I) BURRELL R E; (GILL-I) GILLIS S H; (SCHE-I) SCHECHTER P; (NUCR-N) NUCRYST PHARM CORP

CYC 106

PI US 2003180378 A1 20030925 (200377)* 41 A61K033-38

WO 2004037187 A2 20040506 (200430) EN A61K000-00

RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS
 LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
 DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
 KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG
 PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ
 VC VN YU ZA ZM ZW

ADT US 2003180378 A1 CIP of US 2000-628735 20000727, CIP of US 2001-840637
 20010423, CIP of US 2001-916757 20010727, CIP of US 2002-128208 20020423,
 CIP of US 2002-131509 20020423, CIP of US 2002-131511 20020423, CIP of US
 2002-131568 20020423, CIP of US 2002-159587 20020530, US 2002-277298
 20021022; WO 2004037187 A2 WO 2003-US33446 20031022

PRAI US 2002-277298 20021022; US 2000-628735 20000727;
 US 2001-840637 20010423; US 2001-916757 20010727;
 US 2002-128208 20020423; US 2002-131509 20020423;
 US 2002-131511 20020423; US 2002-131568 20020423;
 US 2002-159587 20020530; US 2002-277320 20021022;
 US 2002-277356 20021022; US 2002-277358 20021022;
 US 2002-277362 20021022; US 2002-277673 20021022;
 US 2003-364983 20030212

IC ICM A61K000-00; A61K033-38

ICS A61K033-24

AB US2003180378 A UPAB: 20041027

NOVELTY - Treatment of diseases e.g. autoimmune conditions involves injecting or inhaling a free standing powder of a nanocrystalline metal-containing compound.

ACTIVITY - Antimicrobial; Antibacterial; Anti-inflammatory; Fungicide; Immunosuppressive; Cytostatic; Dermatological; Vulnerary; Antipsoriatic; Antiasthmatic; Respiratory-Gen.; Tuberculostatic; Auditory; Ophthalmological; Antiarteriosclerotic; Gastrointestinal-Gen.; Antiseborrheic; Uropathic; Antipruritic; Antitubercular; CNS Gen.; Antiarthritic; Vasotropic; Virucide.

The antiinflammatory activity of nanocrystalline derived silver solution (S1) (containing 400 ppm of Ag) was evaluated in rats. *Pseudomonas aeruginosa* (strain 5888) suspension (400 µl) was intrathecally administered into the bronchi of each rat. A solution of silver nitrate (400 ppm) in deionized water was used as control. The rats were then dosed with (S1) through nebulizer for 2 - 2.5 hours. The rats were again dosed with (S1) 3 times a day for additional 1.5 days. The lungs from sacrificed rats were histopathologically analyzed. The lungs were normal to slightly inflamed/moderately to severely inflamed in rats treated with (S1)/control solution respectively. The results showed that (S1) had pulmonary anti-inflammatory activity.

MECHANISM OF ACTION - Microbial growth inhibitor. The microbial growth inhibitory efficacy of a silver solution derived from Aticoat (RTM; burn dressing) was evaluated against *Pseudomonas aeruginosa* (A). Mueller-Hinton agar plates streaked with (A) were exposed to nebulized silver solution. The plates were then incubated at 35 deg. C for 16 hours. In the viability testing from the plates exposed to silver solution (370 mg/ml) no re-growth occurred as compared to the control plates exposed to silver nitrate solution.

USE - For the treatment of bacterial condition, microbial condition, inflammatory condition, fungal condition, viral condition, autoimmune condition, idiopathic condition, noncancerous growth, cancerous condition, skin condition, or integument condition (e.g. burn, eczema, erythroderma, insect bite, mycosis fungoides, pyoderma gangrenosum, eythrema multiforme, rosacea, onychomycosis, acne, psoriasis, Reiter's syndrome, pityriasis rubra pilaris, hyperpigmentation, vitiligo, hypertrophic scarring, keloid, lichen planus, age related skin disorders and hyperproliferative variants of the disorders of keratinization), a respiratory condition (e.g. lupus pneumonitis, asthma, emphysema, bronchitis, pulmonary edema, acute respiratory distress syndrome, bronchopulmonary dysplasia, pulmonary fibrosis, pulmonary atelectasis, tuberculosis, pneumonia, sinusitis, pharyngitis, mucositis, chronic obstructive pulmonary disease, bronchiectasis, and cystic fibrosis), musculo-skeletal condition (e.g. tendonitis, osteomyelitis, fibromyalgia, bursitis and arthritis), a circulatory condition (e.g. arteriosclerosis, septicemia, leukemia, ischemic vascular disease, lymphangitis and atherosclerosis), cancer (e.g. tumors and hematologic malignancies), mucosal conditions and serosal conditions (e.g. pericarditis, Bowen's disease, prostatitis, sinusitis, digestive disorders, toxic epidermal necrolysis syndrome, Stevens Johnson syndrome, cystic fibrosis, bronchitis, pneumonia, pharyngitis, common cold, ear infections, sore throat, sexually transmitted diseases, inflammatory bowel disease, colitis, hemorrhoids, thrush, dental conditions, oral conditions, conjunctivitis, and periodontal conditions) (all claimed). In industrial applications to reduce and prevent microbial growth on industrial surfaces e.g. heating pipes and furnace filters, and to prevent spread of microorganisms e.g. heating and air circulation systems within building.

ADVANTAGE - The metal containing materials enhance therapeutic efficacy of the dry powder formulations by forming metastable high levels

of metal hydroxide species, which provide therapeutic properties directly or indirectly; and by releasing cluster of metals. The dry powder formulations can efficiently treat variety of conditions by facilitating access of the metals to remote areas. The method induces apoptosis and modulates matrix metalloproteinases.

Dwg.0/9

FS CPI

FA AB; DCN

MC CPI: B05-A03B; B14-A01; B14-A01B1; B14-A02; B14-A03; B14-A04; B14-C01; B14-C03; B14-C09; B14-D07C; B14-E04; B14-E10A; B14-E10C; B14-F01B; B14-F02; B14-F07; B14-G02D; B14-H01; B14-H03; B14-J05; B14-K01; B14-N01; B14-N02; B14-N03; B14-N04; B14-N05; B14-N06; B14-N07; B14-N16; B14-N17; B14-S06; D08-A; D08-A05; D08-B09A; D09-A01; D09-E

TECH UPTX: 20031128

TECHNOLOGY FOCUS - INORGANIC CHEMISTRY - Preferred Components: The metal-containing compound is metals or alloys. The metal-containing compound is metal oxides, metal nitrides, metal borides, metal halides and metal hydrides. The metal-containing compound comprises a metal selected from silver, gold, platinum or palladium (preferably silver), an ionic compound, atoms, molecules or clusters, an atomically disordered crystalline compound, or an antimicrobial compound. Preferred Powder: The free-standing powder has an average particle size of at most two microns.

ABEX UPTX: 20031128

ADMINISTRATION - Administration is by injection with a needle less injector, inhalation with a dry powder inhaler (claimed) to the hyperplastic tissue, tumor tissue or cancerous lesion. Administration is also by oral, topical route or in the form of a dressing.

EXAMPLE - No relevant example given.

L151 ANSWER 13 OF 20 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2003-247939 [24] WPIX

DNC C2003-063803

TI Composition useful for removing human cerumen from the external ear canal comprises bicarbonate or enzyme and an aqueous vehicle comprising a demulcent and a surfactant.

DC A96 B04 D16 D21 E19

IN CAGLE, G D; OWEN, G R; RIDRUEJO, N J; WALL, G M

PA (ALCO-N) ALCON INC; (CAGL-I) CAGLE G D; (OWEN-I) OWEN G R; (RIDR-I) RIDRUEJO N J; (WALL-I) WALL G M

CYC 34

PI WO 2003003976 A2 20030116 (200324)* EN 29 A61K000-00
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
W: AU BR CA CN JP KR MX NO NZ PH PL SG US ZA

EP 1337228 A2 20030827 (200357) EN A61K007-00
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
NO 2004000005 A 20040102 (200416) A61K000-00
BR 2002010493 A 20040622 (200442) A61K038-43
KR 2004018416 A 20040303 (200443) A61K033-10
US 2004126436 A1 20040701 (200444) A61K033-00
AU 2002345778 A1 20030121 (200452) A61K000-00
MX 2003010881 A1 20040201 (200473) A61K033-10

ADT WO 2003003976 A2 WO 2002-US19756 20020621; EP 1337228 A2 EP 2002-744528
20020621, WO 2002-US19756 20020621; NO 2004000005 A WO 2002-US19756
20020621, NO 2004-5 20040102; BR 2002010493 A BR 2002-10493 20020621, WO
2002-US19756 20020621; KR 2004018416 A KR 2003-717312 20031231; US
2004126436 A1 Provisional US 2001-302959P 20010703, Cont of WO
2002-US19756 20020621, US 2003-705441 20031110; AU 2002345778 A1 AU

2002-345778 20020621; MX 2003010881 A1 WO 2002-US19756 20020621, MX 2003-10881 20031127

FDT EP 1337228 A2 Based on WO 2003003976; BR 2002010493 A Based on WO 2003003976; AU 2002345778 A1 Based on WO 2003003976; MX 2003010881 A1 Based on WO 2003003976

PRAI US 2001-302959P 20010703; US 2003-705441 20031110

IC ICM A61K000-00; A61K007-00; A61K033-00; A61K033-10; A61K038-43
ICS A61K033-10

AB WO2003003976 A UPAB: 20030410
NOVELTY - A composition comprises bicarbonate or an enzyme and an aqueous vehicle comprising a demulcent and a surfactant.
ACTIVITY - Auditory.
MECHANISM OF ACTION - None given.
USE - For removing human cerumen from the external ear canal (claimed). Also useful for treating otic and nasal conditions; and cleansing the middle or external ear of the viscous exudate (e.g. otitis media, mucoid otitis media, serous otitis media or chronic otitis media).
ADVANTAGE - The composition exhibits superior stability and is more viable and safe. The composition maintains a stable pH of 40 deg. C for three months after the preparation.
Dwg.0/10

FS CPI
FA AB; DCN
MC CPI: A12-V01; B04-C02A1; B04-C03A; B04-C03B; B04-C03D; B04-L05; B05-C04; B10-A17; B10-A22; B10-E04C; B12-M06; B14-N02; B14-N04; D05-C03; D05-H17A3; D08-B13; E10-A17B; E10-A22A; E10-E04H; E33-D

TECH UPTX: 20030410
TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The composition further comprises a preservative, buffer and an enzyme stabilizing agent. The composition is packaged in a bottle within an aluminum foil.

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - The demulcent is povidone, glycerin, or propylene glycol, derivatives (preferably glycerin (0.5 - 15 wt/vol.%)). The buffer is citrate. The preservative is benzalkonium halide, alexidine salt, chlorhexidine salt, hexamethylene biguanimide or its polymers (preferably hexamethylene biguanidine). The surfactant is Tetronic 1304 (0.05 - 1 wt/vol.%).

TECHNOLOGY FOCUS - POLYMERS - The demulcent is polyvinyl alcohol, polyethylene glycol or cellulose. The surfactant is polysorbate, 4-(1,1,3,3-tetramethylbutyl)phenol/poly(oxyethylene)polymer, poly(oxyethylene)-poly(oxypropylene)block copolymer, polyethylene glycol ester of fatty acid or 12-18C polyoxypropylene ether of higher alkane (preferably poly(oxyethylene)-poly(oxypropylene)block copolymer). The preservative is poly(dimethylimino-2-butene-1,4-diyl)chloride-alpha-(4-tris(2-hydroxyethyl)ammonium)dichloride. The enzyme stabilizing agent is monomeric or polymeric polyol.

TECHNOLOGY FOCUS - BIOLOGY - The enzyme is a lipase, protease and/or amylase, proteolytic enzyme (preferably pancreatin, trypsin, subtilisin, collagenase, keratinase, carboxypeptidase, papain, bromelain, aminopeptidase, elastase, Aspergillo peptidase, S. griseus (pronase E) and/or dispase (Bacillus polymyxa), microbially derived enzyme, or alkyl trypsin (preferably methyl trypsin (50 - 500 AU/ml)).

TECHNOLOGY FOCUS - INORGANIC CHEMISTRY - The bicarbonate is sodium bicarbonate (0.5 - 15 wt/vol.%). The buffer is phosphate, borate, Tris and/or their salts. The enzyme stabilizing agent is calcium ions or borate/boric acid.

ABEX

UPTX: 20030410

EXAMPLE - The composition comprising (wt/volume%): sodium bicarbonate (5), sodium citrate.2H₂O (3), glycerin (7), Tetronic 1304 (0.25), benzalkonium chloride (0.01), and water (balance) was prepared. The composition showed an absorbency at 2 hours for human 280 nm cerumen of 1659 units/gm/ml.

L151 ANSWER 14 OF 20 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2003-239119 [23] WPIX

DNC C2003-061222

TI New N-formyl hydroxylamine compounds useful for treatment of bacterial infection.

DC B03

IN GERCIA, A S; JACOBS, J; JAIN, R K; PATEL, D V; YUAN, Z; GARCIA ALVAREZ, S; GARCIA, A S; ALVAREZ, S G; BROWN, R B; MCCORQUODALE, M S

PA (VICU-N) VICURON PHARM INC; (ALVA-I) ALVAREZ S G; (JACO-I) JACOBS J; (JAIN-I) JAIN R K; (PATE-I) PATEL D V; (YUAN-I) YUAN Z; (BROW-I) BROWN R B; (MCCO-I) MCCORQUODALE M S; (NOVS) NOVARTIS AG; (VERS-N) VERSICOR INC

CYC 88

PI WO 2002102790 A1 20021227 (200323)* EN 35 C07D401-12

RW: AT BE CH CY DE DK EA ES FI FR GB GR IE IT LU MC NL PT SE TR

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK

DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ

LC LK LT LU LV MA MD MK MN MX NO NZ OM PH PL PT RO RU SE SG SI SK

TJ TM TN TR TT UA US UZ VN YU ZA ZW

US 2003045479 A1 20030306 (200324) A61K038-05

US 2003210101 A1 20031113 (200382) H03L007-04

EP 1401828 A1 20040331 (200424) EN C07D401-12

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT

RO SE SI TR

CZ 2003003388 A3 20040317 (200430) C07D401-12

KR 2004010721 A 20040131 (200436) C07D401-12

SK 2003001524 A3 20040707 (200447) C07D401-12

AU 2002321062 A1 20030102 (200452) C07D401-12

HU 2004000208 A2 20040628 (200452) C07D401-12

BR 2002010377 A 20040810 (200455) C07D401-12

CN 1511152 A 20040707 (200467) C07D401-12

ZA 2003008379 A 20040929 (200468) 72 A61K000-00

JP 2005502606 W 20050127 (200510) 126 C07D207-16

IN 2003001963 P4 20041211 (200530) EN C07D401-12

ADT WO 2002102790 A1 WO 2002-EP6604 20020614; US 2003045479 A1 Provisional US 2001-298419P 20010615, Provisional US 2002-360313P 20020227, US

2002-171706 20020614; US 2003210101 A1 Provisional US 2002-360313P

20020227, US 2003-374446 20030226; EP 1401828 A1 EP 2002-754681 20020614,

WO 2002-EP6604 20020614; CZ 2003003388 A3 WO 2002-EP6604 20020614, CZ

2003-3388 20020614; KR 2004010721 A KR 2003-716435 20031215; SK 2003001524

A3 WO 2002-EP6604 20020614, SK 2003-1524 20020614; AU 2002321062 A1 AU

2002-321062 20020614; HU 2004000208 A2 WO 2002-EP6604 20020614, HU

2004-208 20020614; BR 2002010377 A BR 2002-10377 20020614, WO 2002-EP6604

20020614; CN 1511152 A CN 2002-810596 20020614; ZA 2003008379 A ZA

2003-8379 20031028; JP 2005502606 W WO 2002-EP6604 20020614, JP

2003-506263 20020614; IN 2003001963 P4 WO 2002-EP6604 20020614, IN

2003-CN1963 20031210

FDT EP 1401828 A1 Based on WO 2002102790; CZ 2003003388 A3 Based on WO 2002102790; SK 2003001524 A3 Based on WO 2002102790; AU 2002321062 A1 Based on WO 2002102790; HU 2004000208 A2 Based on WO 2002102790; BR 2002010377 A Based on WO 2002102790; JP 2005502606 W Based on WO 2002102790

PRAI US 2002-360313P 20020227; US 2001-298419P 20010615;

US 2002-171706 20020614; US 2003-374446 20030226

IC ICM A61K000-00; A61K038-05; C07D207-16; C07D401-12; H03L007-04

ICS A61K031-401; A61K031-4025; A61K031-4402; A61K031-4427; A61K031-4439;
A61K031-455; A61K031-4709; A61K031-4725; A61P031-00; A61P031-04;
A61P043-00; C07D403-12; C07D405-12; C07K005-04; C12N001-00;
C12N005-00

AB WO2002102790 A UPAB: 20030407

NOVELTY - N-Formyl hydroxylamine compounds, their salts or prodrug are new.

DETAILED DESCRIPTION - N-Formyl hydroxylamine compounds of formula (I), their salts or prodrug are new.

X = -CH₂-, -S-, -CH(OH)-, -CH(OR)-, -CH(SH)-, -CH(SR)-, -CF₂-,
-C=N(OR- or -CH(F)-;

R = alkyl;

R₁ = aryl or heteroaryl;

R₂ - R₅ = H, or alkyl;

R₂ + R₄, R₂ + R₅, R₃ + R₄ and R₃ + R₅ = 4-7C cycloalkyl;

n = 0-3.

Provided that when n is 0 then X is -CH₂-.

An INDEPENDENT CLAIM is included for preparation of (I).

ACTIVITY - Antibacterial; Antiarteriosclerotic; Antiarthritic; Immunosuppressive; Ophthalmological; Periodontal; Vulnerary; Virucide; Gastrointestinal-Gen.; CNS-Gen.; Dermatological; Gynecological.

MECHANISM OF ACTION - Peptidyl deformylase (PDF) inhibitor.

The antibacterial properties of compound (I) were demonstrated for their ability to inhibit PDF selectively. The IC₅₀ of the compounds against MMP-7 (matrix metalloproteinases)

was 10-100 micro M. No results for specific compounds are given.

USE - For treating and/or preventing an infectious disorder, preventing bacterial contamination of a cell culture medium (claimed), particularly infectious disorders, caused by bacterial and prokaryotic organisms, microbial infections, including central nervous system infection, external ear infection, infection of the middle ear (e.g. acute otitis media), infections of the cranial sinuses, eye infections, infections of oral cavity (e.g. infection of teeth, gums and mucosa), upper and lower respiratory tract infection, genitourinary infection, gastrointestinal infection, gynecological infection, septicemia, bone and joint infection, skin and skin structure infection, bacterial endocarditis, burns, antibacterial prophylaxis of surgery, antibacterial prophylaxis in immunosuppressed patients (e.g. patient receiving cancer chemotherapy, organ transplant patients) and chronic disease caused by infectious organisms e.g. arteriosclerosis.

ADVANTAGE - The compounds exhibit oral bioavailability greater than 70% and superior selectivity for PDF over matrix metalloproteinases-7 (MMP-7) (matrilysin).

Dwg.0/0

FS CPI

FA AB; GI; DCN

MC CPI: B07-D03; B07-F01; B14-A01; B14-F06; B14-N01; B14-N02;

B14-N03; B14-N05; B14-N07; B14-N17

TECH UPTX: 20030407

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preparation (claimed): Preparation of (I) involves reacting a compound of formula (II) with a compound of formula (III) to obtain (I) in free form which may be converted into salt form or vice versa.

Y = protecting group;

X' = NH or O.

ABEX UPTX: 20030407

ADMINISTRATION - The dosage of (I) is 0.015-50 (preferably 5-20) mg/kg/day and administered locally, systemically, orally, topically, parenterally, subdermally, by inhalation.

EXAMPLE - To a solution of 2-((benzyloxy-formyl-amino)-methyl)-hexanoic acid (1 equivalent (eq)) in dry dioxane (4 ml) at room temperature under nitrogen was added successively Hunig's base (3.3 eq), pyrrolidine-2-carboxylic acid pyridin-2-ylamide (1.1 eq) and O-(7-aza-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate HATU (1.1 eq). The mixture was stirred at room temperature for 22 hours. The mixture was partitioned between ethyl acetate and 10% citric acid. The organic layer was washed with brine and saturated NaHCO₃, dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by flash chromatography to give the 1-(2-R-((formyl-hydroxy-amino)-methyl)-hexanoyl)-pyrrolidine-2-S-carboxylic acid pyridin-2-ylamide.

DEFINITIONS - Preferred Definitions:

X = -CH₂-;

R₂- R₄ = H;

R₅ = n-butyl;

n = 1;

R₁ = 2-pyridyl (substituted on 4-position by ethyl or methyl) or 2-pyridyl N-oxide (substituted on 5-position by fluoro or trifluoromethyl).

L151 ANSWER 15 OF 20 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2002-500631 [53] WPIX

DNC C2002-141847

TI Novel fusion protein useful for inhibiting protease activity associated with a disorder such as emphysema, asthma, comprises a first protease inhibitor comprising **alpha 1-antitrypsin** and a second protease inhibitor.

DC B04 D16

IN BARR, P J; GIBSON, H; PEMBERTON, P; GIBSON, H L

PA (ARRI-N) ARRIVA PHARM INC; (BARR-I) BARR P J; (GIBS-I) GIBSON H; (PEMB-I) PEMBERTON P

CYC 101

PI WO 2002050287 A2 20020627 (200253)* EN 134 C12N015-62
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
 NL OA PT SD SE SL SZ TR TZ UG ZM ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
 DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
 KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT
 RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM
 ZW

AU 2002041661 A 20020701 (200264) C12N015-62

US 2003073217 A1 20030417 (200329) C12N009-99

EP 1366175 A2 20031203 (200380) EN C12N015-62

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
 RO SE SI TR

JP 2004537970 W 20041224 (200502) 219 C12N015-09

ADT WO 2002050287 A2 WO 2001-US49256 20011218; AU 2002041661 A AU 2002-41661 20011218; US 2003073217 A1 Provisional US 2000-256699P 20001218, Provisional US 2001-331966P 20011120, US 2001-25514 20011218; EP 1366175 A2 EP 2001-988344 20011218, WO 2001-US49256 20011218; JP 2004537970 W WO 2001-US49256 20011218, JP 2002-552164 20011218

FDT AU 2002041661 A Based on WO 2002050287; EP 1366175 A2 Based on WO 2002050287; JP 2004537970 W Based on WO 2002050287

PRAI US 2001-331966P 20011120; US 2000-256699P 20001218;
 US 2001-25514 20011218

IC ICM C12N009-99; C12N015-09; C12N015-62

ICS A61K038-55; A61K038-57; A61P011-00; A61P011-06; A61P019-04;

A61P027-16; A61P031-18; A61P043-00; C07H021-04; C07K014-47;

C07K014-81; C07K019-00; C12N001-15; C12N001-19; C12N001-21;
C12N005-06; C12N005-10; C12N015-15; C12P021-02; C12P021-04

AB WO 200250287 A UPAB: 20021031

NOVELTY - A fusion protein (I) comprising a first protease inhibitor comprising an **alpha 1-antitrypsin** or its functionally active portion, and a second protease inhibitor or its functionally active protein, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a polynucleotide (II) encoding (I);
- (2) an expression vector (III) comprising (II);
- (3) a host cell (IV) comprising (III);
- (4) a pharmaceutical composition (V) comprising (I) admixed with a pharmaceutically acceptable vehicle; and
- (5) production of (I).

ACTIVITY - Antiasthmatic; auditory; anti-HIV. dermatological; antiinflammatory; antiallergic; antipsoriatic; virucide; vulnerary; antibacterial; immunosuppressive; antirheumatic; antiarthritic; antitumor; antiulcer; osteopathic; cytostatic; nephrotropic; protozoacide; nootropic; neuroprotective; hypotensive.

MECHANISM OF ACTION - Inhibitor of protease activity (claimed); gene therapy.

Experimental protocol is given, but no results are given.

USE - (I) Is useful for inhibiting protease activity associated with a disorder such as emphysema, asthma, chronic obstructive pulmonary disease, cystic fibrosis, otitis media, otitis external or HIV infection, or for treating an individual suffering from or at risk for a disease or disorder involving unwanted protease activity (claimed).

(I) is useful for treating dermatological diseases such as atopic dermatitis, eczema and psoriasis, in inflammatory responses to viral infection, and for treating herpes infection, corneal or epidermal ulceration, chronic non-healing wounds, sepsis, rheumatoid arthritis, periodontal disease, tumor metastasis and tumor angiogenesis, gastric ulceration, osteoporosis, Paget's disease, glomerulonephritis, scleroderma, malaria, bacterial infection, Alzheimer's disease, hypertension and muscular dystrophy. (II) is useful in gene therapy.

Dwg.0/6

FS CPI

FA AB; DCN

MC CPI: B04-C01G; B04-E02H; B04-E03H; B04-E08; B04-F0100E; B04-L05C; B04-M01; B04-M0100E; B04-N04A0E; B11-A02; B12-M05; B14-A01; B14-A02; B14-A02B1; B14-A03; B14-C03; B14-C06; B14-C09; B14-D07; B14-E08; B14-F02B; B14-G02; B14-G02A; B14-H01; B14-J01; B14-K01A; B14-N01; B14-N02; B14-N10; B14-N17; B14-N17B; B14-N17C; B14-S03A; D05-A02C; D05-C12; D05-H08; D05-H12C; D05-H12E; D05-H14; D05-H17C; D05-H18

TECH UPTX: 20020820

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preparation: (I) Is prepared by culturing (IV) under conditions appropriate for expressing (I) and purifying (I) (claimed).

Preferred Protein: In (I), the second protease inhibitor is secretory leukocyte protease inhibitor or a tissue inhibitor of metalloproteases, preferably TIMP-1. The second protease inhibitor inhibits serine protease, metalloprotease, aspartyl protease or cysteine protease. (I) comprises amino acids from about 1-394 of **alpha 1-antitrypsin**, and amino acids from about 1-107 of secretory leukocyte protease inhibitor. The carboxy terminus of amino acids from 1-394 of **alpha 1-antitrypsin** is linked to the amino terminus of amino acids from 1-107 of secretory leukocyte

protease inhibitor or the carboxy terminus of amino acids from 1-107 of secretory leukocyte protease inhibitor is linked to the amino terminus of amino acids from 1-394 of **alpha 1-antitrypsin**

(I) comprises from about amino acids 1-394 of **alpha 1-antitrypsin**, and amino acids from about 1-184, preferably 1-126 of tissue inhibitor of metalloproteases-1. The carboxy terminus of amino acids from 1-394 of **alpha 1-antitrypsin** is linked to the amino terminus of amino acids from 1-184, preferably 1-126 of tissue inhibitor of metalloproteases-1 or the carboxy terminus of amino acids from 1-184, preferably 1-126 of tissue inhibitor of metalloproteases-1 is linked to the amino terminus of amino acids from 1-394 of **alpha 1-antitrypsin**. (I) comprises from about amino acids 1-394 of **alpha 1-antitrypsin** and amino acids 1-127 of tissue inhibitor of metalloproteases-1, where the **alpha 1-antitrypsin** is covalently linked to the tissue inhibitor of metalloproteases-1 through a disulfide bound between amino acid 127 of the tissue inhibitor of metalloproteases-1 and a free cysteine residue of the **alpha 1-antitrypsin**. The free cysteine residue of the **alpha-antitrypsin** polypeptide is at a position 232 in a sequence comprising 394 amino acids fully defined in the specification.

ABEX

UPTX: 20020820

WIDER DISCLOSURE - Also disclosed are:

- (1) a kit comprising (I); and
- (2) a method of producing (V).

ADMINISTRATION - (I) Is administered by intravenous, topical, subcutaneous, intramuscular, intra-articular, oral or intraocular route or by inhalation.

No dosage details are given.

EXAMPLE - Construction of secretory leukocyte protease inhibitor (SLPI)/**alpha 1-antitrypsin** (AAT) and tissue inhibitor

of metalloproteases-1 (TIMP-1)/AAT fusion proteins was as follows.

A fusion protein comprising amino acids 1-107 of human SLPI fused to amino acids 1-394 of human AAT was constructed and referred to as SLAPI. The nucleotide sequence which was used in the construction of the SLAPI fusion protein had 1525 base pairs fully defined in the specification. A fusion protein comprising amino acids 1-184 of human TIMP-1 fused to amino acids 1-394 of human AAT was constructed and referred to as TAPI. The nucleotide sequence which was used in the construction of the TAPI fusion protein had 1756 base pairs fully defined in the specification. Expression vectors were constructed as follows. pHG42, a vector for assembling the expression cassette for yeast expression was cloned by sequentially adding polymerase chain reaction (PCR) cloned fragments of the *Saccharomyces cerevisiae* ADH2 promoter and terminator and the URA3 gene into pBluescript.

Briefly, the ADH2 promoter was amplified with 5'-Xho and BamH1 sites, a 3'-Xba1 site and cloned into pBlsc cut with Xho1/Xba1. The ADH2 terminator was amplified with 5'-Xba1 and Sal1 sites, a 3'-Not1 site and cloned into the ADH2 promoter-containing pBlsc vector Xba1/Not1 to create pHG40. The URA3 gene was amplified with 5'-BamH1 and 3'-Xho1 sites, cloned into pHG40 to generate pHG42. Genes to be expressed were cloned into the Xba1/Sal1 sites 5'- to 3'- and the entire cassette was removed as a Not1/Xho1 fragment for ligation into yeast expression vectors. pHG62 was a yeast expression vector containing the entire *S. cerevisiae* 2 micron sequence cloned into pBlsc. The B form of 2 micron DNA was amplified by PCR from *S. cerevisiae* DNA in 2 fragments as Not1/EcoR1 and EcoR1/Xho1 fragments using the unique EcoR1 site of 2 micron DNA.

The entire 2 micron DNA vector was excised Not1/Xho1 for ligation and transformation yeast. Coding sequences for the fusion proteins were constructed. Coding sequences for the fusion proteins were constructed. A

synthetic SLPI gene was chemically synthesized with yeast-preferred codons coding for the mature peptide, amino acids 1-107 and cloned into pUC19. PCR primers were designed with a 5'-XbaI site and a 3'-NcoI site to subclone SLPI as a fusion with AATyc2. A synthetic AAT gene (AATyc2) was chemically synthesized with yeast-preferred codons that encoded a methionine residue, and amino acids 1-394 of mature AAT, and cloned into pCR4TOPO. A three fragment ligation was assembled with pHG42 XbaI/SalI vector, DNA encoding AATyc2 as a NcoI/SalI fragment and cloned into Escherichia coli to create MetSLPI/MetAATyc2 pHG42. The NotI/XhoI fragment of MetSLPI/MetAATyc2 pHG42 was cloned into pHG62 NotI/XhoI, pKC64 NotI/XhoI, or pKC65 NotI/XhoI. Other expression vectors which were used in the construction of SLAPI and other protease inhibitors were pKC64 and pKC65, which were modified versions of pHG62 with the yeast LEU2 gene inserted at the novel Pst site of 2 micron DNA.

L151 ANSWER 16 OF 20 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
 AN 2001-367273 [38] WPIX
 DNC C2001-112564
 TI Bioadhesive pharmaceutical composition for treating mucosal epithelial ulceration and/or erosions comprises bioadhesive substance, active substance having **matrix metalloproteinases** inhibitory activity and vehicle.
 DC A96 B05 C03
 IN GIZURARSON, S; HOLBROOK, W P; KRISTMUNDSOTTIR, T; SKULASON, S
 PA (LIPH-N) LIF-HLAUP EHF BIO-GELS PHARM INC
 CYC 95
 PI WO 2001028515 A1 20010426 (200138)* EN 52 A61K009-00
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
 NL OA PT SD SE SL SZ TZ UG ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM
 DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
 LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE
 SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
 AU 2000078164 A 20010430 (200148) A61K009-00
 EP 1267826 A1 20030102 (200310) EN A61K009-00
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
 RO SE SI
 JP 2003512310 W 20030402 (200325) 42 A61K045-00
 AU 778498 B2 20041209 (200508) A61K009-00
 ADT WO 2001028515 A1 WO 2000-IS13 20001022; AU 2000078164 A AU 2000-78164
 20001022; EP 1267826 A1 EP 2000-968217 20001022; WO 2000-IS13 20001022; JP
 2003512310 W WO 2000-IS13 20001022; JP 2001-531110 20001022; AU 778498 B2
 AU 2000-78164 20001022
 FDT AU 2000078164 A Based on WO 2001028515; EP 1267826 A1 Based on WO
 2001028515; JP 2003512310 W Based on WO 2001028515; AU 778498 B2 Previous
 Publ. AU 2000078164, Based on WO 2001028515
 PRAI IS 1999-5228 19991022
 IC ICM A61K009-00; A61K045-00
 ICS A61K009-02; A61K009-06; A61K009-08; A61K009-10; A61K009-12;
 A61K009-127; A61K009-48; A61K009-70; A61K031-00; A61K031-085;
 A61K031-135; A61K031-14; A61K031-167; A61K031-235; A61K031-245;
 A61K031-327; A61K031-352; A61K031-4418; A61K031-4704; A61K031-5375;
 A61K031-60; A61K031-65; A61K033-22; A61K033-30; A61K035-60;
 A61K035-72; A61K035-78; A61K047-00; A61K047-30; A61K047-32;
 A61K047-34; A61K047-36; A61K047-38; A61K047-42; A61K047-46;
 A61P001-00; A61P001-02; A61P001-04; A61P011-00; A61P015-00;
 A61P015-02; A61P027-16; A61P029-00; A61P043-00
 AB WO 200128515 A UPAB: 20010711
 NOVELTY - A bioadhesive pharmaceutical composition for treating mucosal
 epithelial ulceration and/or erosions comprises a bioadhesive substance, a

biologically active substance having **matrix metalloproteinases** inhibitory activity and an optional vehicle. The bioadhesive substance and the vehicle release the active substance into the epithelia of the mucosa without affecting its normal flora.

ACTIVITY - Antiulcer; gastrointestinal; gynecological; uropathic; cytostatic; antibacterial; virucide.

MECHANISM OF ACTION - **Metalloproteinase** inhibitor.

USE - The composition is useful for the manufacture of a medicament for the treatment of mucosal epithelial ulceration and/or erosion. The mammal is horse, cow, cat, dog, hamster, guinea pig or other pets or animals for breeding. The formulation is also useful in the treatment of primary herpes simplex, recurrent herpes, coxsackie virus infections in oral or other mucosal surfaces etc.

ADVANTAGE - The formulation does not affect the normal flora or the mucosa and reduces the risk of side effects

Dwg.0/3

FS CPI

FA AB; DCN

MC CPI: A12-V01; B04-B01C1; B04-B01C2; B04-C02; B04-C03; B04-F02; B05-A03A; B05-B02C; B05-C08; B06-A01; B06-A02; B06-D13; B06-F05; B07-A02; B07-E03; B10-A04; B10-A13D; B10-A22; B10-B02A; B10-B02F; B10-B02G; B10-B03B; B10-C03; B10-E02; B12-M01A; B12-M02B; B12-M03; B12-M07; B12-M08; B12-M10A; B12-M11C; B12-M11F; B14-C07; B14-D07C; B14-L09; B14-N17B; B14-R03; B14-S12; C04-B01C1; C04-B01C2; C04-C02; C04-C03; C04-F02; C05-A03A; C05-B02C; C05-C08; C06-A01; C06-A02; C06-D13; C06-F05; C07-A02; C07-E03; C10-A04; C10-A13D; C10-A22; C10-B02A; C10-B02F; C10-B02G; C10-B03B; C10-C03; C10-E02; C12-M01A; C12-M02B; C12-M03; C12-M07; C12-M08; C12-M10A; C12-M11C; C12-M11F; C14-C07; C14-D07C; C14-L09; C14-N17B; C14-R03; C14-S12

TECH UPTX: 20010711

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The active substance is released in a profile comprising release of 10% within at least 10 minutes and at least 20% within at least 30 minutes. The active substance is contained in a concentration of 0.05-0.5 (especially 0.1-0.3) wt% of the composition and the bioadhesive substance in an amount of 0.05-10 (especially 0.1-5) wt% of the composition. The composition is in the form of a hydrogel, gel, film, cream, ointment, lotion, liniment, liposome, solution, suspension, foam, stick, spray, paste, patch, plaster, suppository or gelatin capsule (especially hydrogel or gel with bioadhesive properties to mucosal membranes). The composition also comprises bioadhesive component(s) (selected from more than 20 specified): bioadhesive/water gelling agents such as carbopol 934, carbopol 940, carbopol 941, carbopol 971, carbopol 974, carbopol 980, carbopol 981, carbopol 1342, carbopol 1382, carboxymethylcellulose and hydroxypropylmethylcellulose or their salts, xanthan gums, and/or polycarbophil. The biologically active substance is in dissolved or in particulate form and is selected from tetracyclines or their derivatives such as tetracycline, doxycycline, minocycline or oxytetracycline and in a concentration below antimicrobial concentration. The composition also comprises additional active compound selected from (30 specified): anesthetics such as benzocaine, mepiracaine, astringents such as calamine, zinc oxide, wound cleansers such as benzalkonium chloride, tannic acid, wound healing agents such as fish oils, shark, liver oil and antihistamines such as promethazine and azatadine. The composition further comprises additional ingredients selected from (16 specified) surfactants, organic solvents, pH controlling agents, propellents and/or water.

ABEX UPTX: 20010711

ADMINISTRATION - The composition is administered to a surface of the mucosa including parts which are inflamed, ulcerated, surface eroded wholly or partially extending through the surface of the epithelial layer

but only extending just into the underlying lamina propria. The mucosal surface is selected from surfaces of nose, lungs, mouth, eye, ear, gastrointestinal tract, genital tract, vagina and rectum. The active substance is applied in a volume of 0.01-0.5 ml for oral, nasal and ocular mucosa and in a volume not exceeding 30 ml for rectal or vaginal mucosa. The formulation is administered to splenectomized subjects, subjects with cancer or using anticancer drugs or antibiotics, anti-inflammatories, subjects subject to hyper/hypothyroidism or having problems with malabsorption such as diarrhea.

EXAMPLE - Inhibitory activity of doxycycline against metalloproteinases was evaluated using Zymography method (Mackay et al., Cancer Res., 50(18), 5997-6001, 1990). Complete inhibition of metalloproteinase 2 was obtained with 100 microM (48 microg/ml) concentration and 50 microM (24 microg/mol) against metalloproteinase 9.

L151 ANSWER 17 OF 20 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2001-167802 [17] WPIX

DNC C2001-049999

TI Treatment of eye and ear infections prevent tissue destruction by parasitic or microbial infestation by administering protease inhibitor e.g. secretory leucocyte protease inhibitor.

DC B04

IN LEZDEY, D; LEZDEY, J

PA (JDSC-N) J & D SCI INC

CYC 1

PI US 6174859 B1 20010116 (200117)* 4 A61K038-00

ADT US 6174859 B1 US 1999-286740 19990406

PRAI US 1999-286740 19990406

IC ICM A61K038-00

AB US 6174859 B UPAB: 20010328

NOVELTY - Treatment of optic and otic infections, inflammation and kallikrein activity caused by parasites and microbes comprises administration of protease inhibitor comprising **alpha -1 antitrypsin** (AAT), secretory leukocyte protease inhibitor (SLPI) and/or antiplasmin inhibitor, in a carrier, at the site of infection.

An INDEPENDENT CLAIM is included for a composition comprising 0-20 mg/ml of protease inhibitor, 0-1.5 weight% of steroidal antiphlogistic, 0-5 weight% of non-steroidal antiphlogistic and 0-1.5 weight% of hyaluronic acid,

in

an aqueous carrier base.

ACTIVITY - Antiinflammatory; antiparasitic; antimicrobial; ophthalmological; auditory.

MECHANISM OF ACTION - Protease inhibitor.

USE - Used for treating eye and ear infections, which can lead to irreversible damage and loss of sight or hearing, particularly infections due to Pseudomonas, and the protozoan parasites Cryptosporidium parvum and Schistosoma mansoni, which are usually water borne.

ADVANTAGE - The combination of protease inhibitors with the other ingredients is synergistic, so that both antibiotics and antiphlogistics may be used in smaller doses. The therapeutic effect is higher and treatment time shorter.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B04-C02A2; B04-N02; B14-B02; B14-N03; B14-N04; B14-S09

TECH UPTX: 20010328

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred components: The method includes using a steroid, preferably dexamethasone, betamethasone or triamcinolone acetone, antibiotics, preferably active against

Pseudomonas; bradykinin antagonists and hyaluronic acid to promote healing, particularly of corneal injury.

ABEX UPTX: 20010328

ADMINISTRATION - Administration is as an ointment or as liquid drops in buffer or physiological saline.

EXAMPLE - A mixture of **alpha-1 antitrypsin** (5 mg), hydroxypropyl methylcellulose (2.5 g) and ionically balanced pH 7.4 phosphate buffer to make to 100 g was prepared. Drops were dosed into the infected ear of a patient suffering from swimmer's ear three times a day. Pain was reduced with the initial dose.

L151 ANSWER 18 OF 20 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2000-611339 [58] WPIX

CR 2000-572151 [50]; 2000-587294 [50]; 2000-594139 [50]

DNC C2000-182850

TI Treating herpes virus infection and associated disease by administering **alpha-1 antitrypsin** or compound with similar activity.

DC B05 C03 D16

IN SHAPIRO, L

PA (UYTE-N) UNIV TECHNOLOGY CORP

CYC 87

PI WO 2000051625 A1 20000908 (200058)* EN 86 A61K038-08

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SL SZ TZ UG ZW

W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM EE ES FI
GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU
LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
TR TT TZ UA UG UZ VN YU ZA ZW

AU 2000038640 A 20000921 (200065) A61K038-08

ADT WO 2000051625 A1 WO 2000-US5557 20000303; AU 2000038640 A AU 2000-38640 20000303

FDT AU 2000038640 A Based on WO 2000051625

PRAI US 1999-153942P 19990915; US 1999-123167P 19990305

IC ICM A61K038-08

ICS A61K038-57; A61P031-22

AB WO 2000051625 A UPAB: 20001214

NOVELTY - Treating herpes virus (HV) infection and associated disease comprises administering an agent (I) with mammalian **alpha 1-antitrypsin** (aaT) or aaT-like activity.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a pharmaceutical composition comprising a peptide of formula (A) or its salts.

Nt = amino acid (aa), including C, acetyl, succinyl or is absent;

X1 = aa, including F or A;

X2 = aa, including C, V, L, M, I, A, C or S;

X3 = aa, including F, A, V, M, L, I, Y or C;

X4 = aa, including L, A, F, I, V, C, G or S;

X5 = aa, including M, A, I, L, V, F or G;

Ct = aa, including C, an amide or ester, or is absent.

aa Has L- or D-configuration.

ACTIVITY - Antiviral; cytostatic; neuroprotective; antipyretic; dermatological; antiulcer; hepatotropic; antidiarrheal; antibacterial.

Herpes simplex-1 or -2 was used to infect semi-continuous human lung fibroblasts in the presence or absence of aaT, then virus removed and the cells cultured. The amount of virus produced was determined by enzyme-linked immunosorbent assay and the measured optical density was 0.8 in the absence of aaT but only 0.5 when aaT was present at 3 mg/ml.

MECHANISM OF ACTION - Serine protease **inhibitor**;
trypsin inhibitor.

USE - Used for treating HV infection mediated by an endogenous serine protease or SP-like activity and **inhibiting** the spread or onset of viral infection mediated by endogenous SP or SP-like activity, and for preventing sexually transmitted diseases (all claimed) by intravaginal or intrarectal administration of (I) or its derivatives that can **inhibit** caspase, proteinase-3, cathepsin G and/or elastase. (I) Is used for treating infection by herpes simplex-1 and -2 viruses, cytomegalovirus, Epstein-Barr virus, varicella zoster virus, herpes zoster and human herpes viruses 5, 6 and/or 8. (I) Is used for treating malaise, fever, chills, rhinitis, diarrhea, atopic eczema, encephalitis, keratoconjunctivitis, pharyngitis, gingivostomatitis, hepatitis, recurrent orofacial mucocutaneous lesions or herpes labialis, chicken pox skin sores, erythema multiforme, idiopathic burning mouth, aphthous ulceration, Behcet's syndrome, mononucleosis, Burkitt's lymphoma and other tumors and neuropathies. Particularly, (I) is used against HV infections of the mucosa (oral, **middle ear**, gastrointestinal, urogenital, airway/lung, eye, peritoneal membranes etc.), including sexually transmitted diseases. Treatment with (I) is also used to restore defective levels of functional endogenous aaT and to prevent development of such a condition, in treating infections by viruses other than herpes, to prevent bacterial colonization concurrent with viral infection and also very generally wherever **inhibition** of serine protease activity is required, e.g. in medicine, biology, agriculture or microbial fermentation.

Dwg.0/2

FS CPI

FA AB; GI; DCN

MC CPI: B04-C01A; B07-D13; B07-E04; B07-F03; B10-A08; B10-A10; B10-A17; B14-A01; B14-A02A3; B14-C04; B14-D07C; B14-E02; B14-E08; B14-H01; B14-N03; B14-N04; B14-N06B; B14-N12; B14-N16; B14-N17; C04-C01A; C07-D13; C07-E04; C07-F03; C10-A08; C10-A10; C10-A17; C14-A01; C14-A02A3; C14-C04; C14-D07C; C14-E02; C14-E08; C14-H01; C14-N03; C14-N04; C14-N06B; C14-N12; C14-N16; C14-N17; D05-H17A6; D05-H17B6

TECH UPTX: 20001114

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred materials: (I) Comprises:
(i) aaT, particularly isolated from wild-type, mutant or transgenic mammalian sources;
(ii) a peptoid substituted by oxadiazole, thiadiazole or triazole, phenylene dialkanoate, tetrazole, guanidinobenzoic acid, phenylsulfonylamide, sulfide, sulfoxide, sulfone, amidine, amidinophenol or their derivatives, or
(iii) peptides (A).

ABEX UPTX: 20001114

SPECIFIC COMPOUNDS - About 90 compounds are used e.g:
(benzyloxycarbonyl)-L-valyl-N-(1-(2-(5-(3-methylbenzyl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-methylpropyl)-L-prolinamide (Ia).
27 Peptides (A) are used e.g. Phe-Val-Phe-Leu-Met.

ADMINISTRATION - (I) is administered at 1 mug to 100 mg/kg/day, preferably 10-25 mg/kg/day, systemically or topically. When administered topically, (I) may be combined with an anesthetic, analgesic and/or antibiotic.

L151 ANSWER 19 OF 20 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 1997-077259 [07] WPIX

CR 2000-205215 [18]

DNC C1997-024781

TI Reversible cysteine protease inhibitors used to treat e.g. arthritis, - and tumour invasion, inflammation and malaria, are new or known N, N'-substd. ethylene di amine derivs..

DC B04 B05 C03

IN KLAUS, J L; KUO, E Y; PALMER, J T; RASNICK, D
 PA (AXYS-N) AXYS PHARM INC; (ARRI-N) ARRIS PHARM CORP
 CYC 73

PI WO 9640737 A1 19961219 (199707)* EN 83 C07K005-00
 RW: AT BE CH DE DK EA ES FI FR GB GR IE IT KE LS LU MC MW NL OA PT SD
 SE SZ UG
 W: AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL
 IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL
 PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN

AU 9659755 A 19961230 (199716)
 ZA 9604751 A 19970326 (199718) 78 C07K000-00
 NO 9705742 A 19980205 (199816) C07D295-26
 EP 832099 A1 19980401 (199817) EN
 R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
 CZ 9703906 A3 19980415 (199821)
 JP 11507045 W 19990622 (199935) 94 C07C311-18
 NZ 309560 A 19990828 (199939)
 KR 99022395 A 19990325 (200023) C07K005-00
 AU 723658 B 20000831 (200046) C07K005-00
 TW 438591 A 20010607 (200175) A61K031-535
 CN 1192219 A 19980902 (200276) C07K005-00

ADT WO 9640737 A1 WO 1996-US8559 19960603; AU 9659755 A AU 1996-59755
 19960603; ZA 9604751 A ZA 1996-4751 19960606; NO 9705742 A WO 1996-US8559
 19960603, NO 1997-5742 19971205; EP 832099 A1 EP 1996-917069 19960603, WO
 1996-US8559 19960603; CZ 9703906 A3 WO 1996-US8559 19960603, CZ 1997-3906
 19960603; JP 11507045 W WO 1996-US8559 19960603, JP 1997-501116 19960603;
 NZ 309560 A NZ 1996-309560 19960603, WO 1996-US8559 19960603; KR 99022395
 A WO 1996-US8559 19960603, KR 1997-708875 19971205; AU 723658 B AU
 1996-59755 19960603; TW 438591 A TW 1996-106569 19960601; CN 1192219 A CN
 1996-195858 19960603

FDT AU 9659755 A Based on WO 9640737; EP 832099 A1 Based on WO 9640737; CZ
 9703906 A3 Based on WO 9640737; JP 11507045 W Based on WO 9640737; NZ
 309560 A Based on WO 9640737; KR 99022395 A Based on WO 9640737; AU 723658
 B Previous Publ. AU 9659755, Based on WO 9640737

PRAI US 1995-474993 19950607

REP 2.Jnl.Ref; JP 63275575; WO 9418185

IC ICM A61K031-535; C07C311-18; C07D295-26; C07K000-00; C07K005-00
 ICS A61K031-18; A61K031-27; A61K031-495; A61K038-04; A61K038-55;
 C07C311-08; C07C311-15; C07C311-16; C07D295-20; C07D295-215;
 C07D295-22; C07K005-02

ICI C07M007:00

AB WO 9640737 A UPAB: 20021125

Reversible cysteine **protease** inhibitors (I) with a dissociation
 constant for inhibition (K_i) of not more than 100 mM comprise two
 N-substituted. R', R'' linked via an opt. substd. ethylene diamine. R', R'' =
 acyl, alkoxycarbonyl, sulphonyl, sulphamoyl, sulphinyl, carbamoyl,
 peptidyl, acylpeptidyl, alkoxycarbonylpeptidyl, sulphonylpeptidyl,
 sulphamoylpeptidyl, sulphinylpeptidyl or carbamoylpeptidyl.

Also claimed are the following. (A) a method of inhibiting a cysteine
protease inhibitor, by reversibly binding an inhibitor of formula
 A-NR3-CHR1-CH2-NR4-X (Ia); A, X = R', R''; R1 = H or aminoacid side chain;
 R3, R4 = H; or R3+R4 = opt. substd. ethylene; (B) a cysteine
protease inhibited by an inhibitor of formula (Ia); and (C) the
 detection of cysteine **protease** in a sample by (i) assaying the
 sample for **protease** activity using a **protease**
 substrate and (ii) assaying for **protease** activity in the
 presence of a known concentration of (Ia). Cpds. of formula A1-NR23-CHR21-CH2-
 NR24-X1 (Ib), and their salts, isomers and mixts. of isomers are new. A1,
 X1 = independently X1R13 (but not both H); R13 = H,
 alkoxycarbonylalkanoyl, alkoxycarbonyl, alkanoyl (opt. substd. by carboxy,

alkoxycarbonyl or heterocyclalkylalkanoyl amino), cycloalkylcarbonyl, heterocycloalkylcarbonyl (opt. substd. by OH, alkyl, heterocycloalkyl, alkanoyl, alkyloxycarbonyl, arylalkoxycarbonyl or heterocycloalkylcarbonyl), carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, arylcarbamoyl, aralkylcarbamoyl, aralkanoyl, aroyl, alkylsulphonyl, arylsulphonyl, aralkylsulphonyl, alkylsulphamoyl, dialkylsulphamoyl, arylsulphamoyl, alkylsulphiny, dialkylaminosulphiny or arylsulphiny; X1 = bond, -Y-Z-[X3-X4-Z]n-CO- or -Y-Z-[X3-X4-Z]n-CO-NH-CO-; n = 0-9; X3-X4 = -CO-NR14-, -CH2NR14-, -COCH2- or -NR14CO; Y = CHR14- or -NR14-; Z = -(CH2)2-, -C(R15)(R16)- or -N(R16)-; R14 = H; R15 = H or Me; R16 = H, alkyl (opt. substd. by OH, alkoxy, amino, alkylamino, dialkylamino, ureido, alkylureido, mercapto, alkylthio, carboxy, carbamoyl (opt. substd. by 1-2 alkyl), alkylsulphiny, alkylsulphonyl, guanidino, -P(O)(OR12)2, -OP(O)(OR12)2, -OP(O)(R12)2, all opt. protected), cycloalkyl, cycloalkylalkyl, aryl or aralkyl (both opt. ring substd. by 1-3 OH, NH2, guanidino, halo, alkyl, haloalkyl, alkoxy or aryl, all opt protected); or R14+R16 = -CH2CH2CH2-, -(CH2)4 or 1,2-phenylene dimethylene (opt. substd. by OH, protected OH or oxo); R12 = H or alkyl; R21 = H, CN, CO2H, alkoxy, carbonyl, alkanoyl, carbamoyl, (opt. substd. by 1-2 alkyl), alkoxyalkylcarbamoyl, aminoalkylcarbamoyl, R16 or X2R13; X2 = -Y-Z-[X3-X4-Z]n-CO- or -Y-Z-[X3-X4-Z]n-CO-NH-CO-; R23, R24 = R14; or R3+R4 = opt. substd. ethylene.

USE - (Ia) are useful in treating cysteine-**protease** -associated disorders (claimed), including arthritis, muscular dystrophy, inflammation, tumour invasion, glomerulonephritis, malaria and other parasite-borne infections. (I) are for human or veterinary use. The cpds. are useful in treating periodontal disease such as gingivitis, leishmaniasis, filariasis, osteoporosis, osteoarthritis and especially viral diseases by inhibiting **proteases** necessary for viral replication. The cpds. are useful in disorders involving interleukin-1B converting enzyme (ICE) in the treatment of inflammation and immune-based disorders of the lung, airways, CNS and surrounding membranes, eyes, ears, joints, bones, connective tissues, cardiovascular system, gastrointestinal and urogenital systems, the skin and mucosal membranes; including infections such as meningitis and salpingitis, septic shock, reperfusion injury, disseminated intravascular coagulation and/or adult respiratory distress syndrome, acute or chronic inflammation due to antigens, antibodies and/or complement deposition, diabetes mellitus, multiple sclerosis, Alzheimer's disease, cancer metastasis, cholangitis, colitis, encephalitis, endocarditis and pancreatitis. Bone and cartilage reabsorption may be treated along with excessive deposition of extracellular **matrix**. The cpds. may be used in the treatment of tumours that produce IL1 as a growth factor and in preventing cachexia-related tumours. The cpds. may also be used in drug potentiation, involving co-admin. or sequential admin. with a drug which could be inactivated via endogenous proteolysis. (I) may be used as antibacterial agents to prevent tissue damage. (I) may also be used for the removal, identification or inhibition of contaminating cysteine **proteases** in a sample; bound to a chromatographic support to form an affinity chromatography column, for removing cysteine **proteases** or identify new ones; in diagnostic kits used with fluids such as blood or saliva, or in cell cultures (fungi, yeast, bacteria, plant, viral or mammalian). Most of the cpds. are selective inhibitors of cysteine **protease**, and others also inhibit other **proteases** such as serine, aspartyl and other **metalloproteases**, to a lesser extent.

Admin. in the treatment of cysteine-mediated disorders is e.g. oral, subcutaneous, transdermal or intraperitoneal.

ADVANTAGE - The cpds. function reversibly, with tight binding (low Ki values) between inhibitor and target enzyme.

Dwg.0/5
 FS CPI
 FA AB; DCN
 MC CPI: B05-B01P; C05-B01P; B10-A17; C10-A17; B10-B01; C10-B01; B11-C08E3;
 C11-C08E3; B12-K04A; C12-K04A; B14-A03B; C14-A03B; B14-C03; C14-C03;
 B14-C09; C14-C09; B14-D07C; C14-D07C; B14-H01B; C14-H01B

L151 ANSWER 20. OF 20 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 1996-277462 [28] WPIX

DNC C1996-088005

TI Regulating metallo proteinase activity by adjusting concentration of nitric oxide

- useful for treating tumour metastasis, otitis media, pulmonary emphysema, etc..

DC B05

IN MURRELL, G A C; MURRELL, G A

PA (NYRU-N) NEW YORK SOC RUPTURED & CRIPPLED MAINTAI

CYC 20

PI WO 9616648 A1 19960606 (199628)* EN 40 A61K031-20
 RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
 W: AU CA JP NZ

AU 9642479 A 19960619 (199640) A61K031-20

ADT WO 9616648 A1 WO 1995-US15529 19951121; AU 9642479 A AU 1996-42479 19951121

FDT AU 9642479 A Based on WO 9616648

PRAI US 1994-346146 19941129

REP 1.Jnl.Ref

IC ICM A61K031-20

AB WO 9616648 A UPAB: 19960719

Regulating the activity of **matrix metalloproteinases**

in a biological tissue comprises adjusting the concentration of nitric oxide to which the **metalloproteinases** are exposed.

Also claimed are: (A) a method for inhibiting metastasis of malignant tumour cells comprising decreasing the concentration of nitric oxide in the vicinity of the cells; (B) a method for treating **otitis media** comprising admin. of an agent that reduces the concentration of nitric oxide in the **middle ear** sinuses; (C) a method for treating pulmonary emphysema comprising admin. by inhalation of an agent that decreases the local concentration of nitric oxide in the pulmonary tissue; (D)

a method for treating scleroderma comprising admin. of an agent that increases the concentration of nitric oxide in the vicinity of skin affected by the scleroderma; and (E) a method for preventing loosening of surgical implants comprising admin. of an agent that decreases the concentration of

nitric oxide in the vicinity of the implant.

The concentration of nitric oxide to which the **metalloproteinases** are exposed is pref. decreased by 50-100% below the concentration of nitric

oxide that is present in the absence of an agent that decreases the nitric oxide concentration The agent is monomethyl arginine.

USE - The methods can be also used for treating or alleviating diseases of collagen metabolism such as systemic scleroderma, for reducing bone inflammation caused by degeneration of surgical implants and for treating adult respiratory distress syndrome and periodontal disease.

Dwg.0/6

FS CPI

FA AB; DCN

MC CPI: B10-A17; B14-F02D2; B14-H01B; B14-N02; B14-N17

=> d his

(FILE 'HOME' ENTERED AT 14:02:58 ON 21 JUN 2005)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 14:03:04 ON 21 JUN 2005

L1 1 S US20040175383/PN OR (US2003-731375# OR WO2003-US39053 OR US20
E BARR P/AU
L2 259 S E3,E7,E22-30
E PEMBERTON P/AU
L3 34 S E3,E4,E8,E10
E ANTONELLI P/AU
L4 12 S E3,E7
E SCHULTZ G/AU
L5 208 S E3,E13
E SCHULTZ GREG/AU
L6 94 S E3-E5,E8,E9
E SUNDIN D/AU
L7 10 S E7,E8
E ARRIVA/PA,CS
L8 9 S E3-E10
E U FL/PA,CS
E U OF FL/PA,CS
E UN FL/PA,CS
E UN OF FL/PA,CS
E UNI FL/PA,CS
E UNI OF FL/PA,CS
E UNIV FL/PA,CS
L9 15 S E5-E10
E UNIV OF FL/PA,CS
L10 59 S E5-E8,E10-E24
L11 4780 S E25-E79
E UNIVER FL/PA,CS
E UNIVER OF FL/PA,CS
E UNIVERS FL/PA,CS
E UNIVERS OF FL/PA,CS
E UNIVERSITY FL/PA,CS
L12 56 S E6-E18
E UNIVERSITY OF FL/PA,CS
L13 1247 S E33-E205
E FLORIDA/PA,CS
L14 69197 S E3,E4

FILE 'REGISTRY' ENTERED AT 14:09:55 ON 21 JUN 2005

L15 1 S ILOMASTAT/CN
E C20H28N4O4/MF
L16 32 S E3 AND NC4-C6/ES AND 2/NR
L17 7 S L16 AND BUTANEDIAMIDE
L18 6 S L17 NOT 200866-76-8
L19 6 S L15,L18
SEL RN
L20 0 S E1-E6/CRN
L21 674 S (?MATRIX?(L)?METALLO?(L)(?PROTEINASE? OR ?PROTEASE?))/CNS
L22 583 S (?MATRIX?(L)(?METALLOPROTEINASE? OR ?METALLOPROTEASE?))/CNS
E MMP
L23 790 S E3-E102
L24 674 S L21,L22
L25 349 S L24 AND L23
L26 674 S L24,L25

jan delaval - 21 june 2005

L27 441 S L23 NOT L26
E ANTITRYPSIN
L28 83 S E3
L29 85 S ANTI TRYPSIN
E AAT
L30 452 S E3
E SCAN
E RAAT
L31 4 S L30 AND L28,L29
L32 141 S ALPHA()1() (ANTITRYPSIN OR ANTI TRYPSIN OR TRYPSIN INHIBIT?)

FILE 'HCAPLUS' ENTERED AT 14:18:38 ON 21 JUN 2005

L33 20912 S L28-L32
L34 5525 S ALPHA()1() (ANTITRYPSIN OR ANTI TRYPSIN)
L35 5582 S ALPHA()1(L) (ANTITRYPSIN OR ANTI TRYPSIN)
L36 1441 S ALPHA()1(L) TRYPSIN(L) INHIBIT?
L37 22445 S L33-L36
L38 43494 S L26 OR L27
L39 15830 S ?MATRIX?(L)?METALLO?(L) (?PROTEINASE? OR ?PROTEASE?)
L40 15738 S ?MATRIX?(L) (?METALLOPROTEINASE? OR ?METALLOPROTEASE?)
L41 15 S ?MATRIXMETALLO?(L) (?PROTEINASE? OR ?PROTEASE?)
L42 15 S ?MATRIXMETALLOPROTEINASE? OR ?MATRIXMETALLOPROTEASE?
L43 13586 S MMP?
L44 48294 S L38-L43
L45 100 S L19
L46 215 S ILOMASTAT OR CS610 OR CS 610 OR GM6001 OR GM 6001 OR GALARDIN
L47 227 S L45,L46
E OTITIS/CT
E E3+ALL
L48 471 S E1,E2,E3
E OTITI? MEDI?
L49 1294 S OTITI? MEDI?
L50 1656 S E12
E TYMPANIC MEMBRANE/CT
E E3+ALL
L51 112 S E2
L52 407 S TYMPAN?(L)MEMBRAN?
E AUDITORY CANAL/CT
L53 116 S AUDITORY CANAL
E MIDDLE EAR
E MIDDLE EAR/CT
E E3+ALL
L54 439 S E2
E TYMPANOSOMY/CT
E TYMPANOSTOMY/CT
L55 35 S TYMPANOSTOM?
E OTORRHEA/CT
E OTORRHEA
L56 37 S E3-E5
E EAR/CT
L57 9213 S E3-E63
L58 12277 S E3+OLD,NT,PFT,RT OR E54+OLD,NT,PFT,RT
L59 12960 S L48-L58
L60 23 S L59 AND L37
L61 73 S L59 AND L44
L62 2 S L59 AND L47
L63 4 S L1-L14 AND L60-L62
E PEMBERTON P/AU
L64 37 S E3,E4,E9,E10
L65 4 S L64 AND L60-L62

L66 4 S L63,L65
 L67 84 S L60-L62 NOT L66
 L68 76 S L67 AND (PY<=2002 OR PRY<=2002 OR AY<=2002)
 L69 19 S L68 AND L37
 L70 5 S L69 AND L44
 L71 0 S L69 AND L47
 L72 19 S L69,L70
 SEL DN AN 3-5 10-12 15 16
 L73 8 S L72 AND E1-E24
 L74 57 S L68 NOT L69-L73
 SEL DN AN 17 37 48 49 L74
 L75 4 S E25-E36 AND L74
 L76 3 S L75 NOT 3/SC
 L77 15 S L66,L73,L76 AND L1-L14,L33-L76
 SEL HIT RN

FILE 'REGISTRY' ENTERED AT 14:52:28 ON 21 JUN 2005

L78 6 S E37-E42
 L79 1 S L78 AND L19
 L80 4 S L78 AND L26,L27
 L81 1 S L78 AND L28-L32

FILE 'REGISTRY' ENTERED AT 14:53:40 ON 21 JUN 2005

FILE 'HCAPLUS' ENTERED AT 14:54:03 ON 21 JUN 2005

FILE 'MEDLINE' ENTERED AT 15:10:48 ON 21 JUN 2005

L82 16 S L19
 L83 217 S L46
 L84 217 S L82,L83
 L85 2253 S L28-L32
 L86 10309 S L34-L36
 L87 12523 S L85,L86
 L88 2843 S L26 OR L27
 L89 22594 S L39-L43
 L90 25406 S L88,L89
 E ALPHA 1-ANTITRYPSIN/CT
 E E3+ALL
 L91 12523 S E42+NT OR L87
 E MATRIX METALLOPROTEINASE/CT
 E E4+ALL
 E E2+ALL
 E E26+ALL
 L92 53496 S E6+NT OR L90
 E EAR/CT
 L93 59245 S E3+NT
 E OTITIS/CT
 E E3+ALL
 L94 83145 S E3+NT
 L95 47 S L93,L94 AND L91
 L96 148 S L93,L94 AND L92
 L97 6 S L93,L94 AND L84
 L98 176 S L95-L97 AND PY<=2002
 L99 44 S L98 NOT AB/FA
 L100 132 S L98 NOT L99
 L101 112 S L100/ENG
 L102 20 S L100 NOT L101
 SEL DN AN 15 17
 L103 2 S L102 AND E1-E4
 SEL DN AN L101 6 9 23 36 40 46 64 67 68 71 82 96

L104 12 S L101 AND E5-E28
 E TYMPANOSTOMY/CT
 E E3+ALL
 E E2+ALL
 L105 1404 S E8+NT
 L106 8396 S E7+NT
 L107 1 S L105,L106 AND L84
 L108 4 S L105,L106 AND L87
 L109 3 S L105,L106 AND L90
 L110 8 S L105,L106 AND L91,L92
 L111 8 S L107-L110
 L112 8 S L111 AND PY<=2002
 L113 19 S L103,L104,L112 AND L82-L112

FILE 'MEDLINE' ENTERED AT 15:31:40 ON 21 JUN 2005

FILE 'WPIX' ENTERED AT 15:31:52 ON 21 JUN 2005

L114 19 S L46/BIX
 E ILOMASTAT/DCN
 E ILOMASTAT/SDCN
 E ILOMASTAT/CN
 L115 1 S E3
 E RA2BM/DCN
 L116 16 S E66-E72
 L117 19 S L114,L116
 L118 523 S L34/BIX OR L35/BIX OR L36/BIX
 E ANTITRYPSIN/CN
 L119 2 S E4-E6
 E RAOY1/DCN
 E RAOY1/DCN
 L120 13 S E128-E133
 E RAOAQU/DCN
 L121 80 S E3-E13
 L122 552 S L118-L121
 L123 2318 S L39/BIX OR L40/BIX OR L41/BIX OR L42/BIX OR L43/BIX
 E MATRIX/CN
 L124 9 S E4-E16
 L125 196 S (RAAP2X OR RA9NRC OR RA7N1V OR RA6RBL OR RA2UUK OR RA2S00 OR
 L126 2422 S L123,L125
 L127 1003 S A61P027-16/IPC
 L128 4268 S P921/M0,M1,M2,M3,M4,M5,M6
 L129 8414 S (B12-L04 OR C12-L04 OR B14-N02 OR C14-N02)/MC
 L130 1 S L117 AND L127-L129
 L131 21 S L122 AND L127-L129
 L132 51 S L126 AND L127-L129
 L133 0 S L131 AND L132
 L134 5156 S A61K031-56/IPC OR (B04-J02 OR C04-J02)/MC
 L135 2 S L131,L132 AND L134
 E RAOY1W/DCN
 L136 13 S E3-E8
 E RAOY1W/SDCN
 L137 1 S E3
 E RAO120/DCN
 L138 1369 S E3-E17
 E RAO120/SDCN
 L139 2 S E3
 L140 552 S L136 OR L122
 L141 21 S L140 AND L127-L129
 L142 21 S L131,L141
 L143 5158 S L139,L134

L144 2 S L143 AND L142
L145 2 S L130,L135,L144
L146 1 S L145 AND OTIT?/BIX
L147 70 S L131,L132,L142 NOT L145
L148 7 S L147 AND OTIT?/BIX
L149 3 S L147 AND (TYMPAN? OR AUDITORY CANAL OR MIDDLE EAR OR OTORRH?)
L150 16 S L147 AND EAR/BIX
L151 20 S L146,L148,L149,L150

FILE 'WPIX' ENTERED AT 15:48:50 ON 21 JUN 2005

=>